

## PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/145852>

Please be advised that this information was generated on 2017-12-05 and may be subject to change.

**Regulation of  
bacterial-induced  
arthritis**

**A.G.M. van de Langerijt**



# Regulation of bacterial- induced arthritis





# Regulation of bacterial- induced arthritis

een wetenschappelijke proeve  
op het gebied van de Medische Wetenschappen

## PROEFSCHRIFT

ter verkrijging van de graad van doctor  
aan de Katholieke Universiteit Nijmegen,  
volgens besluit van het College van Decanen  
in het openbaar te verdedigen  
op woensdag 9 november 1994  
des ochtends om 10.30 uur precies

door

**Alexander Gerardus Maria van de Langerijt**

geboren op 7 augustus 1961  
te Oisterwijk

Promotor: Prof.dr. W.B. van den Berg

Co-promotor: Dr. P.L.E.M. van Lent

Aan Daniëlle

Aan mijn ouders

Thesis committee:

Prof.dr. J.J.A. Hoogkamp Korstanje

Prof.dr. J.H.M. Berden

Prof.dr. F.C. Breedveld

The investigations presented in this thesis were performed at the department of Rheumatology, University Hospital St. Radboud, Nijmegen, The Netherlands.

The research was financially supported by the Dutch League against Rheumatism ('Het Nationaal Reumafonds')

The printing of this thesis was financially supported by the Dutch League against Rheumatism ('Het Nationaal Reumafonds'), Roussel B.V., Dr. Saal van Zwanenberg Stichting en EG&G Wallac.

ISBN 90-9007603-4

Druk: Drukkerij Benda BV, Nijmegen

# CONTENTS

	page
Abbreviations	8
<b>Chapter 1</b> General introduction	9
<b>Chapter 2</b> Treatment of rats with monoclonal anti-CD4 induces long-term resistance to streptococcal cell wall-induced arthritis. <i>Eur. J. Immunol. 22: 57-61, 1992.</i>	25
<b>Chapter 3</b> Cross-reactivity to proteoglycans in bacterial arthritis: lack of evidence for in vivo role in induction of disease. <i>Clin. Immunol. Immunopathol. 71: 273-280, 1994.</i>	33
<b>Chapter 4</b> Cell migration studies in the adoptive transfer of adjuvant arthritis in the Lewis rat. <i>Immunology 81: 414-419, 1994.</i>	43
<b>Chapter 5</b> Regulation of resistance against adjuvant arthritis in the Fisher rat. <i>Clin. Exp. Immunol. 94: 150-155, 1993.</i>	51
<b>Chapter 6</b> Susceptibility to adjuvant arthritis: relative importance of adrenal activity and bacterial flora. <i>Clin. Exp. Immunol. 97: 33-38, 1994.</i>	59
<b>Chapter 7</b> Role of $\beta 2$ integrins in the recruitment of phagocytic cells in joint inflammation in the rat. <i>Clin. Immunol. Immunopathol. in press.</i>	67
<b>Chapter 8</b> Summary and concluding remarks	79
Samenvatting	85
Dankwoord	89
Curriculum vitae	91

## ABBREVIATIONS

AA	adjuvant arthritis
APO-SUS	apomorphine susceptible
APO-UNSUS	apomorphine unsusceptible
AVP	arginine vasopressin
CIA	collagen-induced arthritis
CNS	central nervous system
CRF	corticotropin-releasing factor
EAE	experimental allergic encephalomyelitis
FIA	Freund's incomplete adjuvant
GF	germ-free
HLA	human leukocyte antigen
hsp	heat shock protein
HPA-axis	hypothalamus-pituitary-adrenal axis
IL-1/2	interleukin-1/2
LPS	lipopolysaccharide
mAb	monoclonal antibody
MHC	major histocompatibility complex
M.tb.	Mycobacterium tuberculosis
RA	rheumatoid arthritis
ReA	reactive arthritis
RF	rheumatoid factor
SCW	streptococcal cell wall
TNF- $\alpha$	tumor necrosis factor- $\alpha$
VLA-4	very late antigen-4

# CHAPTER 1

## GENERAL INTRODUCTION





# GENERAL INTRODUCTION

## RHEUMATOID ARTHRITIS

Rheumatoid arthritis (RA) is a chronic, systemic disease affecting about 1-2% of the population. Its aetiology is unknown. The disease is characterized by inflammations mainly in the joints and composed of exacerbations and remissions. The susceptibility to RA is weakly associated with the human leukocyte antigen (HLA) DR4 (1), indicating a genetic predisposition. The disease is more often seen in women than in men (ratio 3:1) (2).

### Autoimmunity

Normally the immune system is able to discriminate between "self" and "non-self" (3). As a result, it can respond to an unlimited variety of invading foreign antigens while simultaneously it remains nonresponsive or tolerant to its own self-antigens. In autoimmune diseases however, the immune tolerance against self antigens is broken. Due to this defect autoantibody producing B cells and/or autoreactive T cells are able to attack self-structures.

RA is regarded to be an autoimmune disease even though, besides a so called rheumatoid factor (RF) no crucial autoreactivity has been demonstrated against a particular self antigen. The term RF represents a population of antibodies, which are directed against epitopes on the Fc fragment of autologous IgG (4). They form immune complexes, which can be detected in rheumatoid synovial fluid and tissue. These complexes can fix complement, which points towards involvement in inflammatory reactions (5). RF appears to be frequently present in sera of RA patients, although it can not be considered as the sole criterion for the diagnosis of RA.

Regarding the cellular immunity several studies have already shown that T cells play an important role in RA. One of the first reports on this subject observed that removal of T cells by thoracic duct drainage lead to an improvement of RA (6). Furthermore, reinjection of these removed lymphocytes resulted in a relapse in some patients, as did cessation of the thoracic duct drainage in almost all patients. Later studies showed that also total lymphoid irradiation (7) and cyclosporin A treatment (8) were able to improve RA. Finally, clinical studies are initiated recently to treat RA with the chimeric monoclonal anti-CD4 antibodies cM-T412. The first data show that treatment with anti-CD4 is associated with a sustained decrease in the number of circulating CD4+ T cells. The side effects of anti-CD4 treatment included fever, rigor, chills and hypotension, but no serious infectious complications (9). Regarding clinical improvement the data are not unequivocal. One study reports no clinical improvement, even though histological analysis showed a decrease in the synovial inflammation (10). However, another study reported significant improvement in 12 refractory RA patients (11). It was shown that antibody dosage and treatment regimen are the crucial factors determining clinical outcome. Furthermore, it was observed that the percentage of mAb coated lymphocytes in the synovial fluid correlated with the degree of clinical improvement. It

was suggested that the amount of anti-CD4 monoclonal antibody entering the RA joint may determine clinical efficacy.

## **Relationship between RA and bacteria**

Induction of arthritis is likely to be dependent on the concerted action of three distinct factors: antigen presenting molecules, an arthritis triggering antigen and antigen specific T cells. In this molecular triad the antigen plays an important role for as well the induction as the maintenance of RA. Unfortunately, up to now the antigen is still unknown, although there are several arguments for an involvement of bacteria in the pathogenesis of chronic joint inflammation. For instance arthritis has been associated with bacterial infections of the throat (acute rheumatic fever) (12), the gastrointestinal or urinary tract (Reiter's syndrome, reactive arthritis) (13,14), jejunal bypass surgery for obesity, which often results in a bacterial overgrowth (15), inflammatory bowel diseases like M. Crohn (16) and *Borrelia burgdorferi* inducing Lyme disease (17). Furthermore several arthritis models exist, which can be induced by the injection of bacteria.

Since RA is a chronic and systemic disease, it indicates that the antigen must be continuously present in either the circulation and/or joint. Combining this with the association between bacteria and arthritis one can think of two likely mechanisms, explaining this autoimmune disease. First of all a specific T cell response against bacterial fragments, which may be present in the circulation or persist in the joint. This persistence in the joint can for instance be explained by trapping of the antigen in immune complexes or by electrostatic interactions of cationic antigens and negatively charged cartilage (18-20). Another likely hypothesis for the induction and chronicity of arthritis is cross-reactivity between epitopes on bacteria or viruses and cartilage.

In reactive arthritis (ReA) the antigens triggering the arthritis are thought to be antigens of the microbes that cause the infections of the gut, such as chlamydia, yersinia or salmonella (21). Antigens of these bacteria have been indeed detected in synovial cells (22-26), and T cell specificity for these antigens has been found in the synovium (27-29).

In RA there are several indications for a direct role of cartilage in the pathogenesis of RA. For instance, destructive forms of rheumatoid arthritis tend to decline at the moment the cartilage is fully destroyed. Moreover, total joint replacement often results in a complete remission of arthritis in that joint. Candidate autoantigens in RA include cartilage proteoglycan aggregates, type II collagen and the heat-shock proteins (hsp). Regarding the human articular cartilage proteoglycans, T cell responses have been found in some patients with RA (30,31), but also in healthy subjects (30-32). Furthermore, these studies showed no simple relationship between T cell responsiveness and disease status. This was also the case for other candidate antigens in RA. For example, T cells responsive to purified type II collagen have been cloned from arthritic joints (33). On the one hand, T cell responses among patients with RA are generally low (34) and T cells from healthy individuals are also able to respond to type II collagen (35). Similarly, studies on hsp as autoantigen have demonstrated that T cell clones from RA inflammatory sites can lyse autologous target cells pulsed with hsp60 (36). In addition, it has been described that RA synovial T cells respond better to members of the hsp60 family than peripheral blood T cells (37). On the other hand, mycobacterium bovis hsp65 is not necessarily an immunodominant T cell antigen in RA (38) and cells from joints of some adult patients with RA do not respond to human hsp60 (39). All these data suggest that

more work is needed to further elucidate, whether reactivity against any of these autoantigens has any relevance in the etiopathogenesis of RA.

## ANIMAL MODELS

Since RA is a complicated autoimmune disease, arthritis models have been developed, which closely resemble the human disease. Most of these experimental models are developed in rat or mice and can be divided in unilateral or systemically induced arthritis models. A well known unilateral model is the antigen-induced arthritis, which can be induced by intra-articular injection of antigen into the knee joint of animals previously immunized with the same antigen. In contrast to the unilateral arthritis, the systemically-induced arthritis models result in a polyarthritis. In general, the polyarthritic animal models can be induced in susceptible strains by either structures of the joint itself, like collagen-induced arthritis (CIA)(40) and proteoglycan-induced arthritis (41), by bacteria, like yersinia-induced arthritis (42), adjuvant arthritis (AA)(43) and streptococcal cell wall (SCW)-induced arthritis (44) or by non-immunogenic synthetic oils, like pristane arthritis (45) and CP20961-induced arthritis (46). In addition, there is the spontaneously developing MRL-1pr/1pr mouse model (47). Since a more detailed discussion of all the animal models goes beyond the scope of this thesis, we will now only focus on CIA, AA, SCW-induced arthritis and the CP20961-induced arthritis.

### Collagen-induced arthritis

Collagen-induced arthritis (CIA) is an experimentally induced autoimmune model of chronic erosive arthritis. It can be induced in certain strains of rats (40) and mice (48) by intradermal injection of intact ("native") type II collagen, a major component of articular cartilage. Both B and T cells are crucial for the development of arthritis. The importance of antibodies has been demonstrated in experiments in which anti-CII mAb can induce a transient arthritis when transferred to healthy animals (49,50) or nude rats (51). Evidence that T cells play a major role in the development of CIA was obtained from observations, that arthritis does not develop in nude (52) or cyclosporin A-treated rats (53) and that disease can be adoptively transferred with T cell lines or clones (54). Furthermore, the development of disease can be prevented with antibodies directed to CD4 (55) and TCR (56-58). Regarding the pathogenesis, it is suggested that in the active model, binding of anti-CII mAbs to the articular surface may direct the inflammatory process towards this tissue. This may explain the extensive cartilage destruction observed in CIA.

### Adjuvant arthritis

Regarding the bacterial-induced arthritis models, most models use either heat-killed bacteria or bacterial fragments. The oldest and most widely used model is adjuvant arthritis (AA). This model is induced by an intradermal administration of heat-killed

*Mycobacterium tuberculosis* (M.tb.) suspended in Freund's incomplete adjuvant (FIA)(43). The volume, type of oil, and composition of the emulsion are important variables that determine the incidence of arthritis (59,60). Most research on this model has been performed in the susceptible Lewis rat and therefore this will be discussed in more detail. However, AA can also be induced in certain mice (61). In addition, several other studies showed that DA rats injected with FIA alone could develop a mild transient arthritis (62,63), while the Lewis strain remained resistant for this type of induction. In the Lewis rat the polyarthritis develops within 14 days and subsides again after  $\pm$  4 weeks. Interestingly, after this recovery period the Lewis rats are resistant to a renewal injection of M.tb. in oil (64).

In contrast to CIA, AA is primarily a cellular mediated disease. This hypothesis is supported by several studies, which have shown that T lymphocytes play an important role in this arthritis model. For instance, cyclosporin A treatment could prevent the development of disease (65). Furthermore, AA could not be induced in nude rats (66), and was transferable to naive recipients (67). Finally, treatment with the anti-T-lymphocyte antibodies anti-CD4 (68) and anti-TCR (69) were able to prevent arthritis.

Regarding the pathogenesis of this disease, combinations studies on AA and CIA resulted in an extraordinarily severe arthritis (70,71). This synergy provides evidence that AA and CIA are induced by fundamentally different pathogenic mechanisms. In contrast, other studies support the view that at least certain aspects of the pathogenesis of these two models may be the same. For instance, anti-CII antiserum suppressed AA (72) and transfer of spleen cells of donor rats given CII/FIA, which themselves did not induce disease, could suppress the subsequent arthritic response to AA (73).

Interestingly, several data suggest that in AA the pathogenesis is an autoimmune process, which is triggered by structural mimicry between bacterial antigens and cartilage proteoglycans. From studies with the T helper clone (A2b) isolated from AA rats, one was able to pinpoint a reactivity against the 180-186 epitope of the bacterial 65kD heat shock protein (74). Interestingly, this 65kD protein was able to induce an antigen-specific suppression of AA (75,76), and a recent study showed that disease could be inhibited by a peptide analogue of the 180-188 epitope (77).

Reports that AA can be adoptively transferred by T cells were the first indications that crossreactive responses against self-determinants might be involved (67). More recent observations confirm the latter hypothesis, since in the adoptive transfer of AA some of the donor T cells were able to migrate to the synovium (78). Furthermore, the A2b clone was able to respond to cartilage proteoglycan and could induce disease in irradiated syngeneic recipients (79,80). Finally, in vivo AA could be modulated with fractions of proteoglycans (81,82). All these data suggest that crossreactivity between bacterial and cartilage antigens is a likely mechanism for the pathogenesis of this disease. On the other hand, there are several data, which indicate that during the initiation of AA also other mechanisms may play a role. For instance, arthritis can be induced with the non-immunogenic oil CP20961 and this disease is indistinguishable from the classical AA (46). Furthermore, even more surprising are the data that lymphocytes from these CP20961 treated rats recognized the bacterial antigen M.tb. (83). These data suggest that the oil may also induce a second mechanism, which can be described as a nonspecific immunomodulation resulting in expression of normally suppressed autoimmunity.

Inbred rat strains have been found to differ in their susceptibility to AA, indicating that genetic factors control the susceptibility to AA. For example, Lewis rats are highly susceptible to AA, while F344 (Fisher) rats, despite the fact that they share the same

RT1.B and RT1.D MHC class II loci with Lewis, are not susceptible to AA (84). Interestingly, F344 rats kept and bred under germ-free conditions are susceptible to AA (85), whereas colonization of the germ-free rats with gram-negative bacteria again suppressed the disease susceptibility (86). The relevance of these findings are discussed below.

### **Streptococcal cell wall-induced arthritis**

Another important bacterial arthritis model is the streptococcal cell wall (SCW)-induced arthritis. It can be induced by an intraperitoneal injection of a sterile, aqueous suspension of bacterial cells or cell wall fragments from group A streptococci (44). In addition, a similar disease can be induced with cell wall fragments of other bacteria, such as *Lactobacillus casei* or *Eubacterium aerofaciens* (87,88). The latter gram-positive bacteria are the major residents of the human intestinal flora. This indicates that large amounts of potentially arthritogenic stimuli are continuously present in the gastrointestinal tract.

Injection of this poorly biodegradable material results in an acute systemic illness together with swelling and redness of the joints. This acute disease occurs after 1 day, wanes after 4-7 days and is dependent on activation of the alternative pathway of complement (89). Acute disease is inducible in all rat strains and in nude or thymectomized rats, indicating independence of functional T cells. The acute phase is followed by a chronic, erosive polyarthritis, which mainly involves peripheral joints. In contrast with the acute phase, the chronic joint inflammation only develops in a limited number of rat strains, namely Lewis and Sprague Dawley rats (90,91).

In the SCW-induced arthritis persistence of the poorly degradable fragments is of utmost importance for chronicity, since administration of mutanolysin (a muralytic enzyme which effectively degrades SCW) after injection of the cell walls, resulted in prevention of this chronic joint disease (92). In addition, when chronic inflammation has subsided, arthritis can be reactivated by systemic challenge with homologous or heterologous cell walls or with bacterial lipopolysaccharide (LPS)(93,94). Due to these latter observations the SCW-induced arthritis significantly differs from AA. In line with the previously described models the chronic phase of the SCW-induced arthritis is also T cell dependent. Arthritis could not be induced in athymic (nude) Lewis rats (95) and cyclosporin A was able to effectively inhibit the chronic phase in euthymic Lewis rats (96). Furthermore, a SCW specific T cell line was able to induce arthritis in naive syngeneic recipients (97) and the development of disease could be prevented by treating the animals with antibodies directed against CD4 (98) or the TCR (99).

The susceptibility to this form of arthritis is still not completely understood. As in AA, also in the SCW-induced arthritis F344 rats are resistant when compared to Lewis rats (100). This suggests that susceptibility is not dependent on the MHC genes alone. Furthermore, several other studies showed that susceptibility could not be explained by persistence of the antigen, since in the body and joints this was comparable in both strains. However, due to the importance of T cells in the chronic phase, this difference may be explained at the level of T cell immunity. Regarding to this it was shown that the susceptible Lewis rats were able to mount a marked SCW-specific T cell response against SCW material after various immunization protocols, while the F344 rats were totally unable to do so (101). This unresponsiveness of the F344 rats was not due to a general

defect of the immune system, since control studies with other antigens showed that the F344 rats were capable of mounting distinct T cell responses. In addition, it was shown that depletion of T suppressor cells *in vitro* resulted in a restoration of the T cell response. This demonstrated that active suppression can play an important role in the F344 strain. Of course the immune system of resistant F344 rats will have a good reason not to respond to the SCW material. Again a likely explanation might be the existence of crossreactivity between bacterial epitopes and cartilage proteoglycans. Along this line, the F344 strain simply recognizes the danger of responding to these potential cross-reactive epitopes and as a result the F344 strain remains resistant to SCW-induced arthritis.

There are several mechanisms supposed to be involved in self-tolerance and thus may be indirectly responsible for the resistance of the F344 strain. First of all there is a mechanism, which operates at the level of T cell development and called clonal deletion. In this process T cells, which express the  $\alpha\beta$  T cell receptor with specificity for peptides derived from self structures will be deleted from the repertoire (102). This deletion or programmed cell death is better known as apoptosis. In addition, mechanisms of peripheral tolerance exist and both clonal anergy (103) and active suppression have been postulated to fulfill this role. Regarding the mechanism of anergy, mature self-reactive T cells recognize their specific antigen in the periphery and instead of being activated, these cells become functionally inactivated. This process of clonal anergy appears to be correlated to the inability to produce IL-2 (104). Finally, self-tolerance can be maintained by active suppression (105). In this process T cells with a specificity for suppression inducing epitopes can inhibit the response of T cells to self-antigens.

Several studies have investigated, whether this tolerance against bacterial fragments is acquired early in life through contact with bacteria of the gut flora. Therefore the susceptibility of the germ-free F344 strain was analysed and it was observed that these rats were susceptible to SCW-induced arthritis and were also able to mount a SCW specific T cell response (106). These data in germ-free animals, together with similar findings in AA suggest that the gut flora plays a important role in the induction and maintenance of immunological tolerance to bacterial antigens. However, whether this tolerance against bacterial antigens can be considered as cross-tolerance against cartilage fragments is tempting to suggest but remains to be further investigated.

## THE NEUROENDOCRINE SYSTEM

Apart from immunological tolerance, recent studies found increasing evidence of interactions of the central nervous system (CNS), the neuroendocrine system and the immune system. In these systems the hypothalamus-pituitary-adrenal (HPA) axis is an important loop, which is able to connect joint inflammation with the brain.

Inflammatory stimuli such as bacterial fragments are able to dramatically increase the production of interleukin-1 (IL-1) and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) (107,108). Both non-specific proinflammatory cytokines are predominantly produced by macrophages and possess a wide variety of biological activities, of which the activation of the HPA axis is an important one (109,110). Although the precise site of action is unknown, they either directly or indirectly act at the level of the hypothalamus to release corticotropin-releasing factor (CRF) and arginine vasopressin (AVP)(111,112). These neurohormones

are both secreted into the hypophysial portal system and play major and synergistic roles in the regulation of pituitary ACTH secretion, which in turn stimulates the production of glucocorticoids by the adrenal cortex. Along this line the HPA axis can exert a negative feedback on the immune system, and thus may be an important mechanism in the modulation of joint inflammation. How important this may be, can be illustrated by the findings of Sternberg et al. (113). They were able to show that the Lewis rat, which is susceptible for several other autoimmune diseases, has a defect in its ability to biosynthesize CRH in the hypothalamus (114). As a result the Lewis rat was unable to significantly increase its corticosteroid levels when a stressful situation, like the injection of SCW material, was induced. In addition, they showed that the F344 strain could produce high corticosteroid levels to the same stimulus and that these rats became susceptible for SCW-induced arthritis when they were treated with the glucocorticoid receptor antagonist RU 486. From these data it was postulated that the production of high levels of corticosterone is a mechanism of the F344 strain to protect itself from disease development. However, this hypothesis is not in agreement with the observation that the germ-free (GF) F344 rats are susceptible. In contrast to the low CRH production in the Lewis rats, the same rats appear to have an increased AVP production, which probably serves as a mechanism to compensate for insufficient CRH and glucocorticoid secretion (115).

In contrast with the indirect systemic immunosuppressive effects of CRH, a recent study reported that locally produced CRH can exert proinflammatory effects, since anti-CRH treatment could suppress a locally induced inflammation (116). Similarly, local proinflammatory effects may explain the observation that the CRH protein was expressed at high levels in the inflamed joints of Lewis rats and virtually absent in the F344 rat joints (117). Furthermore, these data illustrate the complex interrelationships of the nervous, endocrine, immune and inflammatory systems.

Interestingly, a similar impaired glucocorticoid response has been described for the Obese strain of chickens (118). In addition, it was shown in experimental allergic encephalomyelitis (EAE), an autoimmune disease model for the central nervous system (CNS), that the resistant PVG rats produce higher levels of corticosterone to ether stress than susceptible Lewis rats (119). During this inflammatory process, which normally lasts 5-7 days, an increase in corticosterone appeared to be essential for the recovery phase of this disease, as has been demonstrated after adrenalectomy in Lewis rats (120). Furthermore, adrenalectomized PVG rats became highly susceptible to EAE and steroid replacement therapy was able prevent the fatal outcome of this disease. These data again indicate that the endogenous production of glucocorticoids plays an important role in the regulation of inflammatory processes, like in experimental autoimmune diseases.

Recently, it has been demonstrated that also patients with RA have a defective hypothalamic response to immune and inflammatory stimuli. This was showed in a decreased ACTH/cortisol and increased prolactin production during stress (121,122). Both cortisol and prolactin are hormones which can exert its effects on the immune system, although prolactin augments immune reactivity instead of suppressing it (123). These data again indicate the relationships between the neuroendocrine and immune system. Future research will further elucidate the relevance of the neuroendocrine system in RA and bacterial arthritis models.



## AIM OF THE STUDY

In this thesis we explored mechanisms underlying the regulation of susceptibility to bacterial-induced arthritis in various rat strains. The observation that T lymphocytes play an important role in these models is taken as a starting point of this research.

In chapter 2 we investigated the involvement of the CD4+ cells in the induction and maintenance of the SCW-induced arthritis. Therefore CD4+ cells were depleted before the onset of arthritis or in an established disease. In addition, we performed long-term studies to examine mechanisms of resistance to bacterial-induced arthritis.

In chapter 3 we studied the relevance of the *in vitro* cross-reactive responses between bacterial epitopes and cartilage in the pathogenesis of bacterial-induced arthritis. Therefore we performed a histological analysis in different arthritis models and compared the level of proteoglycan depletion at different timepoints after arthritis induction. Moreover we examined, whether the release of proteoglycan fragments in the synovial fluid was able to elicit an inflammation in Lewis rats, which were previously immunized with SCW/FIA.

In chapter 4 the pathogenesis of bacterial-induced arthritis was further analysed, by performing adoptive transfer experiments. In this study it was tested, whether donor T lymphocytes are capable of specific migration to the joints and subsequently initiate arthritis. These experiments may give indirect evidence, on whether antigen specific T lymphocytes are able to recognize defined antigens in the joint.

Next, we examined the contributing role of the neuroendocrine system in determining the susceptibility to bacterial-induced arthritis. We focused in chapter 5 on active suppression and/or adrenal activity as determinants regulating the resistance against adjuvant arthritis in the Fisher rat. In chapter 6 both systems were further investigated. Using different Wistar lines and both conventional and germfree rats, we analysed the relative importance of the adrenal activity and bacterial flora in determining the susceptibility to bacterial-induced arthritis.

Finally, in chapter 7 it was investigated, whether adjuvant arthritis could be suppressed by blocking the influx of inflammatory cells with antibodies against adhesion molecules.

## REFERENCES

1. van Zeben D, Hazes JMW, Zwinderman AH, Cats A, Schreuder GMT, D'Amaro J, Breedveld FC. Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a follow-up study. *Arthritis Rheum* 34: 822-30, 1991.
2. Ması AT, Medsger THA. Epidemiology of the rheumatic diseases. In: *Arthritis and allied conditions*. Mc Arthy DJ, Lea & Febiger, Philadelphia, 11th ed.: Ch 3, 1989.
3. Cohen IR. The self, the world and autoimmunity. *Scient Am* 255: 34-42, 1988.
4. Carson D. Rheumatoid factor. In: *Textbook of Rheumatology* ed 2. edited by WN Kelly, ED Harris Jr, S Ruddy and EB Sledge. WB Saunders Philadelphia: 664-679, 1985.
5. Sabharwal UK, Vaughan JH, Fong S, Bennet PH, Carson DA and Curd JG. Activation of the classical pathway of complement by rheumatoid factors: assessment by radioimmunoassay for C4. *Arthritis Rheum* 25: 161-167, 1982.

6. Paulus HE, Machleder HI, Levine S, Yu DTY, MacDonald S. Lymphocyte involvement in rheumatoid arthritis. Studies during thoracic duct drainage. *Arthritis Rheum* 20: 1249-62, 1977.
7. Tanay A, Field EH, Hoppe RT, Strober S. Long-term followup of rheumatoid arthritis patients treated with total lymphoid irradiation. *Arthritis Rheum* 30: 1-10, 1987.
8. Weinblatt ME, Coblyn JS, Fraser PA, Anderson RJ, Spragg J, Trentham DE, Austen KF. Cyclosporin A treatment of refractory rheumatoid arthritis. *Arthritis Rheum* 30: 11-7, 1987.
9. Moreland LW, Bucy RP, Tilden A, Pratt PW, Lobuglio AF, Khazaeli M, Everson MP, Daddona P, Ghayeb J, Kilgarriff C, Sanders ME, Koopman WJ. Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. *Arthritis Rheum* 36: 307-18, 1993.
10. Tak PP, van der Lubbe PA, Daha MR, Kluin PhM, Meinders AE, Breedveld FC. Reduction of synovial inflammation without clinical improvement after CD4 monoclonal antibody treatment in early rheumatoid arthritis. *Clin Rheumatol* 13: 188, 1994 (abstract no 139).
11. Choy EHS, Pitzalis C, Bijl JA, Kingsley GH, Panayi GS. The amount of anti-CD4 monoclonal antibody (mAb) entering the rheumatoid (RA) joint may determine clinical efficacy. *Clin Rheumatol* 13: 188, 1994 (abstract no 138)
12. Cantazarro FJ, Stenson CA, Morris AJ, Chamowitz R, Rammelkamp CH, Stolzer BL, Perry WD. Role of the streptococcus in the pathogenesis of rheumatic fever. *Am J Med* 17: 749-55, 1954.
13. Catterall RD. Infection and immunology. In: *The rheumatic diseases* (DC Dumonde, ed.), Blackwell Scientific Oxford UK, pp. 147-53, 1976.
14. Keat A. Reiter's syndrome and reactive arthritis in perspective. *New Engl J Med* 309: 1606-15, 1983.
15. Utsinger PD. Bypass disease: a bacterial antigen-antibody systemic immune complex disease. *Arthritis Rheum* 23: 758-66, 1980.
16. van den Broek MF, van de Putte LBA, van den Berg WB. Crohn's disease associated with arthritis: a possible role for crossreactivity between gut bacteria and cartilage in the pathogenesis of arthritis. *Arthritis Rheum* 30: 1077-9, 1988.
17. Steere AC, Malawista EE, Suydmann DR, Shope RE, Andiman WA, Ross MR, Steele FM. Lyme disease: an epidemic of oligoarticular arthritis in children and adults in three Connecticut communities. *Arthritis Rheum* 20: 7-17, 1977.
18. van den Berg WB, van Beusekom HJ, van de Putte LBA, Zwarts WA, van der Sluis M. Antigen handling in antigen induced arthritis in mice: an autoradiographic and immunofluorescence study using whole knee joint sections. *Am J Pathol* 108: 9-16, 1982.
19. van den Berg WB, van de Putte LBA, Zwarts WA, van der Sluis M. Electrical charge of antigen determines intraarticular antigen handling and chronicity of arthritis in mice. *J Clin Invest* 74: 1850-9, 1984.
20. van den Berg WB, van de Putte LBA. Electrical charge of antigen determines its localization in the mouse knee joint. Deep penetration of cationic BSA in hyaline articular cartilage. *Am J Pathol* 121: 224-34, 1985.
21. Toivanen A, Toivanen P, (eds). *Reactive arthritis*. Boca Raton: CRL Press, 1988.
22. Granfors K, Jalkanen S, Von Essen R, et al. Yersinia antigens in synovial fluid cells from patients with reactive arthritis. *N Engl J Med* 320: 216-21, 1989.
23. Hammer M, Zeidler H, Klimsa S, Heesemann J. Yersinia enterocolitica in the synovial membrane of patients with Yersinia induced arthritis. *Arthritis Rheum* 33: 1795-1800, 1990.
24. Viitanen AM, Arstila TP, Lahesmaa R, Granfors K, Skurnik M, Toivanen P. Application of the polymerase chain reaction and immunofluorescence techniques to the detection of bacteria in Yersinia-triggered reactive arthritis. *Arthritis Rheum* 34: 89-96, 1991
25. Schumacher HRJr, Magge S, Cherman PV, Sleckman J, Rothfuss S, Clayburne G, Sieck M. Light and electron microscopic studies on the synovial membrane in Reiter's syndrome: immunocytochemical identification of chlamydial antigen in patients with early

- disease. *Arthritis Rheum* 31: 937-46, 1988
26. Granfors K, Jalkanen S, Lindberg AA, et al. Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis. *Lancet* 336: 685-8, 1990.
  27. Gaston JSH, Life PF, Granfors K, et al. Synovial T lymphocyte recognition of organisms that trigger reactive arthritis. *Clin Exp Immunol* 76: 348-53, 1989.
  28. Hermann E, Fleisher B, Mayet WJ, Poralla T, Meyer zum Buscherfelde KH. Response of synovial T cell clones to *Yersinia enterocolitica* in patients with *Yersinia* reactive arthritis. *Clin Exp Immunol* 75: 365-70, 1989.
  29. Sieper J, Kingsley G, Palacios-Boix A, Pitzalis C, Treharne J, Hughes R, Keat A, Panayi GS. Synovial T lymphocyte specific immune response to *Chlamydia trachomatis* in Reiter's disease. *Arthritis Rheum* 34: 588-97, 1991.
  30. Glant T, Csongor J, Szucs T. Immunopathologic role of proteoglycan antigens in rheumatoid joint disease. *Scand J Immunol* 11: 247-52, 1980.
  31. Sigal LH, Johnston SL, Phillips PE. Cellular immune responses to cartilage components in rheumatoid arthritis and osteoarthritis. *Clin Exp Rheumatol* 6: 589-66, 1988.
  32. Goodacre JA, Middleton S, Patterson A, Ferreira P, Lessan K, Pearson J. Activation of human and murine T lymphocytes by cartilage proteoglycans. *Biochem Soc Trans* 18: 677-8, 1990.
  33. Londei M, Savill CM, Verhoef A, et al. Persistence of collagen type II-specific T cell clones in the synovial membrane of a patient with rheumatoid arthritis. *Proc Natl Acad Sci USA*. 86: 636-40, 1989.
  34. Desai BV, Dixit S, Pope RM. Limited proliferative response to type II collagen in rheumatoid arthritis. *J Rheumatol* 16: 1310-4, 1989.
  35. Elkayam O, Zinger H, Zisman E, Segal R, Yaron M, Brautbar C, Mozes E. Regulatory T cell activity specific to human type II and III collagens in rheumatoid arthritis. *J Rheumatol* 18: 516-21, 1991.
  36. Li SG, Quayle AJ, Shen Y et al. Mycobacterial and human heat-shock protein-specific cytotoxic T lymphocytes in rheumatoid synovial inflammation. *Arthritis Rheum* 35: 270-81, 1992.
  37. Gaston JSH, Life PF, Bailey LC, Bacon PA. In vitro responses to a 65kDa mycobacterial protein by synovial T cells from inflammatory arthritis patients. *J Immunol* 143: 2594-600, 1989.
  38. Res PCM, Orsini DLM, van Laar JM, Janson AAM, Abou-Zeid C, De Vries RRP. Diversity in antigen recognition by mycobacterium tuberculosis-reactive T cell clones from the synovial fluid of rheumatoid arthritis patients. *Eur J Immunol* 21: 1297-1302, 1990.
  39. De Graeff-Meeder ER, Van der Zee R, Rijkers GT, et al. Recognition of human 60 kD heat shock protein by mononuclear cells from patients with juvenile chronic arthritis. *Lancet* 337: 1368-72, 1991.
  40. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: an experimental model of arthritis. *J Exp Med* 77: 857-868, 1977.
  41. Mikecz K, Giant TT, Buzas E, Poole AR. Proteoglycan-induced polyarthritis and spondylitis adoptively transferred to naive (nonimmunized) BALB/c mice. *Arthritis Rheum* 33: 866-876, 1990.
  42. Hill JL, Yu DTY. Development of an experimental animal model for reactive arthritis induced by *Yersinia enterocolitica* infection. *Infect Immun* 55: 721-26, 1987.
  43. Pearson CM. Development of arthritis, peri-arthritis and periostitis in rats given adjuvants. *Pro Soc Exp Biol Med* 91: 95-101, 1956.
  44. Cromartie WJ, Craddock JG, Schwab JH, Anderle SK, Yang C. Arthritis in rats after systemic injection of streptococcal cells or cell walls. *J Exp Med* 146: 1585-1602, 1977.
  45. Hopkins SJ, Freeman AJ, Jayson MIV. Pristane induced arthritis in BALB/c mice. *Rheumatol Int* 5: 21-8, 1984.
  46. Chang YH, Pearson CM, Abe C. Adjuvant polyarthritis. IV. Induction by a synthetic adjuvant: Immunologic, histopathologic, and other studies. *Arthritis Rheum* 23: 62-71, 1980.
  47. Hang L, Theofilopoulos AN, Dixon FJ. A spontaneous rheumatoid arthritis-like disease in

- MRL/1 mice. *J Exp Med* 155: 1690-8, 1982.
48. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunization against heterologous type II collagen induces arthritis in mice. *Nature* 283: 666-8, 1980.
  49. Stuart JM, Cremer MA, Yownes A, Kang A. Type II collagen-induced arthritis in rats. Passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis. *J Exp Med* 155: 1-16, 1982.
  50. Holmdahl R, Jansson L, Larsson A, Jonsson R. Arthritis in DBA-1 mice induced with passively transferred type II collagen immune serum. Immunohistopathology and serum levels of anti-type II collagen auto-antibodies. *Scand J Immunol* 31(2): 147-57, 1990.
  51. Takagishi K, Kaibara N, Hotokebuchi T, Arita C, Morinaga M, Arai K. Serum transfer of collagen arthritis in congenitally athymic nude rats. *J Immunol* 6: 3864-7, 1985.
  52. Klareskog L, Holmdahl R, Larsson E, Wigzell H. Role of T lymphocytes in collagen II induced arthritis in rats. *Clin Exp Immunol* 51: 117-25, 1983.
  53. Kaibara N, Hotokebuchi T, Takagishi K, Katsuki I. Paradoxical effects of cyclosporin A on collagen arthritis in rats. *J Exp Med* 158: 2007-15, 1983.
  54. Holmdahl R, Klareskog L, Rubin K, Larsson E, Wigzell H. T lymphocytes in collagen II-induced arthritis in mice. Characterization of arthritogenic collagen II-specific T cell lines and clones. *Scand J Immunol* 22: 295-306, 1985.
  55. Ranges GE, Srinam S, Cooper SM. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. *J Exp Med* 162: 1105-10, 1985.
  56. Goldschmidt TJ, Holmdahl R. Anti-T cell receptor antibody treatment of rats with established autologous collagen-induced arthritis: suppression of arthritis without reduction of anti-type II collagen autoantibody levels. *Eur J Immunol* 21: 1327-30, 1991.
  57. Yoshina S, Cleland LG, Mayrhofer G. Treatment of collagen-induced arthritis in rats with monoclonal antibody against the  $\alpha/\beta$  T cell antigen receptor. *Arthritis Rheum* 34: 1039-47, 1991.
  58. Goldschmidt TJ, Holmdahl R. Therapeutic effects of monoclonal antibodies to  $\alpha\beta$ TCR but not to CD4 on collagen-induced arthritis in the rat. *Cell Immunol* 154: 240-8, 1994.
  59. Whitehouse MW, Orr KJ, Beck FWJ, Pearson CM. Freund's adjuvants: Relationship of arthritogenicity in rats to vehicle composition. *Immunology* 27: 311-30, 1974
  60. Lussier A, De Medicis R, Tetreault L. Adjuvant arthritis. Influence of the adjuvant volume and composition on the established arthritis. *Int J Tiss Reac* VI(2): 105-10, 1984.
  61. Knight B, Katz DR, Isenberg DA, Ibrahim MA, Le Page S, Hutchings P, Schwartz RS, Cooke A. Induction of adjuvant arthritis in mice. *Clin Exp Immunol* 90: 459-65, 1992.
  62. Kleinau S, Erlandsson H, Holmdahl R, Klareskog L. Adjuvant oils induce arthritis in the DA rat. I. Characterization of the disease and evidence for an immunological involvement. *J Autoimmunol* 4: 871-80, 1991.
  63. Cannon GW, Woods ML, Clayton F, Griffiths MM. Induction of arthritis in DA rats by Incomplete Freund's Adjuvant. *J Rheumatol* 20(1): 7-11, 1993.
  64. Currey HLF. Adjuvant arthritis in the rat. Effect of injections of either whole dead mycobacteria or tuberculin. *Ann Rheum Dis* 29: 314-20, 1970.
  65. Borel JF, Feuer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. *Agents Actions* 6: 468-75, 1976.
  66. Kohashi O, Pearson CM, Tamaoki N, Tanaka A, Shimamura K, Ozawa K, Kotani S, Saito M, Hioki K. Role of thymus for N-acetyl muramyl-L-ananyl-D-isoglutamine-induced polyarthritis and granuloma formation in euthymic and athymic nude rats or in neonatally thymectomized rats. *Infect Immun* 31: 758-66, 1981.
  67. Taurog JD, Sandberg GP, Mahowald ML. The cellular basis of adjuvant arthritis. I. Enhancement of cell-mediated passive transfer by concanavalin A and by immunosuppressive treatment of the recipient. *Cell Immunol* 75: 271-82, 1983.
  68. Billingham MEJ, Hicks C, Carney S. Monoclonal antibodies and arthritis. *Agents Actions* 29: 77-87, 1990.
  69. Yoshino S, Schlipkoter E, Kinne R, Hung T, Emmerich F. Suppression and prevention of adjuvant arthritis in rats by a monoclonal antibody to the  $\alpha\beta$  T cell receptor. *Eur J Immunol* 20: 2805-9, 1990.

70. Taurog JD, Kerwar SS, McReynolds RA, Sandberg GP, Leary SL, Mahowald ML. Synergy between adjuvant arthritis and collagen-induced arthritis in rats. *J Exp Med* 162: 962-78, 1985.
71. DeJoy SQ, Ferguson KM, Oronsky AL, Kerwar SS. Studies on the synergy between collagen and adjuvant arthritis in rats. *Cell Immunol* 113: 117-29, 1988.
72. Welles WL, Battisto JR. Suppression of adjuvant arthritis by antibodies specific for collagen type II. *Immunol Commun* 10: 673-85, 1981.
73. Hunt DWC, Corson L, Barker HD, Levy JG, Petty RE. Relationship between collagen-induced and adjuvant arthritis in the Lewis rat. *J Autoimmunity* 6: 691-700, 1993.
74. van der Zee R, van Eden W, Meloen RH, Noordzij A, van Embden JDA. Efficient mapping and characterization of a T cell epitope by simultaneous synthesis of multiple peptides. *Eur J Imm* 19:43-7, 1989.
75. van Eden W, Thole JER, van der Zee R, Noordzij A, van Embden JDA, Hensen EJ, Cohen IR. Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis. *Nature* 331: 171-3, 1988.
76. Billingham MEJ, Carney S, Butler R, Colston MJ. A mycobacterial 65-kD heat shock protein induces antigen-specific suppression of adjuvant arthritis, but is not itself arthritogenic. *J Exp Med* 171: 339-44, 1990.
77. Wauben MHM, Boog CJP, van der Zee R, Joosten I, Schrief A, van Eden W. Disease inhibition by MHC binding peptide analogues of disease-associated epitopes: more than blocking alone. *J Exp Med* 176: 667-77, 1992.
78. DeJoy SQ, Ferguson-Chanowitz K, Oronsky AL, Zabriskie JB, Kerwar SS. Studies on the homing of mycobacterium-sensitized T lymphocytes to the synovium during passive adjuvant arthritis. *Cell Immunol* 130: 195-203, 1990.
79. Holoshitz J, Matitiau A, Cohen IR. Arthritis induced in rats by clones of T lymphocytes responsive to mycobacteria but not to collagen type II. *J Clin Invest* 73: 211-5, 1984.
80. van Eden W, Holoshitz J, Nevo Z, Frenkel A, Klajman A, Cohen IR. Arthritis induced by a T-lymphocyte clone that responds to Mycobacterium tuberculosis and to cartilage proteoglycans. *Proc Natl Acad Sci USA* 82: 5117-20, 1985.
81. Schwartz RL, Garbrecht FC, Thorbecke GJ, Siskind GW. The role of immunity to cartilage proteoglycan in adjuvant arthritis. *J Immunol* 141: 1168-73, 1988.
82. Kingston AE, Carney SL, Hicks CA, Billingham MEJ. In vitro and in vivo effects of proteoglycan fractions in adjuvant treated rats. *Agents Actions* 39: 75-9, 1993.
83. Kingston AE, Kerr N, Billingham MEJ. Changes in cell mediated immune responses during arthritis induced by complete Freund's adjuvant and CP20961 in Lewis and F344 rats. Submitted
84. Battisto JR, Smith RN, Beckmann K, Sternlicht M, Welles WL. Susceptibility to adjuvant arthritis in DA and F344 rats. A dominant trait controlled by an autosomal gene locus linked to the major histocompatibility complex. *Arthritis Rheum* 25: 1194-9, 1982.
85. Kohashi O, Kuwata J, Umehara F, Takahashi T, Ozawa A. Susceptibility to adjuvant-induced arthritis among germ-free, specific pathogen-free, and conventional rats. *Infect Immun* 26: 791-4, 1979.
86. Kohashi O, Kohashi Y, Takahashi T, Ozawa A, Shigematsu N. Suppressive effect of escherichia coli on adjuvant induced arthritis in germ free rats. *Arthritis Rheum* 29: 547-53, 1986.
87. Lehman TJA, Allen JB, Plotz PH, Wilder RL. Polyarthritis in rats following the systemic injection of lactobacillus casei cell walls in aqueous suspension. *Arthritis Rheum* 26: 1259-65, 1983.
88. Severijnen AJ, van Kleef R, Hazenberg MP, van de Merwe JP. Cell wall fragments from major residents of the human intestinal flora induce chronic arthritis in rats. *J Rheumatol* 16: 1061-8, 1989.
89. Schwab JH, Allen JB, Anderle SK, Dalldorf F, Eisenberg R, Cromartie WJ. Relationship of complement to experimental arthritis induced in rats with streptococcal cell walls. *Immunol* 46: 83-8, 1982.
90. Wilder RL, Calandra GB, Gravin AJ, Wright KD, Hansen CT. Strain and sex variation in

- the susceptibility to streptococcal cell wall-induced polyarthritis in the rat. *Arthritis Rheum* 25: 1064-72, 1982.
91. Wilder RL, Allen JB, Wahl LM, Calandra GB, Wahl SM. The pathogenesis of group A streptococcal cell wall-induced polyarthritis in the rat. Comparative studies in arthritis resistant and susceptible inbred rat strain. *Arthritis Rheum* 26: 1442-51, 1983.
  92. Janusz MJ, Chetty C, Eisenberg RA, Cromartie WJ, Schwab JH. Treatment of experimental erosive arthritis in rats by injection of the muralytic enzyme mutanolysin. *J Exp Med* 160: 1360-74, 1984.
  93. Esser RE, Stimpson SA, Cromartie WJ, Schwab JH. Reactivation of streptococcal cell wall-induced arthritis by homologous and heterologous cell wall polymers. *Arthritis Rheum* 28: 1402-9, 1985.
  94. Stimpson SA, Esser RE, Carter PB, Sartor RB, Cromartie WJ, Schwab JH. Lipopolysaccharide induces recurrence of arthritis in rat joints previously injured by polysaccharide-peptidoglycan. *J Exp Med* 165: 1678-88, 1987.
  95. Ridge SC, Zabriske JB, Oronsky AL, Kerwar SS. Streptococcal cell wall arthritis: Studies with nude (athymic) inbred Lewis rats. *Cell Immunol* 96: 231-4, 1985.
  96. Yocum DE, Allen JB, Wahl SM, Calandra GB, Wilder RL. Inhibition by cyclosporin A of streptococcal cell wall-induced arthritis and hepatic granulomas in rats. *Arthritis Rheum* 29: 262-73, 1986.
  97. DeJoy SQ, Ferguson KM, Sapp TM, Zabriske JB, Oronsky AL, Kerwar SS. Streptococcal cell wall arthritis. Passive transfer of disease with a T cell line and crossreactivity of streptococcal cell wall antigens with mycobacterium tuberculosis. *J Exp Med* 170, 369-82, 1989.
  98. van den Broek MF, van de Langerijt LGM, van bruggen MCJ, Billingham MEJ, van den Berg WB. Treatment of rats with monoclonal anti-CD4 induces long-term resistance to streptococcal cell wall-induced arthritis. *Eur J Immunol* 22, 57-61, 1992.
  99. Yoshino S, Cleland LG, Mayrhofer G, Brown RR, Schwab JH. Prevention of chronic erosive streptococcal cell wall-induced arthritis in rats by treatment with a monoclonal antibody against the T cell antigen receptor  $\alpha\beta$ . *J Immunol* 146: 4187-9, 1991.
  100. Anderle SK, Allen JB, Wilder RL, Eisenberg RA, Cromartie WJ, Schwab JH. Measurement of streptococcal cell wall in tissues of rats resistant or susceptible to cell wall-induced chronic erosive arthritis. *Infect Immun* 49:836-7, 1985.
  101. van den Broek MF, van Bruggen MCJ, van den Berg WB, van de Putte LBA. T cell responses to streptococcal antigens in rats: Relation to susceptibility to streptococcal cell wall-induced arthritis in rats. *Cell Immunol* 116: 216-29, 1988.
  102. Kiselow P, Bluthmann H, Staers UD, Steimetz M, von Boehmer H. Tolerance in T cell receptor transgenic mice involves deletion of non-mature CD4+CD8+ thymocytes. *Nature* 333: 742-6, 1988.
  103. Morahan G, Allison J, Miller JFAP. Tolerance of class I histocompatibility antigens expressed extrathymically. *Nature* 339: 622-4, 1989.
  104. Rammensee HG, Kroschewokski F, Frangoulis B. Clonal anergy induced in mature V $\beta$ 8+ T lymphocytes on immunizing Mls-1b mice with Mls-1a expressing cells. *Nature* 339: 541-4, 1989.
  105. Germain RN, Benacerraf B. A single major pathway of T-lymphocyte interactions in antigen-specific immune suppression. *Scand J Immunol* 13: 1-10, 1981.
  106. Van den Broek MF, van Bruggen MCJ, Koopman JP, Hazenberg MP, van den Berg WB. Gut flora induces and maintains resistance against streptococcal cell wall-induced arthritis in F344 rats. *Clin Exp Immunol* 88: 313-7, 1992.
  107. Vacheron F, Guenounou M, Nauciel C. Induction of Interleukin 1 secretion by adjuvant-active peptidoglycans. *Infect Immun* 42. 1049-54, 1983.
  108. Timmerman CP, Mattsson E, Martinez-Martinez L, de Graaf L, van Strijp JAG, Verbrugh HA, Verhoef J, Fleer A. Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans. *Infect Immun* 61: 4167-72, 1993.
  109. Rivier C, Chizzonite R, Vale W. In the mouse, the activation of the hypothalamic-

- pituitary-adrenal axis by a lipopolysaccharide (endotoxin) is mediated through interleukin 1. *Endocrinology* **125**: 2800-5, 1989.
110. Deryk RF, Van Rooijen N, Tilders FJH, Bezedovsky O, Del Rey A, Berkenbosch F. Selective depletion of macrophages prevents increased plasma interleukin-1 concentrations and pituitary-adrenal activation in response to endotoxin administration in rats. *Endocrinology* **129**: 330-8, 1991.
  111. Rivier C, Vale W. Interaction of corticotropin-releasing factor (CRF) and arginine vasopressin (AVP) on ACTH secretion in vivo. *Endocrinology* **113**: 939-42, 1983.
  112. Katsuura G, Gottschall PE, Dahl RR, Arimura A. Adrenocorticotropin release induced by intracerebroventricular injection of recombinant human interleukin-1 in rats: possible involvement of prostaglandin. *Endocrinology* **122**: 1773-9, 1988.
  113. Sternberg EM, Hill JM, Chrousos GP, Kamilaris T, Listwak SJ, Gold PW, Wilder RL. Inflammatory mediator-induced hypothalamic-pituitary-adrenal activity is defective in streptococcal cell wall arthritis susceptible Lewis rats. *Proc Natl Acad Sci USA* **86**: 2374-8, 1989.
  114. Sternberg EM, Young WS III, Bernadini R, Calogero A, Chrousos GP, Gold PW, Wilder RL. A central nervous system defect in corticotropin biosynthesis is associated with susceptibility to streptococcal cell wall arthritis in Lewis rats. *Proc Natl Acad Sci USA* **86**: 4771-5, 1989.
  115. Patchev VK, Kalogeris KT, Zelazowski P, Wilder RL, Chrousos GP. Increased plasma concentrations, hypothalamic content, and in vitro release of arginine vasopressin in inflammatory disease-prone, hypothalamic corticotropin-releasing hormone-deficient Lewis rats. *Endocrinology* **131**: 1453-7, 1992.
  116. Karalis K, Sano H, Redwine J, Listwak S, Wilder RL, Chrousos GP. Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. *Science* **254**: 421-3, 1991.
  117. Crofford LJ, Sano H, Karalis K, Webster EL, Goldmuntz EA, Chrousos GP, Wilder RL. Local secretion of corticotropin-releasing hormone in the joints of Lewis rats with inflammatory arthritis. *J Clin Invest* **90**: 2555-64, 1992.
  118. Breznicshek HP, Faessler R, Klocker H, Kroemer G, Sgonc R, Dietrich H, Jacober R, Wick G. Analysis of the immune-endocrine feedback loop in the avian system and its alteration in chickens with spontaneous autoimmune thyroiditis. *Eur J Immunol* **20**: 2155-9, 1990.
  119. Mason DW, MacPhee IA, Antoni F. The role of the neuroendocrine system in determining genetic susceptibility to experimental allergic encephalomyelitis in the rat. *Immunology* **70**: 1-5, 1990.
  120. MacPhee IA, Antoni FA, Mason DW. Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids. *J Exp Med* **169**: 431-45, 1989.
  121. Chikanza IC, Petrou P, Kingsley G, Chrousos G, Panayi GS. Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. *Arthritis Rheum* **35**: 1281-8, 1992.
  122. Chikanza IC, Petrou P, Chrousos G, Kingsley G, Panayi GS. Excessive and dysregulated secretion of prolactin in rheumatoid arthritis: immunopathogenetic and therapeutic implications. *Br J Rheumatol* **32**: 445-8, 1993.
  123. Chikanza IC, Panayi GS. Hypothalamic-pituitary mediated modulation of immune function: prolactin as a neuroimmune peptide. *Br J Rheumatol* **30**: 203-7, 1991.

## CHAPTER 2

Treatment of rats with monoclonal anti-CD4 induces long-term resistance to streptococcal cell wall-induced arthritis

*Eur. J. Immunol. 22: 57-61, 1992.*





Maries F. Van den Broek,  
Lex G. M. Van de Langerijt,  
Mieke C. J. Van Bruggen,  
Mike E. J. Billingham\* and  
Wim B. Van den Berg

Department of Rheumatology,  
University Hospital Nijmegen,  
Nijmegen and Connective Tissue  
Disease Research\*, Lilly Research  
Centre Ltd., Windlesham

## Treatment of rats with monoclonal anti-CD4 induces long-term resistance to streptococcal cell wall-induced arthritis

To investigate the role of CD4<sup>+</sup> cells in the induction and maintenance of streptococcal cell wall (SCW)-induced arthritis, Lewis rats were treated with a monoclonal antibody against rat CD4 (W3/25). Injection before onset of the arthritis resulted in resistance to SCW arthritis. Treatment with anti-CD4 during ongoing arthritis induced an amelioration of the arthritis, demonstrating that CD4<sup>+</sup> cells are involved in both the induction and effector phases of the chronic arthritis.

After return of CD4<sup>+</sup> cells to normal levels in the circulation, no arthritis occurred in protected rats, despite the continued presence of SCW in the body. Even reinjection of SCW could not induce arthritis in these rats, suggesting that tolerance to SCW had occurred. In addition, these tolerized rats were refractory to actively induced adjuvant arthritis (AA), but were susceptible to passively transferred AA.

Our data imply, that (a) treatment with anti-CD4 plus SCW induces a long-term resistance to SCW-induced arthritis and adjuvant arthritis, (b) SCW and *M. tuberculosis* may use similar mechanisms of regulation of arthritis and (c) active peripheral suppression is not the mechanism of this nonresponsiveness.

### 1 Introduction

T lymphocytes are considered to have an important role in the pathogenesis of rheumatoid arthritis (RA) and many animal models which resemble various aspects of this human disease. Models for chronic polyarthritis are used, because it is more convenient to study the involvement of T lymphocytes in initiation and maintenance of arthritis this way. For some of these models, e.g. adjuvant arthritis (AA), collagen type II-induced arthritis and streptococcal cell wall (SCW)-induced arthritis, the dependence upon T cells has been shown in studies in nude (athymic) rodents [1, 2] and by transferring the disease to naive recipients with T cell lines [3–6] or clones [7, 8]. Another approach to study the role of T lymphocytes is by *in vivo* depletion using (monoclonal) antibodies directed against cell surface determinants on T cells while attempting to induce arthritis. Experiments have been done using prophylactic protocols in collagen type II-induced arthritis [9], in AA [10, 11] and in murine lupus [12]. Patients with RA are also reported to benefit from treatment with anti-CD4 mAb [13]. In addition, we showed that exacerbations, which may be responsible for chronicity of SCW-induced arthritis are fully dependent on CD4<sup>+</sup> T cells [14]. Here we report the use of mAb against rat CD4 (W3/25) in SCW-induced arthritis. This chronic, erosive polyarthritis is induced in susceptible Lewis rats by one *i.p.* injection of a sterile, aqueous suspension of cell walls from *Streptococcus pyogenes*. Prerequisites for chronic disease are persistence of the poorly biodegradable cell walls [15, 16] and functional

T lymphocytes [1, 2, 14, 17–19] that are specific for SCW. To investigate the involvement of CD4<sup>+</sup> cells in the disease, we depleted CD4<sup>+</sup> cells before onset of arthritis or in established disease. Additionally, we performed long-term studies to elucidate the mechanism of (prolonged) resistance to arthritis.

### 2 Materials and methods

#### 2.1 Rats

Female Lewis rats were originally obtained from the Zentral Institut für Versuchstierzucht (Hannover, FRG) and were bred in our own facilities. Rats weighed 125–150 g at the start of the experiments.

#### 2.2 SCW

*Streptococcus pyogenes* T12 organisms were cultured overnight in Todd-Hewitt broth. Cell walls were prepared as described [1, 20]. The resulting 10 000 × g pellet was used throughout the *in vivo* experiments, while the 100 000 × g pellet was used *in vitro*. These preparations contained 11% muramic acid [21]. Bacteria were kindly provided by Dr. Maarten Hazenberg, Erasmus University, Rotterdam, The Netherlands.

#### 2.3 Induction of SCW arthritis

To induce a chronic polyarthritis, rats were injected *i.p.* with a sterile, aqueous suspension of SCW in a dose of 15 μg muramic acid/gram rat body weight. Arthritis was scored macroscopically by measuring hindpaw thickness with a caliper, and by histology. The increase of paw thickness during the longest experiment (150 days) due to growth of rats never exceeded 1 mm.

[19817]

**Correspondence:** Maries F. Van den Broek, Department of Medical Parasitology, University Hospital Nijmegen, Geert Grooteplein Zuid 24, NL 6525 GA Nijmegen, The Netherlands

**Abbreviations:** SCW: Streptococcal cell wall; AA: Adjuvant arthritis; RA: Rheumatoid arthritis; aBSA: Amidated BSA

## 2.4 Induction of AA

Lewis rats were injected intracutaneously at the base of the tail with 1 mg heat killed *Mycobacterium tuberculosis* organism (H<sup>37</sup>Ra, Difco Laboratories, Inc., Detroit, MI) suspended but not emulsified in oil [22].

## 2.5 Passive transfer of AA

Lewis rats were injected with *M. tuberculosis* suspended in oil in four footpads and at the base of the tail (125 µg/50 µl/injection site). Ten days later draining LN were removed, cells were further purified and activated *in vitro* as described [4]. Cells were collected and  $5 \times 10^6$  cells were injected *iv* into recipient rats.

## 2.6 Treatment of rats with mAb

Rats were injected *ip* with 4 mg mouse mAb at days 0 and 3 or at days 13, 16 and 19 after arthritis induction. The experimental group received W3/25 (mouse IgG<sub>1</sub> anti rat CD4) whereas the control group received BOM22 (mouse IgG<sub>1</sub> anti human CD74, kindly provided by Dr Wil A. Allebes, University Transfusion Service, Transplantation Serology [23]).

## 2.7 Histology of ankle joints

Ankle joints were removed and processed for histology as described [24]. Seven micrometer paraffin sections were made and stained with hematoxylin and eosin.

## 2.8 Immunofluorescence

One million splenic T cells (see above) were incubated with 10 ng/ml W3/25 or with BOM22 (control) in PBS supplemented with 0.1% BSA and 0.01% NaN<sub>3</sub>. After 30 min on ice, cells were washed twice and incubated with 1/50 diluted FITC-goat anti mouse IgG<sub>1</sub> (Nordic, Tilburg, The Netherlands). After 30 min on ice, cells were washed thrice and fluorescence was scored.

## 2.9 DTH reaction

Rats were immunized with amidated BSA (aBSA [25]) emulsified in IFA (100 µg aBSA in each forepaw) and boosted with  $2 \times 100$  µg aBSA/IFA in the flanks 1 week thereafter. At day 15, 10 µg aBSA/10 µl PBS were injected into the pinna of the right ear. After 24 and 48 h, the DTH reaction was measured.

## 3 Results

### 3.1 Effect of treatment with anti-CD4 on development of SCW-induced arthritis

Rats were injected *ip* on days 0 and 3 with 4 mg W3/25 (anti CD4) or BOM22 (control). Due to this treatment <2% W3/25<sup>+</sup> cells were detectable in a suspension of

Table 1. Histological score of SCW induced arthritis<sup>a)</sup>

Treatment of rats		n	No. of ankles with score of				
SCW at day	mAb at day		0	1	2	3	
0	W3/25	0-3	10	0	9	1	0
0	BOM22	0-3	10	0	2	6	2
0	W3/25	13-16-19	10	3	3	4	0
0	BOM22	13-16-19	10	0	5	5	0
0-83	W3/25	0-3	4	4	0	0	0
0-83	BOM22	0-3	4	0	0	1	3

a) Histological score at day 19 after the last SCW injection (*i.e.* day 19 or day 102). Infiltrate and exudate was scored using a scale from 0-3 by two independent observers (MFvdB, MCJB) on coded hematoxylin and eosin stained sections: 0 = no infiltrate/exudate; 3 = large mass of infiltrate/exudate.

splenic T cells at day 4, while at day 19 the percentage of W3/25<sup>+</sup> cells was 59% and 62% in the W3/25 group and the BOM22 group, respectively (immunofluorescence data not shown). An arthritogenic dose of SCW was given on day 0.

Treatment with W3/25 in a prophylactic protocol resulted in virtual absence of SCW induced arthritis (Fig. 1) while the control group followed the normal course of arthritis. This difference was also confirmed by histology (Table 1). To investigate the effect of anti CD4 in the established disease, we injected mAb on days 13, 16 and 19. W3/25 induced a decrease of the paw swelling when compared to the control group ( $p = 0.008$  on day 23 and on day 30, Wilcoxon rank test). However, histological analysis showed

### ARTHRITIS SCORE




Figure 1. Rats were injected with 4 mg mAb (W3/25, anti CD4; BOM22, subclass control) at days 0 and 3. An arthritogenic dose of SCW was given at days 0 and 83. Arthritis score is expressed as the sum of thickness of both hindpaws ( $\times 0.1$  mm). Each group consisted of 12 rats.

little difference between rats treated from day 13 on with W3/25 or with BOM22 (Table 1)

### 3.2 Long-term effect of treatment with anti-CD4 on SCW-induced arthritis

Rats were injected on days 0 and 3 with 4 mg W3/25 or with BOM22 (control) SCW arthritis was induced on day 0 in both groups. Even when the level of W3/25<sup>+</sup> lymphocytes had returned to normal (day 19 and later, data not shown), no arthritis occurred in this group, whereas the stimulus (SCW) was presumably still present in the animals [16, 26]. To determine whether the newly formed CD4<sup>+</sup> cells were refractory to SCW or whether the amount of SCW left in the rats was too low we reinjected rats from both groups with an arthritogenic dose of cell walls (Fig. 1) or with one third thereof (= subarthritogenic dose) on day 83. The W3/25 treated group remained resistant to SCW induced arthritis, whereas the control group developed a polyarthritis upon reinjection with SCW with a "normal" severity but with an accelerated onset (1 day after injection vs the normal onset on day 12). Paw swellings in rats that received one third of the arthritogenic dose of cell walls were similar to those shown in Fig. 1 (data not shown). Thus, rats that had developed an SCW-induced arthritis and subsequently recovered displayed an enhanced susceptibility to a further SCW induced arthritis, both with respect to SCW dose and to day of onset (BOM22-treated group). In contrast, rats that are made resistant to SCW-induced arthritis by depletion of CD4<sup>+</sup> cells plus SCW remained resistant to a further challenge, even after full recovery of CD4<sup>+</sup> cells (W3/25-treated group).

Histological analysis confirmed the macroscopically obtained results (Table 1). Injection with rats with anti-CD4 alone on days 0 and 3 followed by an injection with SCW on day 82 does not lead to resistance to SCW-induced arthritis (mean paw thickness on day 20 after SCW: W3/25 = 169 ± 12, BOM22 = 173 ± 15).

### 3.3 AA in rats with a long-term resistance to SCW-induced arthritis

The above data suggest that injection of anti-CD4 together with an arthritogenic stimulus (SCW) results in a long-lasting resistance to arthritis induced by this stimulus. To investigate whether these rats were also resistant to arthritis induced by another stimulus we induced AA, or we passively transferred AA at day 62 (Fig. 2). The group which received a control mAb and SCW displayed an accelerated onset of arthritis upon *M. tuberculosis* admin-

### ARTHRITIS SCORE




Figure 2 Rats were injected with 4 mg mAb (W3/25 = anti CD4) (●) or BOM22 (subclass control) (▲) at days 0 and 3, and an arthritogenic dose of SCW at day 0. At day 62 (- day 0 in this figure) rats were injected with 1 mg *M. tuberculosis* in oil (AA) (●▲) or with *M. tuberculosis*-specific T cells (passive transfer of AA) (○△). Arthritis score is expressed as the sum of thickness of both hindpaws (× 0.1 mm). Each group consisted of three rats.

istration similar to that seen after reinjection of SCW in this group, thus providing evidence for crosspriming. W3/25 and SCW-treated rats were refractory to AA. This data strongly suggests that despite the fact that AA and SCW induced arthritis were induced by different stimuli, the (auto)antigen which is recognized *in vivo* may be the same. Passively transferred AA, however, is inducible to a comparable extent in "tolerant" (anti-CD4-treated) and "non-tolerant" (BOM22-treated) rats, excluding active suppression of arthritogenic cells in the periphery as the mechanism of this tolerance. Proliferative responses against SCW, *M. tuberculosis* or the 65-kDa heat-shock protein were present in the BOM22-treated group (stimulation induces 25, 14 and 10, respectively), but absent in the anti-CD4-treated group (stimulation induces 5, 2 and 2, respectively), stressing the relation between arthritis and specific T cell responses.

### 3.4 Specificity of SCW plus anti-CD4-induced tolerance

To investigate whether the observed immunological non-responsiveness was for bacterial (arthritogenic) antigens only, we immunized rats, which received mAb at days 0 and

Table 2 Influence of treatment with SCW and W3/25 or BOM22 on the induction of DTH reactions in the ear<sup>a)</sup>

Treatment		aBSA priming	DTH <sup>b)</sup>		a) The values represent the mean ± SD from groups of four rats b) A DTH reaction was elicited by injection of 10 µg aBSA in the right ear of rats. The left ear was injected with PBS c) Values are obtained by dividing the measured ear thickness of the right (R) by the left (L)
SCW	mAb		R/L ratio of ear thickness <sup>c)</sup>	24 h	
Day 0	W3/25, Days 0 and 3	Day 80	1.51 ± 0.03	1.61 ± 0.02	
Day 0	BOM21, Days 0 and 3	Day 80	1.53 ± 0.02	1.54 ± 0.02	
-	-	-	1.02 ± 0.01	1.01 ± 0.02	

3 and SCW at day 0 at day 80 with aBSA and tested for cell mediated immunity *in vivo* 15 days after immunization. The response to aBSA as measured by a DTH reaction was similar in rats which were injected with SCW plus anti CD4 (tolerant) and in rats injected with BOM22 plus SCW (responsive) (Table 2) suggesting that the nonresponsiveness resulting in resistance to SCW arthritis and AA is not a nonspecific phenomenon.

#### 4 Discussion

There is considerable evidence suggesting a role for T lymphocytes in the pathogenesis of polyarthritis induced by SCW or mycobacteria in oil (AA) in the rat [1-5, 7, 14, 17, 18, 27]. Furthermore, the induction of resistance to bacterium induced arthritis by low dose tolerance due to administration of the 65 kDa bacterial common antigen (heat shock protein) [18, 28] or cell wall preparations (unpublished observations) stress the importance of (specific) T cells. For AA use of anti CD4 antibodies has demonstrated the dependence of the model on CD4<sup>+</sup> cells [11].

Here we present evidence that CD4<sup>+</sup> cells (predominantly T<sub>H</sub> lymphocytes) are essential for the induction of SCW induced arthritis and are highly involved in the effector phase. In CD4<sup>-</sup> depleted rats SCW induced arthritis was not inducible. Treatment which started in an ongoing arthritis (day 13) induced a significant remission. Interestingly, in rats treated in a prophylactic protocol no arthritis occurred after day 19 whereas at that timepoint CD4<sup>+</sup> cells had returned to normal level and a large amount of SCW was still present in tissues and circulation [15, 16, 26, 29, 30]. One explanation might be the possibility that SCW were unaccessible for the immune system (due to sequestering in phagocytes for instance). Consequently rats were re-injected with an arthritogenic dose of SCW or with one third thereof (nonarthritogenic in naive Lewis rats) at day 83. The subclass control group developed an arthritis with an accelerated onset and a severity comparable to the first SCW induced arthritis. In addition, the arthritogenic and the subarthritogenic dose of SCW induced a similar arthritis. Thus, a previous SCW induced arthritis primes for a subsequent SCW induced arthritis rather than protects which is the case with AA [28]. Rats which received anti CD4 mAb together with SCW however were completely resistant to further attempts to induce SCW arthritis, suggesting a state of tolerance to SCW. This is similar to the situation in AA [11] where anti CD4 treatment plus mycobacteria both prevented the induction of arthritis and rendered the rats resistant to renewed induction of the disease.

To investigate the mechanism of this tolerance, we induced AA and we passively transferred AA 62 days after injection with SCW and mAb. Subclass control treated rats developed both the active and the passive AA, with the former displaying an accelerated onset. Anti CD4 treated rats were resistant to active AA, but developed the passively transferred form. Thus, the state of tolerance is not maintained by active peripheral suppression, but by a mechanism which acts earlier in T cell development (possibly in the thymus).

That pretreatment with anti CD4 at the time of priming with SCW induces resistance to SCW arthritis and AA, and at the time of priming with *M. tuberculosis* induces resistance to AA and to arthritis induced by the non antigenic synthetic adjuvant CP20961 [31] (unpublished observations) suggests that in all three models the same (auto)antigens are involved.

The mechanism by which anti CD4 together with SCW induces specific nonresponsiveness may be similar to tolerance induction to human gamma globulin (HGG) in mice [32]. Administration of HGG together with anti I 3T4 induced a state of HGG specific tolerance which did not involve CD8<sup>+</sup> cells. This may be explained as follows [33-35]: T cells that are stimulated by antigen (signal 1) only become responsive if they also receive signal 2; otherwise they are tolerized. Signal 2 can consist of a signal provided by the APC as a result of cross linking events of surface receptors. Removal of CD4<sup>+</sup> cells or functional blocking of CD4 may result in a weaker contact between MHC antigen complex on the APC and the TcR/CD4 complex on the T cell, thus interfering with the second signal [32, 36]. For this tolerance to be everlasting, the tolerogen has to be present continuously [32]. In this context one can imagine that the presence of certain (auto)antigens which are relevant for arthritis may be auxiliary in the maintenance of tolerance.

Considering the Lewis rat and its enhanced susceptibility to autoimmune diseases in general, and more specifically to bacterium/adjuvant induced arthritides, it is possible that in Lewis rats the natural state of tolerance to autoantigens is a delicate balance which is more easily disturbed than in other rat strains. When the immune system of Lewis rats is strongly stimulated with bacterial and synthetic adjuvants, this state of tolerance can be broken. Control of the already existing autoreactive repertoire is lost and chronic polyarthritis results. The specificity of the existing, but normally controlled, repertoire may determine the organ specificity of the disease. When rats are treated with anti CD4 at the same time that tolerance is broken, the cells to be activated miss a second signal and become tolerant as long as the stimulus remains present. If the stimulus is an autoantigen, breaking of tolerance by nonspecific mechanisms together with anti CD4 may induce permanent protection in individuals susceptible to autoreactivity.

*We thank Wil Allicbes (Universitair Transfusie Service, Nijmegen) for providing BOM22, Caroline Hicks (Lilly Research Centre Ltd, Windlesham, GB) for W3/25 and Maarten Haasbergen (Department of Immunology, Erasmus University Rotterdam) for culturing *S. pyogenes* organisms. In addition we thank Piet Spaan (Central Animal Laboratory) for animal care.*

Received July 31 1990; in revised form September 14 1991.

#### 5 References

- 1 Cromarty W J, Craddock J G, Schwab J G, Anderle S K and Kang C. *J Exp Med* 1977; 146: 1585.
- 2 Ridge S C, Zabriskie J B, Oronsky A L and Kerwar S S. *Cell Immunol* 1985; 96: 231.
- 3 Pearson C M and Wood F D. *J Exp Med* 1964; 120: 547.

- 4 Taugros, J D, Sandberg, G P and Mahowald, M L, *Cell Immunol* 1983 75 271
- 5 DeJoy S Q, Ferguson K M, Sapp, T M, Zabriskie, J B, Oronsky A L and Kerwar S S, *J Exp Med* 1989 170 369
- 6 Trentham D E, Dynesius, R A and David, J R, *J Clin Invest* 1978 62 359
- 7 Van Eden W, Holoshitz, J, Nevo, Z, Frenkel, A, Klajman, A and Cohen, I R, *Proc Natl Acad Sci USA* 1985 82: 5117
- 8 Holmdahl, R, Klareskog, L, Rubin, K, Larsson, E and Wigzell, H *Scand J Immunol* 1985 22 295
- 9 Ranges, G E, Sriram, S and Cooper, S M *J Exp Med* 1985 162 1105
- 10 Larsson P, Holmdahl R, Dencker, L and Klareskog, L, *Immunology* 1985 56 383
- 11 Billingham, M E J, Hicks C and Carney, S, *Agents Actions* 1990 29 77
- 12 Wofsy, D, Ledbetter J A, Hendler, P L and Seaman, W E, *J Immunol* 1985 134 852
- 13 Herzog, C, Walker C, Pichler, W, Aeschlimann, A, Wassmer, P, Stockinger, H, Knapp, W, Rieber, P and Muller, W, *Lancet* 1987 ii 1461
- 14 Van den Broek M F, Van Bruggen, M C J, Stimpson, S A, Severijnen A J, Van de Putte, L and Van den Berg, W B *Clin Exp Immunol* 1990 79 297
- 15 Janusz M J, Chetty, C, Eisenberg, R A, Cromartie, W J and Schwab, J H, *J Exp Med* 1984 160 1360
- 16 Wilder R L, Allen, J B, Wahl, L M, Calandra, G B and Wahl, S M, *Arthritis Rheum* 1983 26 1442
- 17 Van den Broek M F, Van Bruggen, M C J, Van den Berg W B and Van de Putte, L, *Cell Immunol* 1988 116 216
- 18 Van den Broek, M F, Hogervorst E J M, Van Bruggen, M C J, Van Eden W, Van der Zee, R and Van den Berg W B, *J Exp Med* 1989 170 449
- 19 Wilder R L, Allen J B and Hansen, C T, *J Clin Invest* 1987 79 1160
- 20 Fox, A, Brown, R R, Anderle S K, Chetty, C, Cromartie, W J, Groder, H and Schwab, J H, *Infect Immun* 1982 35 1003
- 21 Hadzys, O, *Anal Biochem* 1974 60 512
- 22 Pearson, C M, *Proc Soc Exp Biol Med* 1956 112 95
- 23 Allebes, W A, Knops, R, Bontrop, R E, Otting, N, Raemakers, J, Haanen, C and Capel P J A, *Scand J Immunol* 1990 32 441
- 24 Van den Berg, W B, Van Beusekom, H J, Van de Putte, L, Zwarts, W A and Van der Sluis, M, *Am J Pathol* 1982 108 9
- 25 Danon, D, Goldstein L, Mankovsky, Y, Skutelsky, E, *J Ultrastruct Res* 1972 38 500
- 26 Eisenberg, R, Fox, A, Greenblatt J J, Anderle, S K, Cromartie W J and Schwab, J H, *Infect Immun* 1982 38 127
- 27 Van den Broek, M F, *APMIS* 1989 97 861
- 28 Van Eden, W, Thole, J E R, Van der Zee, R, Van Embden, J D A, Hensen, E and Cohen, I R, *Nature* 1988 331 171
- 29 Anderle, S K, Allen, J B, Wilder, R L, Eisenberg, R A, Cromartie, W J and Schwab, J H, *Infect Immun* 1985 49 836
- 30 Allen, J B, Malone, D G, Wahl, S M, Calandra, G B and Wilder R L, *J Clin Invest* 1985 76 1042
- 31 Chang Y, Pearson, C M and Abe, C, *Arthritis Rheum* 1980 23 62
- 32 Benjamin, R J, Qin, S, Wise, M P, Cobbold S P and Waldmann, H, *Eur J Immunol* 1988 18 1079
- 33 Jenkins M K, Pardoll, D M, Mizuguchi, J, Quill H and Schwartz, R H, *Immunol Rev* 1987 95 113
- 34 Lamb, J R, Feldmann M, *Nature* 1984 308 72
- 35 Bretscher, P and Cohn, M, *Science* 1970 169 1042
- 36 Dialynas D P, Wilde D P, Marrack, P, Pierres A, Wall, K A, Harvan, W, Otten, G, Loken, M R, Picrcres, M, Kappler J and Fitch, F W, *Immunol Rev* 1983 74 29



## CHAPTER 3

Cross-reactivity to proteoglycans in bacterial arthritis: lack of evidence for in vivo role in induction of disease

*Clin. Immunol. Immunopathol* 71: 273-280, 1994.





## Cross-Reactivity to Proteoglycans in Bacterial Arthritis: Lack of Evidence for *in Vivo* Role in Induction of Disease

A G M VAN DE LANGERIJT, A E KINGSTON,\* P L E M VAN LENT, M E J BILLINGHAM,\* AND  
W B VAN DEN BERG

Department of Rheumatology University Hospital Nymegen P O Box 9101 6500 HB Nymegen The Netherlands and \*Connective Tissue Disease Research Lilly Research Centre Windlesham Surrey United Kingdom

Cross-reactivity between bacterial epitopes and cartilage components has been assumed to play a role in the pathology of bacterial-induced arthritis models. In this study, we report prominent proteoglycan (PG) depletion in Safranin-O stained ankle joint sections from collagen-induced arthritic rats. In adjuvant arthritis and streptococcal cell wall-induced arthritis (SCW-A), however, only limited PG degradation was observed. *In vitro*, PG fractions were able to stimulate T lymphocytes from these arthritic rats. To investigate the contribution of cross-reactivity, Lewis rats were primed with SCW in Freund's incomplete adjuvant (SCW/FIA). This immunization protocol resulted in *in vitro* stimulatory responses to the SCW antigens and cartilage PG antigens, but not to joint inflammation *per se*. Next, papain was injected intraarticularly to create a situation in which a large amount of potential cross-reactive cartilage epitopes are released. Interestingly, no inflammatory reaction could be observed in the papain-injected joints of SCW/FIA-primed rats.

These data suggest that cross-reactivity between bacterial epitopes and PG does not seem to be a key element in the onset of joint inflammation in bacterial-induced arthritis. However, it cannot be ruled out that at later time points cross-reactivity will contribute to joint inflammation. © 1994 Academic Press, Inc.

### INTRODUCTION

Chronic polyarthritis can be induced in susceptible rat strains by either structures of the joint itself, like collagen type II (1), or by bacteria. Two well-studied bacterial models are the adjuvant arthritis (AA), induced by an intradermal immunization of heat-killed mycobacteria suspended in Freund's incomplete adjuvant (FIA) (2), and the streptococcal cell wall-induced arthritis (SCW-A), which can be induced by a single intraperitoneal injection of a sterile, aqueous suspension of SCW (3). For AA and SCW-A, both polymorph and mononuclear phagocytic cells (3, 4) as well as T lymphocytes (5-7) play an important role in the development and maintenance of disease. In addition, we showed that the susceptibility to SCW-A in the Lewis

and F344 strains appears to be correlated with the ability to mount a marked T cell response against SCW material (8).

However, the exact pathogenesis of these bacterial-induced arthritis models is still unknown. Several *in vitro* studies suggest that cross-reactivity between bacterial epitopes and cartilage may play a role in disease development (9-11). In addition to this, it is possible to induce arthritis in BALB/c mice by immunization with human fetal PG (12).

Interestingly, *in vivo* studies which do indicate that cross-reactivity may play an active part in disease development are very limited. In this respect, two studies reported modulatory effects with PG fractions (11, 13). However, whether these observed effects may also support that cross-reactivity is the initiating factor leading to disease development remains to be elucidated (14).

Therefore, we performed this *in vivo* study to examine the relevance of *in vitro* cross-reactive responses against cartilage PG in the pathogenesis of bacterial arthritis. First, we investigated by histological analysis of Safranin-O stained total knee joint sections, whether cartilage of the inflamed ankle joints was depleted of PG at different time points after arthritis induction. Compared to the collagen-induced arthritis (CIA) only limited damage was found in the bacterial models, which is not compatible with a strong autoimmune component. Moreover, we looked *in vitro* whether we were able to detect any stimulatory effects by PG fractions in lymphocytes from AA and SCW-A rats.

Finally, we performed experiments in which the cysteine protease papain was injected intraarticularly in SCW/FIA-primed rats (instead of intraperitoneal model). Injection of papain resulted in a marked depletion of PG within 24 hr, thus providing high levels of potential cross-reactive PG epitopes to initiate inflammation. However, signs of persisting inflammation were absent.

Our data show that it is unlikely that the observed cross-reactive T cell responses between bacterial epitopes and PG are important mechanisms leading to

joint inflammation in SCW-bacterial arthritis. However, whether these cross-reactive responses become more important during the chronic phase of the arthritis cannot be ruled out.

## MATERIALS AND METHODS

### Rats

Female Lewis rats were originally obtained from the Zentral Institute for Versuchstierzucht (Hannover, Germany) and were bred in our own facilities. The rats weighed between 140 and 170 g at the beginning of each experiment and were fed standard food and tap water *ad libitum*.

### Induction of Arthritis

AA was induced by an intradermal injection at the base of the tail with 100  $\mu$ l of 10 mg/ml mycobacterium tuberculosis (Mtb) (H37RA, Difco Laboratories, Inc., Detroit, MI) suspended in FIA (Difco Laboratories). Before injection the Mtb was finely ground in a pestle and mortar and suspended evenly in FIA.

SCW-A was induced by an intraperitoneal (ip) injection of a sterile, aqueous suspension of SCW in a dose of 10  $\mu$ g muramic acid/g rat body wt. In order to obtain this SCW material, *Streptococcus pyogenes* T12 organisms were cultured overnight in Todd-Hewitt broth. Bacteria were kindly provided by Dr H Verheul (Organon International, Oss, The Netherlands). After mechanical disruption (Braun MSK Cell homogenizer), the material was treated with RNase, DNase, and trypsin as described (3). Cell walls were further isolated by differential centrifugation steps as described (15), and the resulting 10,000g pellet was used throughout the *in vivo* experiments, while the 100,000g pellet was used *in vitro*. The 10,000g preparation contained 15% muramic acid (16).

Type II CIA was induced by an intradermal injection into the tail base of 2 mg of native bovine nasal septum type II collagen. The type II collagen was prepared by standard procedures (17) and was prepared for injection at a concentration of 20 mg/ml in a 50/50 emulsion of 0.1 M acetic acid and FIA.

### Priming of Rats

Female Lewis rats were primed in both forepaws by a subcutaneous injection of arthritogenic SCW fragments or ovalbumin (Sigma Chemical Co., St Louis, MO) emulsified in FIA (100  $\mu$ l per injection site). The respective doses of antigen were 1 mg/ml muramic acid or 1 mg/ml ovalbumin. Ten days later, animals received a subcutaneous booster of 100  $\mu$ l at each side.

### T Cell Proliferation Assay

In the arthritis experiments popliteal lymph node were removed aseptically 10 days after arthritis induction.

After a single cell suspension was made the leukocytes were washed twice with RPMI (Flow Labs Inc., McLean, USA). Adherent cells were removed by incubating the cells in a plastic culture flask (Costar) in RPMI containing 10% fetal calf serum (FCS) at a cell density of  $5 \times 10^6$ /ml. After 1 hr in a CO<sub>2</sub> incubator nonadherent cells were aspirated and pooled per group. Next the cells were put into culture with a final density of  $1 \times 10^6$ /ml in 0.2-ml vol of RPMI + 10% FCS + 10 mM pyruvate + 20 mM glutamine + 5  $\mu$ M  $\beta$ -mercaptoethanol + 40  $\mu$ g/ml gentamycin. Cells were cultured in 96-well round-bottom plates (Costar) for 3 days with variable concentrations of different cartilage components, bacterial antigens (100,000g pellet of SCW or Mtb), or control stimuli. Subsequently, 37 kBq [<sup>3</sup>H]thymidine was added per well and cells were harvested 18 hr later. All cultures were done in triplicate and pools of popliteal lymph nodes of three different animals were always used.

### Stimuli for T Cell Proliferation *in Vitro*

The PG subfractions were prepared as described earlier (18, 19).

Peptidoglycans were prepared from arthritogenic SCW material using a formamide extraction. Briefly, 400 mg lyophilized SCW peptidoglycan-polysaccharides was added to 100 ml formamide (J T Baker, Deventer, The Netherlands) and heated at approximately 170°C for 1 hr (20, 21). The mixture was then centrifuged at 30,000g for 30 min to pellet the peptidoglycan fraction. This formamide extraction was repeated four times. After the final extraction the peptidoglycan was washed three times with 0.9% NaCl, dialysed against distilled water, and finally lyophilized. Peptidoglycan fractions always contained less than 2% rhamnose by weight as determined by the method of Z Dische (22).

The cesium chloride (CsCl) top fraction (protein-rich fraction of bovine cartilage PG) was kindly provided by Dr R Kuijer (Department of Orthopedics, Maastricht). Briefly, proteoglycans were separated in collagen type II and PG by guanidinium chloride extraction (23). The non-CII was further separated by density centrifugation (1.47 g/ml CsCl, 108,000g, 10°C, 50 hr) in a protein-rich (top) and a PG-rich (bottom) fraction.

Con A (Flow Labs Inc.) was used as a positive control.

### *In Vivo* Cartilage PG Depletion

Cartilage PG depletion of knee and ankle joint in SCW-primed rats was induced by intraarticular (ia) injection of 1% papain (Merck, Darmstadt, Germany) in 10  $\mu$ l phosphate-buffered saline (PBS) into the right knee and ankle joint of each animal. As a control, an equal volume of PBS was injected into the left knee and ankle joint.

### Measurement of Unilateral Joint Inflammation

The level of joint inflammation was measured by the  $^{99m}\text{Tc}$  uptake method (24). Briefly, rats were anesthetized with pentobarbital (300 mg/kg) and 0.2 ml (7.4 MBq/ml)  $^{99m}\text{Tc}$  was administered subcutaneously. After 30 min the  $^{99m}\text{Tc}$  uptake in the right and the left knee and ankle joint was measured by external gamma counting. The uptake of this small radioisotope is a measure for local blood flow and edema. The severity of inflammation is expressed as right over left ratios and all values exceeding 1.1 were assigned as inflammation. Joint inflammation was also scored histologically, as described below.

### Histology

Knee and ankle joints were removed *in toto* and processed for histology as described (25). Seven-micromolar sections were stained with either hematoxylin and eosin (H&E) to determine the level of inflammation or with Safranin-O which stains glycosaminoglycans; diminished staining would therefore represent PG depletion. Scoring of inflammation and PG depletion was done by two independent observers.

## RESULTS

### Cartilage Destruction in Bacterial Arthritis Models

In order to examine the occurrence of cartilage PG depletion in bacterial arthritis, Safranin-O stained sections of ankle joints were analyzed at various phases of AA and SCW-A. At least four animals per time point were sacrificed and both ankle joints were examined for PG depletion.

AA developed in all Lewis rats with an onset around Day 13. Sections taken at Day 17 revealed massive inflammation in the synovial tissue, but hardly any detectable loss of proteoglycans in the cartilage layers. In fact, the cartilage of the talus and tibia appeared normal and minimal signs of depletion were noted at the margins underneath developing pannus tissue (Fig. 1a). At later time points (Days 28 and 34) extensive bone marrow inflammation and bone erosion was found, but the cartilage of the talus and tibia remained unaffected (Fig. 1b). Distinct cartilage PG depletion was regularly noted in a restricted, central area between the tarsal bones, showing outgrowth of granulation-like tissue (Fig. 1c).

In the SCW-A model all Lewis rats developed a chronic arthritis, with a gradual onset in the ankle joints around Day 5. Sections taken at Days 7 and 10 showed a remarkable absence of cartilage PG loss, comparable to the observations in AA (Fig. 1d). At later time points (Day 17) the degree of inflammation varied considerably, but even in severe cases cartilage PG depletion was restricted to the central area of the

tarsal bones and the margins underlying pannus overgrowth.

For comparison, similar sections were taken from ankle joints of Lewis rats with collagen arthritis. In our hands, 75% of the animals developed an arthritis around Day 16 and these positive rats were further examined at Days 23 and 30. Cartilage PG depletion was clearly present in large parts of the cartilage, including the talus and tibia, and destruction was more marked at Day 30. Consistent with an autoimmune attack at the collagen type II-containing cartilage, even complete loss of the undecalcified cartilage layer was often found (Fig. 1e).

### T Cell Response to Cartilage PG

To test whether any cross-reactive responses against cartilage were present in AA and SCW-A, a lymphocyte proliferation assay was performed on the popliteal lymph nodes 10 days after arthritis induction. A summary of the *in vitro* stimulatory effects for the various antigens is shown in Table 1. T cells from AA rats displayed a clear response to the bacterial antigen Mtb and a significant response to the PG fractions.

Regarding the T cells from SCW-A rats, only a low but significant response was observed against the injected antigen. Interestingly, the T cells responded better to the peptidoglycan than to the SCW material, suggesting that the main T cell epitopes of SCW are on the protein-rich fraction and not on the polysaccharide part of SCW. Furthermore, we were able to detect significant responses against the chondrosarcoma extract and link protein and an additional reactivity to the PG binding region.

### Joint Inflammation Due to Cross-reactive Immunity

To prime for cross-reactive responses Lewis rats were immunized with emulsified SCW/FIA, a protocol which does not lead to arthritis development. The level of immunity in either the SCW/FIA or the control group (OVA/FIA) was tested in a lymphocyte proliferation assay. Both groups of animals showed high responses against the antigen to which they were immunized and only low responses to the control antigen. In addition, the SCW-primed T cells did show a significant response against the protein-rich fraction of bovine cartilage PG (Table 2).

To examine the potential contribution of this cross-reactivity to arthritis, papan was injected at Day 27 in right knee and ankle joints to release cartilage PG epitopes. Three days later, the level of inflammation was determined by the  $^{99m}\text{Tc}$  uptake method. No swelling or edema could be detected in either group. The histology (H&E-stained sections) did confirm the  $^{99m}\text{Tc}$  uptake data, since almost no inflammatory cells could be observed in both ankle and knee joints (Table 3). In addition, sections were stained with Safranin-O to ver-




FIG. 1. Light microscopic analysis of cartilage PG depletion in Safranin O stained ankle joints in different arthritis models. (a) Adjuvant arthritis, Day 17. (b, c) Adjuvant arthritis, Day 28. (d) SCW-A, Day 17. (e) Type II collagen-induced arthritis, Day 23. (f) Negative control. JS, joint space; TL, talus; TS, tarsus; TB, tibia; C, cartilage.

ify whether the cartilage was depleted of PG due to the papain injections. In all Safranin-O stained sections of the right joints marked depletion of PG was observed.

#### DISCUSSION

Several *in vitro* studies do indicate that cross-reactivity between bacterial epitopes and cartilage may play a role (9–11); however, *in vivo* studies which support this hypothesis are very limited (11, 13). Therefore, we performed this *in vivo* study in both AA and SCW-A.

Histological analysis using Safranin-O stained sections showed only minimal PG depletion in both AA and SCW-A. The observation that some depletion was present in the areas of invading pannus are in agreement with an earlier report in AA (26). However, the finding that the cartilage of the talus and tibia was not depleted of PG at all has not been reported so far. To our knowledge only one other study investigated the cartilage of the talus in AA-treated rats by electron microscopy. In that study, it was shown that the proteinaceous outer-surface layer of the cartilage was disrupted (27), but whether the cartilage was depleted of PG was not investigated. Regarding the SCW-A, it also has been reported that extensive cartilage destruction does occur (28). However, major destruction was ob-

served at later stages (Day 42), while only minimal destruction was observed at earlier time points.

As suspected, CIA showed prominent PG depletion and this was observed early on and throughout the entire ankle joint. These data do support earlier studies with H&E sections, which found that large parts of the cartilage became markedly eroded during the arthritis (1, 29). A likely explanation for this extensive PG depletion may be that in CIA, not only T cells play an important role (30), but also anti-CII MoAbs. These immunoglobulins attach to the cartilage surface and direct the inflammatory process toward this tissue. Of interest, CIA can be transferred with these MoAbs (31). Extensive cartilage destruction is also reported in the PG arthritis (32).

To conclude, our results of limited PG degradation during AA and SCW-A development do not fully support the hypothesis that arthritis may be initiated by structural mimicry between bacterial epitopes and cartilage.

The results of the *in vitro* study demonstrate that during induction of AA or SCW there is a recognition of PG components. The proliferative responses of the arthritic lymphocytes to the binding region were better in comparison to the whole chondrosarcoma extract. Regarding the T cells from SCW/FIA-primed mice and




FIG. 1—Continued

TABLE 1

Proliferative Response of Lymph Node Cells 10 Days after Induction of AA or SCW-A

Stimulus	Concentration	Stimulation index	
		AA	SCW-A
M tb.	30 µg/ml	8	—
SCW	30 µg/ml	—	2.3
Peptidoglycan	100 µg/ml	2.3	4
Link protein	1:10	1.3	2.2
Binding region	1:10	1.9	3.5
Chondrosarcoma	1:50	1.3	2.5
Ovalbumine	30 µg/ml	<1	<1
Con A	0.6 µg/ml	44	53
Control cpm		7436	6076

Note. Proliferation was measured by [<sup>3</sup>H]thymidine incorporation during the last 18 hr of a 96-hr culture with various bacterial and PG stimuli. Proliferative responses are expressed as stimulation indices (amount of radioactivity incorporated due to stimulus X divided by that due to medium alone). The values represent the mean of triplicate cultures and the variation was always <10%. Lymph nodes from three animals per group were pooled. Experiment shown represents one out of two experiments.

T cells from AA rats, this has already been reported (10, 11), but in the SCW-A model in the Lewis rat this is the first report which shows cross-reactive responses against PG fractions. Some of the responses in AA were only minimal, but it cannot be ruled out that other components, such as keratan sulphate, chondroitin sulphate, or core protein, may induce higher responses (11). Furthermore, our data also indicate that intact native PG is antigenic, but PG subfractions are even more antigenic, which may suggest that degradation of PG during disease progression can expose sequestered or cryptic epitopes which are even more antigenic. The higher responses against peptidoglycans in the SCW-A may be explained by the fact that the degradation-resistant polysaccharide groups mask the antigenic de-

TABLE 2

Proliferative Response of Lymph Node Cells 23 Days after Immunization and Booster with SCW/FIA or OVA/FIA

Stimulus	µg/ml	Stimulation index	
		SCW/FIA	OVA/FIA
SCW	6	29	3
OVA	30	2	8
CsCl top	30	6	2
Con A	0.6	168	62
Control cpm		901	1648

Note. Values represent the mean incorporation of [<sup>3</sup>H]thymidine given as a stimulation index (amount of radioactivity incorporated due to stimulus X divided by that due to medium alone). Lymph nodes from two animals per group were pooled and the values represent the mean of triplicate cultures. Results shown represent one out of three experiments. Various stimuli are used; SCW, streptococcal cell walls, OVA, ovalbumin, CsCl top, protein-rich fraction of bovine cartilage proteoglycan, Con A, concanavalin A.

TABLE 3

Effect of 1α Injection of 1% Papain in Both Right Knee and Ankle Joint 30 Days after Immunization with SCW/FIA or OVA/FIA

Immunization	R/L ratio of <sup>99m</sup> Tc uptake		Histological scores	
	Knee joint	Ankle joint	Right knee	Right ankle
SCW/FIA	1.1 ± 0.08	1.06 ± 0.09	0.4 ± 0.3	0.2 ± 0.1
OVA/FIA	1.08 ± 0.1	1.07 ± 0.07	0.3 ± 0.2	0.2 ± 0.1

Note. R/L ratios of <sup>99m</sup>Tc uptake 3 days after intraarticular injection of 1% papain in SCW/FIA or OVA/FIA immunized animals. Values represent the mean ± SD from groups of eight animals. After the <sup>99m</sup>Tc uptake assay the joints were removed and the sections stained with hematoxylin and eosin. Inflammation was scored on coded slides, using a scale from 0 to 3 by two independent observers: 0, no inflammation; 3, large mass of inflammation.

terminants on the peptidoglycans. It also suggests that peptidoglycans contain most, if not all, T cell epitopes for SCW-primed T cells. That peptidoglycans are not capable of inducing chronic arthritis is due to lack of persistence. In this respect, the polysaccharide is of importance, since it protects the peptidoglycan from being rapidly degraded (14).

To investigate the relevance of the *in vitro* cross-reactive responses in pathology, Lewis rats were immunized with SCW/FIA. Depletion of PG by an intraarticular injection of papain did not lead to joint inflammation. These data suggest that SCW-specific T cell responses, which *in vitro* cross-react with the protein-rich subfraction of PG, are not able to initiate an inflammation in our experimental circumstances. Together with the histological findings in AA and SCW-A, this indicates that it is unlikely that cross-reactivity to PG fragments is the initiating factor leading to joint inflammation in these models.

Several data do support the latter conclusion. First of all, it has been found in the SCW-A that a clear correlation exists between SCW dissemination and persistence in the joint and chronicity. Treatment with mutanolysin resulted in a decline of the chronic phase of arthritis (33). Mutanolysin degrades cell walls to small fragments, which show poor persistence in the joint and limited arthritogenicity. In this respect SCW-A differs from AA. Furthermore, attempts to induce arthritis with subfractions of PG alone showed that these were never arthritogenic by itself (11). The finding that arthritis can be induced with human fetal PG (12) suggests that fetal PG are different in comparison to mature PG and that other epitopes are involved in PG and bacterial arthritis.

All together, we suggest that cross-reactive responses to PG fragments, which are present during the onset of disease, are not playing a pivotal role in the induction of arthritis. However, since arthritis can be modulated with PG fragments (11, 13), it appears that these cross-reactive responses are under control of similar regulatory mechanisms (34). An identical conclusion can be hypothesized from the 65-kDa experiments.

These data show that both AA and SCW-A can be modulated with 65 kDa (35, 36), and that responses against 65 kDa can be detected in animals with a bacterial-induced arthritis, but 65 kDa by itself is not arthritogenic (37). These results also indicate that responses against 65 kDa are not involved in the actual pathogenesis of bacterial arthritis, but probably act on regulatory mechanisms.

It is important to realize that our study, aimed at the release of cross-reactive PG epitopes, was performed with papain and it cannot be excluded that endogenous enzymes like cathepsins or metalloproteinases may release other, more relevant epitopes. Studies are now in progress to address this issue.

In conclusion, our results imply that during the onset of disease, the observed *in vitro* cross-reactivity between bacterial epitopes and PG may not be the initiating factor leading to joint inflammation. However, whether these cross-reactive responses may contribute to disease progression instead of disease induction remains a matter of debate.

## REFERENCES

- Trentham, D. E., Townes, A. S., and Kang, A. H., Autoimmunity to type II collagen. An experimental model of arthritis. *J Exp Med* 77, 857-868, 1977.
- Pearson, C. M., Development of arthritis, periarthritis and periostitis in rats given adjuvants. *Proc Soc Exp Biol Med* 91, 95-101, 1956.
- Cromartie, W. J., Craddock, J. G., Schwab, J. H., Anderle, S. K., and Yang, C., Arthritis in rats after systemic injection of streptococcal cells or cell walls. *J Exp Med* 146, 1585-1602, 1977.
- Pearson, C. M., and Wood, F. D., Studies of polyarthritis and other lesions induced in rats by injections of mycobacterial adjuvant 1. General clinical and pathologic characteristics and some modifying factors. *Arthritis Rheum* 2, 440-459, 1959.
- Taugrog, J. D., Sandberg, G. P., and Mahowald, M. L., The cellular basis of adjuvant arthritis. I. Enhancement of cell mediated passive transfer by concanavalin A and by immunosuppressive pretreatment of the recipient. *Cell Immunol* 75, 271-282, 1983.
- Dejoy, S. Q., Ferguson, K. M., Sapp, T. M., Zabriskie, J. B., Oronsky, A. L., and Kerwar, S. S., Streptococcal cell wall arthritis. Passive transfer of disease with a T cell line and cross-reactivity of streptococcal cell wall antigens with mycobacterium tuberculosis. *J Exp Med* 170, 369-382, 1989.
- Holoshitz, J., Matthiau, A., and Cohen, I. R., Arthritis induced in rats by cloned T lymphocytes responsive to mycobacteria but not to collagen type II. *J Clin Invest* 73, 211-215, 1984.
- van den Broek, M. F., van Bruggen, M. C. J., van de Putte, L. B. A., and van den Berg, W. B., T cell responses to streptococcal antigens in rats. Relation to susceptibility to streptococcal cell wall induced arthritis. *Cell Immunol* 116, 216-229, 1988.
- van Eden, W., Holoshitz, J., Nevo, Z., Frenkel, A., Klayman, A., and Cohen, I. R., Arthritis induced by a T lymphocyte clone that responds to mycobacterium tuberculosis and to cartilage proteoglycans. *Proc Natl Acad Sci USA* 82, 5117-5120, 1985.
- van den Broek, M. F., van den Berg, W. B., Arntz, O. J., and van de Putte, L. B. A., Reaction of bacterium primed murine T cells to cartilage components. A clue for the pathogenesis of arthritis? *Clin Exp Immunol* 72, 9-14, 1988.
- Kingston, A. E., Carney, S. L., Hicks, C. A., and Billingham, M. E. J., *In vitro* and *in vivo* effects of proteoglycan fractions in adjuvant treated rats. *Agents Actions* 39, 75-79, 1993.
- Mikecz, K., Glant, T. T., Buzas, E., and Poole, A. R., Proteoglycan-induced polyarthritis and spondylitis adoptively transferred to naive (nonimmunized) BALB/c mice. *Arthritis Rheum* 33, 866-876, 1990.
- van Vollenhoven, R. F., Soriano, A., McCarthy, P. E., Schwartz, R. L., Garbrecht, F. C., Thorbecke, G. J., and Siskind, G. W., The role of immunity to cartilage proteoglycan in adjuvant arthritis. *J Immunol* 141, 1168-1173, 1988.
- van den Berg, W. B., van den Broek, M. F., van de Putte, L. B. A., van Bruggen, M. C. J., and van Lent, P. L. E. M., Experimental arthritis. Importance of T cells and antigen mimicry in chronicity and treatment. In "Monoclonal Antibodies, Cytokines and Arthritis" (T. F. Kresina, Ed.), pp. 237-252, Dekker, New York, 1991.
- Fox, A., Brown, R. R., Anderle, S. K., Chetty, C., Cromartie, W. J., Gorder, H., and Schwab, J. H., Arthropathic properties related to the molecular weight of peptidoglycan-polysaccharide polymers of streptococcal cell walls. *Infect Immunol* 35, 1003-1010, 1982.
- Hadzaya, O., A simple method for the quantitative determination of muramic acid. *Anal Biochem* 60, 512-517, 1974.
- Ayad, S., Abedin, M. Z., Grundy, S. M., and Weiss, J. B., Isolation and characterization of an unusual collagen from hyaline cartilage and intervertebral disc. *FEBS Lett* 123, 195, 1981.
- Carney, S. L., "Carbohydrate Analysis—A Practical Approach" (M. F. Chaplin and J. F. Kennedy, Eds.), pp. 97-141, Oxford IRL Press, Oxford, 1986.
- Heinegaard, D., and Axelsson, I., Distribution of keratan sulphate in cartilage proteoglycans. *J Biol Chem* 252, 1971-1979, 1977.
- Lehman, T. J., Allen, J. B., Plotz, P. H., and Wilder, R. L., Polyarthritis in rats following the systemic injection of lactobacillus casei cell walls in aqueous suspension. *Arthritis Rheum* 26, 1259-1265, 1983.
- Stimpson, S. A., and Schwab, J. H., Chronic remittent erosive arthritis induced by bacterial peptidoglycan-polysaccharide structures. In "Pharmacological Methods in the Control of Inflammation" (J. Y. Chang and A. J. Lewis, Eds.), pp. 381-394, A. R. Liss, New York, 1989.
- Dische, Z., and Shettles, L. B., A specific color reaction of methylpentoses and a spectrophotometric micromethod for their determination. *J Biol Chem* 175, 595-603, 1948.
- Oegema, T. R., Hascall, V. C., and Dziewiatkowski, D. D., Isolation and characterization of proteoglycans from the swam rat chondrosarcoma. *J Biol Chem* 250, 6151-6159, 1975.
- van den Berg, W. B., van de Putte, L. B. A., Zwarts, W. A., and Joosten, L. A. B., Electrical charge of the antigen determines intraarticular antigen handling and chronicity of arthritis. *J Clin Invest* 74, 1850-1859, 1984.
- van den Berg, W. B., van Beusekom, H. J., van de Putte, L. B. A., Zwarts, W. A., and van der Sluis, M., Antigen handling in antigen induced arthritis in mice. An autoradiographic and immunofluorescence study using whole joint sections. *Am J Pathol* 108, 9-16, 1982.
- Mohr, W., Wild, A., and Wolf, H. P., Role of polymorphs in inflammatory cartilage destruction in adjuvant arthritis of rats. *Ann Rheum Dis* 40, 171-176, 1981.
- Stanescu, R., Lider, O., van Eden, W., Holoshitz, J., and Cohen, I. R., Histopathology of arthritis induced in rats by active immunization to mycobacterial antigens or by systemic transfer of T lymphocyte lines. *Arthritis Rheum* 30, 779-792, 1987.
- Allen, J. B., Malone, D. G., Wahl, S. M., Calandra, G. B., and Wilder, R. L., Role of the thymus in streptococcal cell wall



- induced arthritis and hepatic granuloma formation *J Clin Invest* 76, 1042-1056, 1985
- 29 Griffiths, M M, Eichwald, E J, Martin, J H, Smith, C B, and Dewitt, C W, Immunogenetic control of experimental type II collagen-induced arthritis *Arthritis Rheum* 24, 781-789, 1981
  - 30 Brahn, E, and Trentham, D E, Experimental synovitis induced by collagen-specific T cell lines *Cell Immunol* 118, 491-503, 1989
  - 31 Stuart, J M, Cremer, M A, Yownes, A, and Kang, A, Type II collagen-induced arthritis in rats. Passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis *J Exp Med* 155, 1-16, 1982
  - 32 Dayer, E, Mathai, L, Glant, T T, Mikecz, K, and Poole, A R, Cartilage proteoglycan-induced arthritis in BALB/c mice. Antibodies that recognize human and mouse cartilage proteoglycan and can cause depletion of cartilage proteoglycan with little or no synovitis *Arthritis Rheum* 33, 1394-1405, 1990
  - 33 Janusz, M J, Chetty, C, Eisenberg, R A, Cromartie, W J, and Schwab, J H, Treatment of experimental erosive arthritis in rats by injection of the muralytic enzyme mutanolysin *J Exp Med* 160, 1360-1374, 1984
  - 34 van den Broek, M F, van de Langerijt, L G M, van Bruggen, M C J, Billingham, M E J, and van den Berg W B, Treatment of rats with monoclonal anti-CD4 induces long-term resistance to streptococcal cell wall-induced arthritis *Eur J Immunol* 22, 57-61, 1992
  - 35 van Eden, W, Thole, J E R, van der Zee, R, Noordzij, A, van Embden, J D A, Hensen, E J, and Cohen, I R, Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis *Nature* 331, 171-173, 1988
  - 36 van den Broek, M F, Hogervorst, E J M, van Bruggen, M C J, van Eden, W, van der Zee, R, and van den Berg, W B, Protection against streptococcal cell wall-induced arthritis by pretreatment with the 65 kD mycobacterial heat shock protein *J Exp Med* 170, 449-466, 1989
  - 37 Billingham, M E J, Carney, S, Butler, R, and Colston, M J, A mycobacterial 65-kD heat shock protein induces antigen-specific suppression of adjuvant arthritis, but is not itself arthritogenic *J Exp Med* 171, 339-344, 1990

Received September 13, 1993, accepted with revision January 13, 1994

## CHAPTER 4

Cell migration studies in the adoptive transfer of adjuvant arthritis  
in the Lewis rat

*Immunology 81: 414-419, 1994.*



## Cell migration studies in the adoptive transfer of adjuvant arthritis in the Lewis rat

A G M VAN DE LANGERIJT, S G VOLSEN,\* C A HICKS,\* P J CRAIG,\* M E J BILLINGHAM\* & W B VAN DEN BERG *Department of Rheumatology, University Hospital Nijmegen, Nijmegen, The Netherlands and \*Connective Tissue Disease Research, Lilly Research Centre, Windlesham, Surrey, U K*

### SUMMARY

Adjuvant arthritis (AA) can be induced in Lewis rats by a single injection of either heat-killed *Mycobacterium tuberculosis* or the lipoidal amine CP20961. Concanavalin A (Con A)-stimulated T cells isolated from AA rats are able to adoptively transfer the disease to naive syngeneic recipients. It is unclear, however, whether these transferred cells traffic directly to the joint and initiate arthritis, or whether secondary host cells are responsible for activation of the disease. In the current investigation, T cells labelled with the vital fluorescent dyes Hoechst H33342 and Zynaxis PKH26-G were used to adoptively transfer adjuvant disease to naive recipients. At various stages of disease development sections of ankle joints, together with a range of soft tissues, were examined by fluorescence microscopy to determine the distribution of labelled donor cells in the recipients. Intensely fluorescent lymphocytes were observed in the liver, spleen and lymph nodes within 24 hr of adoptive transfer. Foci of such cells were clearly visible in the primary lymphoid tissues as late as 14 days after transfer. However, close examination of both ankle joint sections and patellar fat pad cells throughout the time-course of the study failed to detect any labelled cells at the lesion site. To develop these observations further we performed adoptive transfers to nude Lewis rats (rnu/rnu) and found that they were only moderately sensitive and developed, at best, a transient arthritis. This observed difference could not be explained by a generalized lack of an inflammatory response, since we were able to elicit a zymosan peritonitis in the nude rats. However, in nude Lewis rats a striking increase in adoptively transferred AA was obtained after reconstitution with  $4 \times 10^6$  naive syngeneic spleen cells. These combined observations suggest that a host-derived immune cell population is crucial for arthritis induction in the adoptive transfer system.

### INTRODUCTION

Rat adjuvant arthritis (AA) is a well-defined model of human rheumatoid arthritis that can be induced by immunization of Lewis rats either with *Mycobacterium tuberculosis* (Mtb) suspended in Freund's incomplete adjuvant (FIA),<sup>1</sup> or with the lipoidal amine CP20961 in paraffin oil.<sup>2</sup> Fourteen days after induction, a progressive infiltrate of mononuclear cells is seen in the ankle joints, with concomitant early signs of bone remodelling. Several studies have already shown the important role of T lymphocytes in this arthritis model. AA cannot be induced in athymic (nude) rats,<sup>3</sup> treatment of rats with anti-T-lymphocyte antibodies prevents the induction of disease,<sup>4,5</sup> and, finally, the disease can be transferred to naive or irradiated syngeneic recipients with concanavalin A (Con A)-expanded T-cell lines<sup>6</sup> or clones.<sup>7</sup>

The possibility that T lymphocytes can migrate specifically to the inflammatory site has been examined in several models

Received 16 August 1993, revised 6 October 1993, accepted 4 November 1993

Correspondence Dr A G M van de Langerijt, Dept of Rheumatology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands

recently. In a dermal inflammation model, it has been demonstrated that a unique, small population of peritoneal exudate lymphocytes can migrate preferentially to cutaneous inflammatory sites<sup>8-11</sup> and reside there for long periods of time. This contrasts with the kinetics of lymphocyte migration into the arthritic joint, which appears to be a major traffic site for all lymphocytes, although they appear to reside there for only a relatively short time.<sup>12</sup> Furthermore, reports on the autoimmune disease experimental allergic encephalomyelitis (EAE), show that only a small percentage of transferred myelin basic protein (MBP)-reactive T cells accumulates in the central nervous system<sup>13,14</sup> and that non MBP-reactive lymphocytes ('bystander cells') can also play a role in mediating passively transferred EAE.<sup>15</sup>

Recently, DeJoy *et al.*<sup>16</sup> reported that in the adoptive transfer of AA some of the donor T cells (adjuvant sensitized) migrate to the synovium, where they may be responsible for disease induction. However, subarthritogenic doses of affinity-purified anti-collagen IgG were co-injected to facilitate adoptive transfer of AA, thereby inducing a more rapid onset of disease. Since this lesion appears to be complement dependent,<sup>17</sup> the co-injected anti-collagen IgG may stimulate the influx of inflammatory cells, including the transferred AA cells. Thus it still

remains to be demonstrated in the 'classical adoptive transfer system' which is primarily mediated by cellular immune mechanisms whether donor T lymphocytes are capable of specific migration to joints and subsequent initiation of arthritis.

We therefore carried out adoptive transfer experiments of AA to naive recipients using either H33342-<sup>+</sup> or PKH26-<sup>+</sup> labelled Con A-stimulated T cells. At various stages of disease development ankle joints and a range of soft tissues were examined by fluorescence microscopy to investigate whether any donor T lymphocytes could be detected. Additionally adoptive transfer experiments were performed on immunocompromised recipients to determine whether a host-derived cell population plays an important role in the induction of disease in the adoptive transfer system.

We were not able to detect any labelled cells in the joints suggesting that the cellular infiltrate at the lesion site is host derived. Transfer experiments to nude Lewis recipients supported this hypothesis, since only moderate arthritis developed in these animals.

## MATERIALS AND METHODS

### Rats

Female Lewis rats were originally obtained from the Central Institute for Versuchstierzucht (Hannover, Germany) and bred in our own facilities or were from Olac Bicester, UK. Female Lewis rnu rnu were obtained from Møllegaard (Skensved, Denmark). The rats weighed between 140 and 170 g at the beginning of each experiment and were fed standard food and tap water *ad libitum*.

### Adoptive transfer of adjuvant arthritis

The technique used was that described by Taugroff *et al.*<sup>1</sup> Briefly, female inbred Lewis rats were injected intradermally at the base of the tail and the hind paws with 250 µg of Mtb (heat-killed human strains C, DT and PN, Central Veterinary Laboratory, Weybridge, UK). The Mtb was finely ground in a pestle and mortar and suspended evenly in light paraffin oil at a concentration of 2.5 mg/ml. In case of the PKH26-GL labelling experiments donor cells originated from CP20961 (Phzer, Groton, CT) (5 mg rat in 0.1 ml paraffin oil) primed animals. Ten days after injection popliteal, inguinal and subaortic lymph nodes and spleens were removed aseptically. After a single-cell suspension was made the T lymphocytes were purified by passage over a nylon-wool column. T cells were then stimulated with Con A (Flow Labs, McLean, VA) (3 µg/ml) for 48 hr in RPMI supplemented with 10% fetal calf serum (FCS), 10 mM pyruvate, 20 mM glutamine and 40 µg/ml gentamycin (Flow Labs) at a concentration of  $2.5 \times 10^6$  cells/ml. After incubation T lymphocytes were washed in phosphate-buffered saline (PBS) and either labelled or immediately injected intravenously into naive syngeneic recipients or irradiated recipients as stated ( $5 \times 10^4$  cells recipient). Arthritis developed within 5 days and was scored macroscopically by measuring hind paw thickness with an industrial micrometer or using the scoring system of Billingham *et al.*<sup>1</sup>

### Labelling of transferred cells

At the end of the *in vitro* Con A stimulation AA T cells were harvested and washed three times with PBS at room temperature. These viable cells were then stained with either H33342 (Calbiochem, La Jolla, CA) or PKH26-GL (Znaxis, Malvern

PA) dye. The H33342 labelling was performed according to methods of Loeffler *et al.*<sup>18</sup> Briefly, lymphocytes were resuspended in a serum-free Hanks balanced salt solution (HBSS) containing 1 µM H33342 at a concentration of  $10^6$  cells/ml and incubated for 30 min in a 37 °C water bath with gentle agitation. Cells were then washed twice in HBSS and viability and fluorescence were assessed by microscopic observation. Labelled T cells were then used to transfer arthritis to naive animals.

The PKH26-GL labelling was performed according to methods of Moran *et al.*<sup>19</sup> Briefly,  $1 \times 10^6$  cells suspended in 5 ml of the kit (Znaxis) diluent was added to a further 5 ml of diluent containing 4 µM PKH26-GL and incubated for 2–3 min at room temperature with gentle shaking. The reaction was stopped by the addition of an equal volume of FCS for 5 min. Twenty-five millilitres of RPMI supplemented with 10% FCS was subsequently added and the cells were pelleted by centrifugation at 400 g for 10 min. Cells were then washed twice, once with RPMI supplemented with 10% FCS and once with PBS. The fluorescence and viability were assessed by microscopy before intravenous (i.v.) injection into naive recipients.

### In vitro mitogen stimulation

In order to assess the effects of cell division on fluorescence intensity, labelled donor T lymphocytes were maintained *in vitro* in the presence of Con A (3 µg/ml) for 7 days. The cultures were examined daily and the percentage labelling established by determining the ratio of fluorescent to non-fluorescent cells. This was accomplished by counting the same haemocytometer field under both fluorescent and normal illumination.


### In vivo cell traffic experiments

Adoptive transfer experiments with H33342-labelled cells were performed four times and these data comprise the following days post-transfer: 1, 2, 3, 4, 5, 7, 9, 10, 13 and 14. Adoptive transfer experiments with PKH26-GL-labelled cells were performed twice and comprise days 2, 5, 7, 9 and 13 post-transfer. At all the above time points groups of three recipients were killed and inguinal and popliteal lymph nodes, thymus, spleen, liver and ankle joints were removed and immediately submerged in liquid nitrogen. Multiple cryostat sections were cut and examined by fluorescence microscopy for the presence of labelled cells.

In the lymph nodes at least three serial sections at different levels in the block were examined. For the larger organs, e.g. liver and spleen at least three sections were taken again at multiple levels in order to obtain as representative a sample as possible. Three sections from at least two levels were examined in the joints. Peripheral blood samples were collected from the dorsal aorta and leucocytes isolated by sedimentation in 0.5% methylcellulose. The percentage of labelled cells in the buffy coat was then determined as described above.

### Patellar fat pad cells

At days 2, 5, 7 and 9 two recipients were killed and the patellar fat pads removed. Single-cell suspensions were made by enzymatic digestion using the method described by Dejoy *et al.*<sup>20</sup> Briefly, the patellar fat pads were digested in serum-free RPMI supplemented with 0.5 mg/ml collagenase, 0.15 mg/ml DNase and 0.05 mg/ml hyaluronidase (Sigma Chemical Co., St Louis, MO). After 90 min of gentle agitation at 37 °C the cell suspension



**Figure 1** Comparison of the severity of AA after adoptive transfer with either labelled (H33342 or PKH26-GL) or non-labelled T lymphocytes. Arthritis was scored as the sum of paw thickness of both hindlegs (cm). Each group consisted of four animals.

was centrifuged at 400 *g* and the cells washed with RPMI. This suspension was filtered through a 60- $\mu$ m Nytek filter (Tetko Elmsford, NY), and at least 100 cells examined by fluorescence microscopy.

#### Irradiation of the recipients

Groups of four recipient Lewis rats were exposed to 2.5 or 5 Gy total body irradiation (TBI). The physical parameters of the X-irradiation were 18 MV, field size, 40  $\times$  40 cm<sup>2</sup>, dose rate 2 Gy/min. One hour after irradiation, arthritis was induced by adoptive transfer of Mitb-primed non-fluorochrome-labelled T cells.

#### Induction of sterile peritonitis

Four rats from the control, non-reconstituted nude and 5 Gy-irradiated groups were injected intraperitoneally (i.p.) with 18 ml of saline containing 1% glycogen (Merck Darmstadt, Germany) or 5 mg of zymosan (Sigma Chemical Co.). Irradiation was performed either 2 or 5 days before induction of the peritonitis. Sixteen hours after injection, rats were killed and the peritoneal cavity washed once with 40 ml of saline. The elicited peritoneal cells were washed, the total cell number determined using a Coulter counter, and differential leucocyte counts performed on Wright-Giemsa-stained cytopspin preparations. At least 200 nucleated cells were identified as polymorphonuclear cells (PMN) or monocytes (Mo).

## RESULTS

#### *In vitro* mitogen stimulation

H33342-labelled lymphocytes were cultured *in vitro* with Con A to investigate whether, during proliferation, the dye was lost due to dilution. Initially, all cells took up the label and, following 7 days of *in vitro* stimulation with Con A, 92% of viable cells remained fluorescent. PKH26-GL has already been shown to be detectable *in vivo* after 121 days [11]. Previous transfer experiments had shown that recipient animals developed macroscopic and histological signs of arthritis as early as 4 days following injection of donor cells. These data therefore suggest that both dyes can be used effectively to determine the distribution of transferred cells during the period of lesion development.

#### *In vivo* cell traffic experiments

Since the labelled cells were still clearly fluorescent following proliferation, adoptive transfer experiments were performed with both dyes to ascertain whether either label affected the severity of the arthritis. Labelled AA cells were transferred to naive recipients, where it was found that neither label had any apparent effect on the incidence or severity of the arthritis in comparison with non-labelled cells (Fig. 1). Time course experiments were performed subsequently using either the H33342 or the PKH26-GL dye, which label the cell nucleus and cytoplasmic membrane, respectively. The results of the cell trafficking experiments were identical for both dyes and representative pictures of both dyes are shown in Fig. 2.

At day 1 post-transfer, the majority of fluorescent cells were localized in the liver and spleen. Small foci of positive lymphocytes were observed in the popliteal and inguinal lymph nodes. Approximately 5% of the peripheral white cells were stained at this time; this increased to a maximum of 90% on day 2 before falling to non-detectable levels at all subsequent time-points. At days 2 and 3, the number of clearly labelled cells in the liver and spleen was seen to decrease, whilst their frequency in the lymph nodes increased. From days 4 to 14, foci of clearly labelled lymphocytes were still observed in the lymph nodes and spleen, but at the later time-points their numbers were reduced. During the same period, the liver and spleen developed a progressive autofluorescent appearance which was particularly marked in the animals which received H33342 labelled cells. Macrophages sequestered the dyes and exhibited intense, particulate cytoplasmic fluorescence. Throughout the entire time course of the experiment, no labelled cells were observed in the thymus.

The examination of ankle joints at all time-points failed to reveal the presence of labelled cells at the lesion site, despite multiple sectioning at different levels of the block. The absence of labelled cells in the joint was not due to a lack of lesion development, since in each adoptive transfer experiment macroscopic symptoms of arthritis were clearly observed.

#### Patellar fat pad studies


Single-cell suspensions of patellar fat pads, prepared by enzymatic digestion, were examined by fluorescence microscopy. No labelled cells could be detected at any time-point.

#### Adoptive transfer to immunocompromised recipients


To determine whether a host-derived T-cell population is essential for arthritis induction, adoptive transfer experiments to immunocompromised (T-cell depleted) recipients were performed. Rats that had received 2.5 Gy TBI developed a slightly less severe arthritis compared with controls. However, recipients that had received 5 Gy TBI developed a significantly milder arthritis ( $P < 0.02$ , Wilcoxon rank test) (Fig. 3).

Adoptive transfer experiments were also performed with nude Lewis (*rnu rnu*) rats, which are profoundly deficient in mature T lymphocytes [1]. These experiments resulted in the initial development of a mild arthritis, which failed to progress ( $P < 0.01$ , Wilcoxon rank test) compared with the control Lewis rats (Fig. 4).

Subsequently, AA was transferred to nude recipients which had been reconstituted with  $4 \times 10^6$  naive syngeneic spleen cells 1 day before the adoptive transfer. Although no significant



**Figure 2.** Analysis of the different tissues by fluorescence microscopy. (a) Liver, day 1 after transfer; (b) spleen, day 2 after transfer; (c) spleen, day 4 after transfer; (d) lymph node, day 14 after transfer. Magnification  $\times 240$ .




**Figure 3.** Adoptive transfer of AA to irradiated and non-irradiated recipients. Arthritis was scored as the sum of paw thickness of both hindlegs (cm). Each group consisted of four animals. Data were tested with the Wilcoxon rank test ( $*P < 0.02$ ).

difference was observed at the onset of disease (nudes versus reconstituted nudes), it appeared that at later time-points the arthritis was significantly more severe and chronic ( $P < 0.05$ ; Wilcoxon rank test) in the reconstituted nude recipients (Fig. 4).

It was noted that about 75% of the nude recipients, but not the reconstituted nude rats, died between day 22 and day 30 post-transfer. Macroscopic analysis did not show any signs of graft-versus-host disease.

#### Induction of sterile peritonitis

Adoptive transfer to T-cell depleted recipients resulted in a mild, non-progressive arthritis. A sterile peritonitis was therefore induced in control, irradiated and nude Lewis rats to determine whether such animals displayed a generalized inability to mount an immune response. In irradiated Lewis rats, it was found that the influx of inflammatory cells was markedly reduced compared to that of control rats. In contrast, the nude Lewis rats



**Figure 4.** Adoptive transfer of AA to naive Lewis rats, nude Lewis (RNU) rats and nude Lewis recipients reconstituted with  $4 \times 10^6$  naive spleen cells (SC) 1 day before transfer. Arthritis was measured using a calliper and the values represent the sum of the thickness of both hindpaws (cm). Each point represents 7–14 animals. Data were tested with the Wilcoxon rank test. Differences between the nudes and the naive Lewis rats were significant,  $*P < 0.01$ . Furthermore, the differences between the nudes and the reconstituted nudes were significant,  $**P < 0.05$ .

**Table 1.** Peritoneal recruitment assay in immunocompromised animals

Recipient	n	Total cell no. $\times 10^7$ obtained from peritoneum	Identification of cells	
			PMN	Mo
Exp. 1				
Lewis	4	$4.1 \pm 2.3$		
Lewis 5 Gy (day - 2)	4	$0.8 \pm 0.2$		
Lewis 5 Gy (day - 5)	4	$0.6 \pm 0.4$		
Exp. 2				
Lewis	4	$8.4 \pm 1.0$	$72 \pm 2$	$28 \pm 2$
Lewis RNU	4	$11.4 \pm 0.7$	$60 \pm 4$	$40 \pm 4$

Peritonitis was induced in Exp. 1 by injection of 1% glycogen and in Exp. 2 by 5 mg of zymosan.

showed the greatest response, recruiting more inflammatory cells to the peritoneum than any other group (Table 1)

## DISCUSSION

Previous studies in rat AA have demonstrated the central role of T lymphocytes in this model.<sup>1,7</sup> Furthermore, it has been reported<sup>17</sup> that a small number of T lymphocytes can be detected by immunocytochemical analysis of the knee synovium from rats undergoing adoptive transfer. Whether the transferred T lymphocytes can migrate specifically to the joint remains a matter of debate. Recently, DeJoy *et al*<sup>16</sup> have used an adoptive transfer system in which they were able to recover labelled cells from the knee synovium of recipients. However, their system appeared to be complement dependent as anti collagen IgG was co-injected. It thus remains to be demonstrated whether donor cells can be detected in the joint lesion when the disease is transferred by AA-specific lymphocytes in the absence of co-injected IgG. In the current study, cell traffic experiments were undertaken to address this issue.

Confirming earlier studies,<sup>19,22,23</sup> our data indicate that both dyes can be effectively used for *in vivo* cell trafficking experiments without affecting the incidence or severity of arthritis. This suggests that the labelling does not alter the functional characteristics of these cells. Perhaps surprisingly we were unable to detect any labelled cells in the ankle joints or patellar fat pads at any time-point in our adoptively transferred arthritis, this suggests that the cellular infiltrate within the joint lesion site is predominantly host derived. It has been reported,<sup>16</sup> that T cells are present within inflamed synovium of adoptively transferred AA, and we have seen T cells in the later stages of adoptively transferred disease (unpublished observations) when lesions are well developed. However, the appearance of T cells within lesion sites in the direct form of CP20961 in these Lewis rats, occurs much later than inflammatory macrophages, which enter the synovium and initiate the arthritis several days before T cells arrive (S C R Meacock and D R Brandon, manuscript submitted for publication). Our present data, therefore, suggest that the transferred T cells confer arthritogenicity to host cells. This does not totally rule out the possibility that a few transferred T cells, undetected during our studies, entered putative lesion sites and set the stage for arthritis, they were certainly present in lymph nodes at day 14, but the overall lack of appearance of labelled cells at lesion sites infers initiation of the actual arthritis by host cells.

The above findings are in agreement with the unpublished experiments of J D Taurog and colleagues (personal communication), who were also unable to detect any <sup>111</sup>In-labelled adoptively transferred cells in the arthritic joint. This contrasts with adoptive transfer of EAE, where several investigators have detected small amounts of labelled cells at the lesion site.<sup>13,14</sup> The difference between adoptively transferred EAE and our findings in AA may reflect the nature of the priming antigen. In EAE the donor cells are primed against MBP, an antigen that is present in large amounts at the lesion site. However, it remains unknown which antigens are recognized by Mtb- or CP20961-primed T cells in joint lesions in either direct or adoptively transferred arthritis.

To support our findings further, adoptive transfer experiments were performed on T-cell depleted recipients. Our data

show that irradiation of recipients reduced their susceptibility to development of adoptively transferred AA in a dose-dependent manner. This finding can be explained by a general immune dysfunction in these animals, as exemplified by their inability to recruit inflammatory cells to a non-specific peritoneal stimulus. These observations concur with those of Taurog *et al*,<sup>20</sup> who have demonstrated that bone marrow reconstitution is essential in T-cell depleted recipients for initiation of arthritis.

Adoptive transfer experiments were also conducted in nude (rnu/rnu) Lewis rats, which are reported to lack almost all mature T lymphocytes.<sup>24</sup> The adjuvant disease transferred to these recipients was mild and non-progressive. The lack of disease development could not be explained by a generalized immunodeficiency, since they were able to recruit inflammatory cells in response to an induced peritonitis. Indeed, these nude rats were able to recruit even more macrophages and granulocytes to the peritoneum in comparison with normal Lewis rats. This is perhaps not surprising, since it has been reported previously that nude rats do have higher numbers of circulating monocytes and granulocytes in peripheral blood.<sup>25</sup> Small numbers of mature lymphocytes have been reported in nude rats,<sup>26</sup> this may explain the observation that these animals developed a mild, adoptively transferred arthritis. Other potential mechanisms must not, however, be ruled out, and the role of the macrophage in adoptively transferred AA, for example, remains in question. The high mortality incidence of the nudes at later time-points could be explained by the housing, since they were not maintained under specific pathogen-free conditions.

Interestingly, the data obtained from experimental transfer of AA to nude rats contrast with adoptive transfer of EAE, since in this model the nude rats were as susceptible as the control recipients.<sup>2</sup> Nevertheless, the latter data supports our present finding, that a host-derived T-cell population is essential for the development of arthritis by adoptive transfer. Supporting evidence for this hypothesis was obtained by reconstituting the nude recipients with  $4 \times 10^6$  naive syngeneic spleen cells. These rats proceeded to develop a more severe arthritis than the non-reconstituted controls.

The cellular interactions responsible for the arthritogenic effect of donor T lymphocytes are difficult to understand. One plausible explanation may be that the passively transferred lymphocytes induce anti-idiotypic T cells in the host lymphoid tissue which are able to migrate specifically to the synovium. These cells have been reported in vaccination experiments in EAE,<sup>28</sup> where anti-idiotypic cells were detected in the popliteal lymph nodes of rats that had been immunized with MBP-primed lymphocytes. An alternative explanation is that transferred T cells may induce the activation of host macrophages which then migrate to the joint and initiate lesion development. The recent observation that AA can be transferred by a macrophage-type of synoviocyte supports this hypothesis.<sup>29</sup> Macrophage involvement would also explain why nude recipients were seen to develop a mild adoptively transferred AA in our experiments. Further experiments are clearly required to test these hypotheses.

In conclusion, our experimental data indicate that in the 'classical' adoptive transfer, which is primarily mediated by cellular immune mechanisms, a host-derived T lymphocyte population is crucial for arthritis development. This is probably controlled within draining lymph nodes where the donor T lymphocytes initiate the host response.



REFERENCES

- 1 PEARSON C M (1956) Development of arthritis, peri-arthritis and periorchitis in rats given adjuvants *Pro Soc exp Biol Med* **91**, 95
- 2 CHANG Y-H, PEARSON C M & ABE C (1980) Adjuvant polyarthritis IV Induction by a synthetic adjuvant immunologic, histopathologic, and other studies *Arthr Rheum* **23**, 62
- 3 KOHASHI O, PEARSON C M, TAMAOKI N, TANAKA A, SHIMAMURA K, OZAWA A, KOTANI S, SAITO M & HIOKI K (1981) Role of thymus for N acetyl muramyl-L-ananyl-D-isoglutamine-induced polyarthritis and granuloma formation in euthymic and athymic nude rats or in neonatally thymectomized rats *Infect Immunol* **31**, 758
- 4 LARSSON P, HOLMDAHL R, BENCKER L & KLARESKOG L (1985) *In vivo* treatment with W3,13 (anti-pan T) but not OX8 (anti-suppressor/cytotoxic T) monoclonal antibodies impedes the development of adjuvant arthritis *Immunology*, **56**, 383
- 5 BILLINGHAM M E J, HICKS C & CARNEY S (1990) Monoclonal antibodies and arthritis *Agents Actions*, **29**, 77
- 6 TAUROG J D, SANDBERG G P & MAHOWALD M L (1983) The cellular basis of adjuvant arthritis II Characterisation of the cells mediating passive transfer *Cell Immunol* **80**, 198
- 7 VAN EDEN W, HOLOSHITZ J, NEVO Z, FRENKEL A, KLAJMAN A & COHEN I R (1985) Arthritis induced by a T lymphocyte clone that responds to mycobacterium tuberculosis and to cartilage proteoglycans *Proc natl Acad Sci U S A* **82**, 5117
- 8 ISSEKUTZ T B, WEBSTER D M & STOLTZ J M (1985) Lymphocyte recruitment in vaccinia virus-induced cutaneous delayed-type hypersensitivity *Immunology*, **58**, 87
- 9 ISSEKUTZ T B, STOLTZ J M & VAN DE MEIDE P (1988) Recruitment of lymphocytes into the skin by T cell lymphokines The role of gamma-interferon *Clin exp Immunol* **73**, 70
- 10 ISSEKUTZ T B, STOLTZ J M & VAN DE MEIDE P (1988) Lymphocyte recruitment in delayed-type hypersensitivity The role of gamma-interferon *J Immunol* **140**, 2989
- 11 ISSEKUTZ T B & STOLTZ J M (1989) Stimulation of lymphocyte migration by endotoxin, tumor necrosis factor, and interferon *Cell Immunol* **120**, 165
- 12 ISSEKUTZ T B & ISSEKUTZ A C (1991) T lymphocyte migration to arthritic joints and dermal inflammation in the rat differing migration patterns and the involvement of VLA-4 *Clin Immunol Immunopathol* **61**, 436
- 13 NAPARSTEK Y, BEN-NUN A, HOLOSHITZ J, RESHEF T, FRENKEL A, ROSENBERG M & COHEN I R (1983) T lymphocyte line production or vaccination against autoimmune encephalomyelitis (EAE) Functional activation induces peanut agglutinin receptors and accumulation in the brain and thymus of line cells *Eur J Immunol* **13**, 418
- 14 SEDGWICK J, BROSTOFF S & MASON D (1987) Experimental allergic encephalomyelitis in the absence of a classical delayed-type hypersensitivity reaction Severe paralytic disease correlates with the presence of interleukin-2 receptor-positive cells infiltrating the central nervous system *J exp Med* **165**, 1058
- 15 KAWAI K, ITO K, IMAMURA K, HICKEY W F, ZWEIMAN B & TAKAHASHI A (1993) Enhancing effects of irrelevant lymphocytes on adoptive transferred experimental allergic encephalomyelitis *J Neuroimmunol* **42**, 39
- 16 DEJOY S Q, FERGUSON-CHANDOWITZ K, ORONSKY A L, ZABRISKIE J B & KERWAR S S (1990) Studies on the homing of mycobacterium-sensitized T lymphocytes to the synovium during passive adjuvant arthritis *Cell Immunol* **130**, 195
- 17 DEJOY S Q, FERGUSON K M, ORONSKY A L & KERWAR A A (1988) Studies on the synergy between collagen and adjuvant arthritis in rats *Cell Immunol* **113**, 117
- 18 LOEFFLER D & RATNER S (1989) *In vivo* localization of lymphocytes labelled with low concentrations of Hoechst 33342 *J Immunol Meth* **119**, 95
- 19 HORAN P K, MELNICOFF M J, JENSEN B D & SLEZAK S E (1990) Fluorescent cell labeling for *in vivo* and *in vitro* cell tracking *Meth Cell Biol* **33**, 469
- 20 TAUROG J D, SANDBERG G P & MAHOWALD M L (1983) The cellular basis of adjuvant arthritis I Enhancement of cell-mediated passive transfer by concanavalin A and by immunosuppressive pretreatment of the recipient *Cell Immunol* **75**, 271
- 21 BILLINGHAM M E J, CARNEY S, BUTLER R & COLSTON M J (1990) A mycobacterial 65-kD heat shock protein induces antigen-specific suppression of adjuvant arthritis, but is not itself arthritogenic *J exp Med* **171**, 339
- 22 SLEZAK S E & HORAN P K (1989) Fluorescent *in vivo* tracking of hematopoietic cells part I technical considerations *Blood*, **74**, 2172
- 23 TEARE G F, HORAN P K, SLEZAK S E & HAY J B (1990) Long term tracking of lymphocytes *in vivo* the migration of PKH-labeled lymphocytes *Cell Immunol* **134**, 157
- 24 VOS J G, BERKVEN S J M & KRUIJT B C (1980) The athymic nude rat I Morphology of lymphoid and endocrine organs *Clin Immunol Immunopathol* **15**, 213
- 25 KLAUSEN B & HOUGFN H P (1987) Quantitative studies of lymphoid organs, blood and lymph in inbred athymic and euthymic LEW rats under germ-free and specific pathogen-free conditions *Lab Anim* **21**, 342
- 26 BROOKS C G, WEBB P J, ROBINS R A, ROBINSON G, BALDWIN R W & GESTING M F W (1980) Studies on the immunobiology of rnu/rnu rats with congenital aplasia of the thymus *Eur J Immunol* **10**, 58
- 27 HINRICKS D J & HUMPHRES R C (1983) The response of the nude (athymic) rat to actively induced and adoptively transferred experimental allergic encephalomyelitis *J Immunol* **131**, 4
- 28 BEN-NUN A, WEKERLE H & COHEN I R (1981) Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein *Nature*, **292**, 60
- 29 RAMOS RUIZ R, BERNABEU C, ARIZA A, FERNANDEZ J M, LARRAGA V & LOPEZ-BOTE J P (1992) Arthritis transferred by cells derived from pre-inflammatory rat synovium *J Autoimmun* **5**, 93

## CHAPTER 5

Regulation of resistance against adjuvant arthritis in the Fisher rat

*Clin. Exp. Immunol.* **94**: 150-155, 1993.



## Regulation of resistance against adjuvant arthritis in the Fisher rat

A. G. M. VAN DE LANGERIJT, P. L. E. M. VAN LENT, A. R. M. M. HERMUS\*, L. B. A. VAN DE PUTTE & W. B. VAN DEN BERG *Department of Rheumatology and \*Department of Chemical and Experimental Endocrinology, University Hospital Nijmegen, Nijmegen, The Netherlands*

(Accepted for publication 24 June 1993)

### SUMMARY

Inbred female Lewis (LEW/N) rats develop a severe chronic arthritis in the adjuvant arthritis (AA) model, histocompatible Fisher (F344/N) rats are resistant and germ-free Fishers (GF F344) are again susceptible. In this study we show that the F344 rat can become susceptible to AA, using *Mycobacterium tuberculosis* (M.tb.) in the powerful adjuvant paraffin oil, instead of mineral oil (Freund's incomplete adjuvant (FIA)). This indicates that the F344 rat does not lack T effector cells. To examine further mechanisms responsible for suppression, we determined the level of plasma corticosterone in response to IL-1 $\alpha$  in Lewis, F344 and GF F344 rats. IL-1 $\alpha$  induced only low amounts of corticosterone in Lewis rats, but high amounts in both F344 and GF F344 rats. The GF F344 rats are susceptible to AA, but the severity of the disease is reduced compared with Lewis rats. This indicates that corticosterone may be an important mechanism to suppress disease development, but not the only mechanism. In addition we investigated whether T suppressor cells play a role in the resistance of the F344 strain. This was performed by pretreating the animals with the immunomodulating drugs cyclophosphamide (Cy) and cyclosporin A (CsA). We were unable to make the F344 rat susceptible to AA, indicating that active suppression does not play a role in the induction phase of arthritis. This finding is confirmed in adoptive transfer experiments of AA from Lewis to F344 rats. Our data suggest the lack of a strong pre-existing suppression in the F344 rats, and indicate that suppression is generated upon bacterial challenge. Whether suppression is overruled probably depends on the power of adjuvants used and potential control by corticosteroids.

**Keywords** adjuvant arthritis susceptibility corticosterone cyclophosphamide cyclosporin adoptive transfer

### INTRODUCTION

Chronic erosive polyarthritis, resembling human rheumatoid arthritis, can be induced in susceptible rat strains by several bacteria. Two well studied models are the adjuvant arthritis (AA) induced by an intradermal immunization of heat-killed mycobacteria suspended in mineral oil [1] and the streptococcal cell wall (SCW)-induced arthritis, which can be induced by a single i.p. injection of a sterile, aqueous suspension of SCW [2]. For the AA as well as the SCW-A the susceptibility to arthritis seems to be regulated by the bacterial flora. In both models Lewis rats are susceptible, the histocompatible conventional Fisher (CV F344) resistant [3,4], and the germ-free Fisher (GF F344) again susceptible [5,6]. Some research has already been performed to explain this difference in susceptibility between the Lewis and F344 rat, but with a different underlying mechanism. We showed that the F344 rat was unable to mount a marked T

cell response against SCW material, and that depletion of T suppressor cells *in vitro* led to a restoration of the T cell proliferative response [7]. This clearly demonstrated that active suppression can play an important role in the resistance of the F344 rat. Interestingly, however, depleting F344 rats *in vivo* of OX8<sup>+</sup> cells did not make this strain susceptible to exacerbations [8]. In addition, Hogervorst *et al.* [9] also found that in AA responsiveness to certain mycobacterial antigen epitopes could be related to susceptibility. However, in this study the non-responsiveness of the F344 appeared not to be due to antigen-specific suppression. On the other hand, Sternberg *et al.* showed *in vivo* that the Lewis strain has an impaired corticosterone response after an i.p. injection of SCW, and that this defect is located in the hypothalamic-pituitary-adrenal (HPA) axis [10]. This finding suggests that the ability to generate high levels of plasma corticosterone is the main mechanism to suppress disease development. However, the latter data are not necessarily in agreement with the observation that the GF F344 is susceptible.

We performed this *in vivo* study to gain more insight into the regulation of susceptibility in bacterial-arthritis models. Using

Correspondence: Dr A. G. M. van de Langerijt, Department of Rheumatology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands.

the AA model we investigated which mechanisms play a role in the resistance of the F344 rat

First we investigated whether the resistance of the F344 strain can be overruled using more powerful adjuvants

In addition we examined whether the GF F344 like the Lewis also has an impaired corticosterone response We therefore compared the corticosterone responses to the inflammatory mediator IL 1 $\alpha$  in both Lewis F344 and GF F344

Finally we investigated the presence of active suppression in CV F344 using pretreatment with low-dose cyclophosphamide (Cy) or low dose cyclosporin A (CsA) drugs proven to have anti-suppressor effects in AA [11-13] and experimental allergic encephalomyelitis (EAE) [14-15] Additionally we performed adoptive transfer experiments of AA using Lewis AA cells given to F344 rats to examine whether the F344 was able to suppress disease development when T effector cells were passively generated

MATERIALS AND METHODS

Rats

Female Lewis rats were originally obtained from the Zentral Institut für Versuchstierzucht (Hannover Germany) and were bred in our own facilities Female F344 rats were also obtained from the Zentral Institut für Versuchstierzucht Germ free (GF) F344 rats were originally obtained from Jackson Laboratories (Bar Harbor ME) and were bred in overpressure isolators in our own facilities The isolators and faeces were screened once every 2 weeks for bacterial contamination The rats weighed between 130 and 180 g at the beginning of each experiment and were fed standard food and tap water *ad libitum*

Induction of adjuvant arthritis

Arthritis was induced by an intradermal injection at the base of the tail with 100  $\mu$ l of 10 mg/ml *Mycobacterium tuberculosis* (Mtb) (H37RA Difco Laboratories Inc Detroit MI) suspended in Freund's incomplete adjuvant (FIA Difco) or paraffin oil Arthritis was scored macroscopically by measuring hind paw thickness with an industrial micrometer One hundred per cent of the animals of the experimental groups developed an arthritis unless otherwise stated

In vivo corticosterone measurements

To diminish the stress caused by the experimental procedures each animal was handled daily by the experimenter for 15 min starting 1 week before decapitation One hour before decapitation animals were injected intraperitoneally with 1  $\mu$ g of human recombinant IL 1 $\alpha$  or saline Human recombinant IL 1 $\alpha$  was a generous gift from Dr P T Lomedico (Roche Research Centre Nutley NJ) After decapitation blood was collected and plasma was stored at -20 C for subsequent hormone measurements Briefly this was carried out by extracting the plasma corticosterone with 75 ml of dichloromethane (Baker Deventer The Netherlands) The water phase was discarded and the dichloromethane phase was evaporated The residue was dissolved in 2 ml 0.2% ethylene-glycol water (EGW) and the concentration of corticosterone in the eluate was measured by a radioimmunoassay using an antiserum raised in sheep against a B21 hemisuccinate bovine serum albumin (BSA) conjugate [16]




Fig 1 Effect of using different oil vehicles on the susceptibility of inbred Lewis F344 and germ free (GF) F344 rats for adjuvant arthritis Rats were immunized with 1 mg of *Mycobacterium tuberculosis* (Mtb) in Freund's incomplete adjuvant (FIA) (a) or 1 mg of Mtb in paraffin oil (b) (Lewis control received paraffin oil alone) Arthritis was measured using a calliper and the values represent the sum of the thickness of both hind paws  $\pm$  s.d. (cm) Each group consisted of four animals  $\square$  Lewis F344  $\blacksquare$  GF F344  $\bullet$  Lewis control

Drug treatment

Cy (Endoxan-Asta 100 mg ASTA Pharma AG Frankfurt am Main Germany) was dissolved in sterile saline immediately before use and injected intravenously as a single dose of 10/25 or 50 mg/kg body weight 2 days before arthritis induction by active immunization [11-12]

CsA (Sandimmune 100 mg/ml Sandoz Pharma AG Basel Switzerland) was suspended in a 1% carboxy methyl cellulose (CMC) vehicle and given daily per os at a dose of 10 mg/kg After 3 weeks AA was induced by active immunization as described above This protocol was proven to be successful in increasing the severity in Lewis rats (M Billingham Lilly Research Centre Windlesham UK personal communication)


Transfer of the adjuvant arthritis

In essence this transfer was performed according to the protocol reported by Taurog *et al* [17] and Billingham *et al* [18] Briefly draining lymph nodes (inguinal lumbar and popliteal) were removed aseptically from rats 10 days after immunization of Mtb (125  $\mu$ g suspended in 0.05 ml paraffin oil) in all four footpads and tail base After a single cell suspension was made the T lymphocytes were purified by incubating the cells on a nylon wool column (60 min 37 C) thereby removing the adherent cells T cells were then stimulated with concanavalin A (Con A 0.6  $\mu$ g/ml) for 48 h in RPMI supplemented with 10% fetal calf serum (FCS) 10 mM pyruvate 20 mM glutamine and 40  $\mu$ g/ml gentamycin (all Flow Labs Inc McLean VA) After 2 days cells were centrifuged down and suspended in PBS at a concentration of  $5 \times 10^6$  cells/ml and injected intravenously (1 ml) into naive non irradiated rats The arthritis was measured as described above for AA


RESULTS

Comparison of FIA with paraffin oil as vehicle for AA induction


AA was induced at day 0 in conventional (CV) Lewis CV F344 and in GF F344 using two different oil vehicles FIA or paraffin oil Figure 1a shows the results of FIA as oil vehicle in which all CV Lewis and 3/4 GF F344 are susceptible to AA and all CV F344 resistant However when paraffin oil was used instead of FIA both the CV Lewis as well as the GF F344 developed a more severe arthritis with an earlier onset (Fig 1b) Interestingly the CV F344 also became susceptible to AA with an onset around day 14 and an incidence of 100% Even a suboptimal




**Fig. 2.** Plasma corticosterone levels in Lewis (■), F344 (▨) and germ-free (GF) F344 (□) rats. Rats of each strain were injected intraperitoneally with PBS control or 1  $\mu$ g of human recombinant IL-1 $\alpha$ . Corticosterone was determined in plasma collected 60 min post-injection. Data shown are means  $\pm$  s.d. of four animals per group.



**Fig. 3.** Effect of cyclophosphamide on the development of arthritis in Lewis (a) and F344 (b) rats. Cyclophosphamide was given intravenously at three different single doses (mg/kg body weight) 2 days before arthritis induction. Arthritis was scored as the sum of the thickness of both hind-legs (cm). Each point represents the mean value  $\pm$  s.d. of four animals. (a) □, Lewis control; ○, Lewis 10 mg/kg; ●, Lewis 25 mg/kg; ◐, Lewis 50 mg/kg. (b) □, F344 control; ○, F344 10 mg/kg; ■, F344 25 mg/kg; ●, F344 50 mg/kg.



**Fig. 4.** Effect of oral cyclosporine A (CsA) pretreatment (10 mg/kg) on the development of adjuvant arthritis in Lewis and F344 rats. Daily treatment was started at day -22 and stopped at day 0, when arthritis was induced. Control rats received the vehicle carboxy methyl cellulose (CMC) alone. Arthritis was scored as the sum of paw thickness of both hind-legs  $\pm$  s.d. (cm). Each point represents the average of eight animals. Data were tested with Student's *t*-test. \**P* < 0.05. □, Lewis; ■, Lewis CsA; ○, F344; ●, F344 CsA.



**Fig. 5.** Adoptive transfer of adjuvant arthritis to naive Lewis (□), F344 (○) and F344 germ-free (GF) (■) recipients. Arthritis was scored as the sum of paw thickness of both hind-legs  $\pm$  s.d. (cm) using a calliper. Each point represents the average of 4-5 animals.

dose of M.tb., 0.1 mg/rat instead of 1 mg/rat, gave a 100% incidence in the CV F344 strain, though less severe (data not shown).

To rule out the possibility that the latter form of arthritis induction might be caused by the adjuvant alone, we tried to induce arthritis in CV Lewis rats with paraffin oil alone, but without success.

#### Corticosterone responses to IL-1 $\alpha$ in CV Lewis, CV F344 and GF F344 rats

Since corticosterone is an important hormone because of its ability to suppress disease development, and can therefore have great influence on susceptibility to AA, we determined plasma corticosterone levels in response to the inflammatory mediator IL-1 $\alpha$  in Lewis, F344 and GF F344 rats.

To exclude stress influences on the steroid levels, animals were handled daily for 6 days before IL-1 challenge. Intraperitoneal IL-1 $\alpha$ , 1 h after injection, induced a marked plasma corticosterone response in CV F344 rats and only a minimal response in CV Lewis (Fig. 2). Interestingly, however, i.p. IL-1 $\alpha$  induced an identical level of plasma corticosterone in the GF F344, compared with the CV F344.

Since handling of the GF F344 in the above experiment occurred outside the isolator, and susceptibility can change into resistance due to conventionalization [6,19,20], we checked whether the GF F344 rats were still susceptible to AA. Therefore, AA was induced in GF F344 rats, which were housed for 1 week in the conventional housing facilities. No difference in susceptibility was observed between the latter group and the GF F344, with a maximum arthritis score of  $1.3 \pm 0.3$  and  $1.4 \pm 0.3$ , respectively.

#### Effect of drug pretreatment and susceptibility to an adoptive transfer

To study whether suppressor cells, already present or generated during the induction phase of the arthritis, are responsible for suppressing disease development, animals were pretreated with low doses of Cy or CsA, drugs proven to have anti-suppressor activity [21,22].

A single dose of Cy (10, 25 or 50 mg/kg body weight) was injected intravenously 2 days before arthritis induction. In the Lewis rat, Cy pretreatment inhibited arthritis development dose-dependently (Fig. 3a). In F344 rats none of the doses used

was able to make the F344 susceptible to AA, and even with a low dose of 10 mg/kg body weight, only one F344 (25%) developed an arthritis (Fig. 3b).

CsA (10 mg/kg body weight) was given orally before arthritis induction. In Lewis rats, CsA induced a more severe arthritis with an earlier onset, compared with the control rats (Fig. 4), which was significant at day 15 ( $P < 0.05$ ; Student's *t*-test). Again no effect of CsA pretreatment was seen in CV F344.

It is still possible that suppressor cells were present, but are as sensitive to immunosuppressive agents as the arthritogenic cells. We therefore investigated whether it was possible to detect any suppressive activity by performing adoptive transfer experiments. As shown in Fig. 5, we were able to induce a chronic arthritis by adoptive transfer in the Lewis recipient with an onset at day 4. Transferring Lewis AA-specific T cells to CV F344 and GF F344 rats induced an identical onset and severity in the first days in CV Lewis, CV F344 and GF F344. At later time points arthritis declined more rapidly in both F344 strains, which may point to generation of suppression at that stage. However, it can not be ruled out that the latter phenomenon is caused by minor histocompatibility differences between Lewis and F344 rats.

## DISCUSSION

In this study we investigated how the F344 rat may regulate its resistance to bacteria-induced arthritis. First, we examined whether a lack of T effector cells is responsible for the resistance of the F344 rat. Using a more potent adjuvant, M.tb. in paraffin oil, we were able to make the F344 rat susceptible, suggesting that the F344 rat does not lack T effector cells for arthritis development, data which are in agreement with arthritis susceptibility in GF F344 rats. Furthermore, this finding indicates that neither clonal deletion [23] nor clonal anergy [24] are the mechanisms by which the F344 regulates its resistance.

In addition, we show that Lewis rats injected with paraffin oil alone did not develop arthritis, suggesting that M.tb. is essential for arthritis induction. This is in contrast with the synthetic adjuvant model [25] or the adjuvant model reported by Kleinau *et al.* [26] and Cannon *et al.* [27], who were able to induce arthritis in DA rats with FIA alone.

Since a lack of T effector cells could not explain the observed differences between the Lewis and F344 strains, we investigated whether the susceptibility can be explained by impaired corticosterone responses to an inflammatory mediator. As can be seen in Fig. 2, the CV F344 rat, resistant to arthritis induction, had identical plasma corticosterone levels in response to IL-1 $\alpha$  to the susceptible GF F344. The latter GF rats developed, however, an arthritis of lower severity compared with the one in Lewis rats (Fig. 1a). This suggests that the ability to generate high levels of corticosterone is an important mechanism of the F344 to suppress arthritis development, but leaving other mechanisms as important for the regulation of resistance.

Another likely candidate may be active suppression, especially since it was shown in *in vitro* studies in the SCW-induced arthritis model, that an impaired T cell proliferative response to the bacterial antigen could be restored by depleting CD8<sup>+</sup> T cells [7]. We were therefore interested to see if we could detect any *in vitro* suppressor activity in the CV F344 rat.

This was first examined by pretreating the animals with low dose Cy or low CsA, both drugs which have been shown *in vivo* to operate on the level of T cells, especially on T suppressor cells [21,22]. In the case of low dose Cy pretreatment in the Lewis strain, we only saw a decrease in arthritis severity, suggesting that even low dose Cy not only acts at the level of T suppressor cells but also at the level of T effector cells. This suppressive effect seen in Lewis can very well explain why we did not see any effect in the F344 strain. Earlier data with Cy pretreatment also show a dose-dependent effect. Low dose pretreatment enhanced the severity of AA in the WKA strain [11] and made the resistant Buffalo strain susceptible to AA [12], while a higher dose suppressed AA in the susceptible Holtzman and susceptible PVG/c strain [28]. Interestingly, low dose Cy also suppressed AA development in the susceptible Holtzman strain. This set of data is at variance with our results, and indicates that the net effect of Cy pretreatment may be strain-dependent. Furthermore, timing of administration is also of importance, since 20 mg/kg Cy given on days 0-2 after adjuvant prevented the development of arthritis in Sprague Dawley rats [29]. Therefore, treatments at later time points are not useful for studying the role of T suppressor cells in the F344. Because we were not able to detect any T suppressor activity in the F344 rat or increase in the severity of arthritis in the Lewis rat, we decided to test CsA pretreatment. The latter was proven to increase the severity in Lewis rats (M. Billingham, Lilly Research Centre, Windlesham, UK; personal communication) and therefore may be more effective for testing whether preexisting T suppressor cells are also responsible for the resistance of the F344 rat.

Indeed, CsA pretreatment was able to increase the severity in the Lewis strain, data which are in agreement with low-dose CsA pretreatment (2 or 4 mg/kg on alternate days for 22 days) in EAE [13]. However, the F344 rat still did not become susceptible to AA, indicating that either the level of suppression was too high to down-regulate, or the T suppressor activity, present during the induction phase of arthritis, does not play a role in the regulation of resistance in the F344 strain. Since CsA pretreatment primarily eliminates the preexisting T suppressor cells and hardly affects T suppressor cells generated during the onset of disease, the latter may still maintain the resistance of the F344. Some evidence for this up-regulation has been found by Kingston *et al.* (Lilly Research Centre, unpublished results), who found by phenotypic analysis that in AA in both Lewis and F344 rats CD8<sup>+</sup> cell numbers are increased, and that in the F344 strain the numbers of these cells remain elevated. This is in contrast to the Lewis strain, where CD8<sup>+</sup> cells decline as disease progresses.

Unfortunately CsA treatment at later time points, to eliminate these up-regulated T suppressor cells, is of limited use, since it has been frequently shown that this results in a suppression in several arthritis models [30-33].

Additional indications that the F344 rat has to up-regulate its suppressor activity were found in adoptive transfer experiments, since the F344 strain was susceptible in the transfer system. Because Lewis and F344 strains are reported to be syngenic at the RT-1.A and RT-1.B region of the MHC region, and only differ with respect to minor histocompatibility antigens [34], we assumed that graft-versus-host reactions would not occur in these adoptive transfer experiments. Interestingly, the arthritis declined rapidly in both the CV and the GF F344 (Fig. 5), which can be explained by either the generation of suppres-

sion or by elimination of the transferred Lewis cells due to minor histocompatibility differences. We have found several indications which do support the latter phenomenon e.g. no increase in the chronicity when the F344 recipient was pre-treated with low dose of Cy before the adoptive transfer and high responses in a mixed lymphocyte assay of T cells from an F344 recipient primed with Lewis T cells (manuscript in preparation).

Of course we considered studying the presence of active suppression in the F344 by *in vivo* treatment with OX8 (antisuppressor cytotoxic T). However several studies in AA [35-36] EAE [37-38] and an exacerbation study with SCW fragments in the F344 rat [8] have shown no effect of *in vivo* CD8 depletion indicating that this cell type plays no major role in the immunoregulation of AA. In contrast in the SCW-A model in Lewis rats an increase in the severity and an earlier onset of disease were found (day 14 in the control group *versus* day 5 in the OX8 treated group). However the latter results are hard to interpret since this acute phase is considered to be T cell-independent [39]. The fact that most studies do not show any effect of this OX8 treatment does not mean that T cells are not capable of maintaining resistance or down regulating inflammation. It has been shown through analysis of murine Th cell lines that CD4<sup>+</sup> T cells can be classified into Th1 and Th2 lines based on the expression of IL-2 and interferon-gamma (IFN- $\gamma$ ) or IL-4, IL-5, IL-6 and IL-10 respectively [40]. Because these two types of T helper cells synthesize lymphokines with profoundly different functions it is possible that *in vivo* these CD4<sup>+</sup> T cells may also be important regulators in the resistance of the F344 strain [41].

Taken together these data indicate that the F344 rat does not lack T effector cells for arthritis development and that the immune system of the F344 is also under control of a delicate balance of reactivity and suppression. Furthermore we confirm that the ability to generate high levels of corticosterone may be an important mechanism of the F344 to suppress disease development. However since we found identical levels in both CV and GF F344 rats this leaves other mechanisms like bacterial flora as important for the regulation of resistance to AA. We cannot exclude the possibility that differences do exist in the kinetics of steroid levels in response to IL-1 $\alpha$ . Therefore time course experiments of steroid levels in cannulated F344 and GF F344 rats are now in progress after IL-1 $\alpha$  challenge and during arthritis development. Finally we have found clear evidence that preexisting active suppression does not play a role in the resistance of the F344. We assume that if any T suppressor mechanism does exist the F344 needs to up-regulate this upon bacterial challenge. Unfortunately we were unable to prove the latter in adoptive transfer experiments since we found several indications that Lewis T cells are eliminated in the F344 due to minor histocompatibility antigens.

#### ACKNOWLEDGMENTS

The authors wish to thank Dr M. Billingham and Dr A. Kingston (Lilly Research Centre, Windlesham, UK) for fruitful discussions and for providing protocols for the CsA pretreatment. We also thank M. Spanjaards for his assistance and Annette Overleg and Jan van Wessel (Central Animal Laboratory) for animal care. This study was supported by a research grant from the Dutch League against Rheumatism.

- Pearson CM. Development of arthritis, periarthritis and periostitis in rats given adjuvants. *Proc Soc Exp Biol Med* 1956; **91**: 95-101.
- Cromartie WJ, Craddock JG, Schwab JH, Anderik SK, Yang C. Arthritis in rats after systemic injection of streptococcal cells or cell walls. *J Exp Med* 1977; **146**: 1585-602.
- Battisto JR, Smith RN, Buckmann K, Sternlicht M, Welles WL. Susceptibility to adjuvant arthritis in DA and F344 rats: A dominant trait controlled by an autosomal gene locus linked to the major histocompatibility complex. *Arthritis Rheum* 1982; **25**: 1194-9.
- Wilder RL, Calandra GB, Garvin AJ, Wright KD, Hinsen CT. Strain and sex variation in the susceptibility to streptococcal cell wall induced polyarthritis in the rat. *Arthritis Rheum* 1982; **25**: 1064-72.
- Kohashi O, Kuwata J, Umehara F, Takahashi T, Ozawa A. Susceptibility to adjuvant induced arthritis among germ free specific pathogen free and conventional rats. *Infect Immun* 1979; **26**: 791-4.
- van den Broek MF, van Bruggen MCJ, Koopman JP, Hazenberg MP, van den Berg WB. Gut flora induces and maintains resistance against streptococcal cell wall induced arthritis in F344 rats. *Clin Exp Immunol* 1992; **88**: 311-7.
- van den Broek MF, van Bruggen MCJ, van de Putte LBA, van den Berg WB. T cell responses to streptococcal antigens in rats: relation to susceptibility to streptococcal cell wall induced arthritis. *Clin Immunol* 1988; **116**: 216-29.
- van den Broek MF, van Bruggen MCJ, Stimpson SA, Scurry AJ, van de Putte LBA, van den Berg WB. Hilaricup reaction of streptococcal cell wall induced arthritis in Lewis and F344 rats: the role of T lymphocytes. *Clin Exp Immunol* 1990; **79**: 297-306.
- Hogervorst FJM, Boog CJP, Wiegman JPA, Wauben MHM, van der Zee R, van Eden W. T cell reactivity to an epitope of the mycobacterium 65kD heat shock protein (hsp 65) corresponds with arthritis susceptibility in rats and is regulated by hsp specific cellular responses. *Eur J Immunol* 1991; **21**: 1289-96.
- Sternberg FM, Hill JM, Chrousos GP, Kamilaris T, Listwak SJ, Gold PW, Wilder RL. Inflammatory mediator induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis susceptible Lewis rats. *Proc Natl Acad Sci USA* 1989; **86**: 2374-8.
- Kayashima K, Koga T, Onoue K. Role of T lymphocytes in adjuvant arthritis. II. Different subpopulations of T lymphocytes functioning in the development of the disease. *J Immunol* 1978; **120**: 1127-36.
- Bersani Amado CA, Barbuto IAM, Jancar S. Comparative study of adjuvant induced arthritis in susceptible and resistant strains of rats. I. Effect of cyclophosphamide. *J Rheumitol* 1990; **17**: 149-52.
- Revelli S, Davila H, Moreno H, Bottasso O. Depressed adjuvant arthritis in chronically *Trypanosoma cruzi* infected rats: reversal by cyclophosphamide. *J Rheumatol* 1992; **19**: 513-16.
- Minagiwa H, Takenaka A, Itoyama Y, Mori R. Experimental allergic encephalomyelitis in the Lewis rat: A model of predictable relapse by cyclophosphamide. *J Neurol Sci* 1987; **78**: 225-35.
- Polman CH, Matthaei I, de Groot CJA, Koetsier JC, Smits T, Dykstra CD. Low dose cyclosporin A induces relapsing remitting experimental allergic encephalomyelitis in the Lewis rat. *J Neuroimmunol* 1988; **17**: 209-16.
- Swcep CGJ, van der Meer MJM, Hermus ARMM *et al*. Chronic stimulation of the pituitary-adrenal axis in rats by interleukin 1 $\beta$  infusion: *in vivo* and *in vitro* studies. *Endocrinology* 1992; **130**: 1153-64.
- Taurog JD, Sandberg GP, Mahowald ML. The cellular basis of adjuvant arthritis. I. Enhancement of cell mediated passive transfer by concanavalin A and by immunosuppressive treatment of the recipient. *Cell Immunol* 1983; **75**: 271-82.



- 18 Billingham MEJ, Carney S, Butler R, Colston MJ. A mycobacterial 65-kD heat shock protein induces antigen-specific suppression of adjuvant arthritis, but is not itself arthritogenic. *J Exp Med* 1990, 171: 339-44
- 19 Kohashi O, Kuwata J, Umehara K, Uemura F, Takahashi T, Ozawa A. Susceptibility to adjuvant-induced arthritis among germfree, specific-pathogen-free and conventional rats. *Infect Immun* 1979, 26: 791-4
- 20 Kohashi O, Kohashi Y, Takahashi T, Ozawa A, Shigematsu N. Suppressive effect of *Escherichia coli* on adjuvant-induced arthritis in germfree rats. *Arthritis Rheum* 1986, 29: 547-53
- 21 Askenase PW, Hayden BJ, Gershon RK. Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses. *J Exp Med* 1975, 141: 697-702
- 22 Altmann DM, Blyth WA. The effects of cyclosporin A on the induction, expression and regulation of the immune response to herpes simplex virus. *Clin Exp Immunol* 1985, 59: 17-22
- 23 Burnet FM. The clonal deletion theory of acquired immunity. New York: Cambridge University Press, 1959
- 24 Morahan G, Allison J, Miller JFAP. Tolerance of class I histocompatibility antigens expressed extrathymically. *Nature* 1989, 339: 622-4
- 25 Chang YH, Pearson CM, Abe C. Adjuvant polyarthritis. IV. Induction by a synthetic adjuvant: immunologic, histopathologic, and other studies. *Arthritis Rheum* 1980, 23: 62-71
- 26 Kleinau S, Erlandsson H, Holmdahl R, Klareskog L. Adjuvant oils induce arthritis in the DA rat. I. Characterization of the disease and evidence for an immunological involvement. *J Autoimmun* 1991, 4: 871-80
- 27 Cannon GW, Woods ML, Clayton F, Griffiths MM. Induction of arthritis in DA rats by incomplete Freund's adjuvant. *J Rheumatol* 1993, 20: 7-11
- 28 Mackenzie AR, Pick CR, Sibley PR, White BP. Suppression of rat adjuvant disease by cyclophosphamide pretreatment: evidence for an antibody-mediated component in the pathogenesis of the disease. *Clin Exp Immunol* 1978, 32: 86-96
- 29 Currey HLF. A comparison of immunosuppressive and antiinflammatory agents in the rat. *Clin Exp Immunol* 1971, 9: 879-87
- 30 Borel JF, Feuer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. *Agents Actions* 1976, 6: 468-75
- 31 Henderson B, Staines NA, Burrai I, Cox JH. The anti-arthritic and immunosuppressive effects of cyclosporine on arthritis induced in the rat by type II collagen. *Clin Exp Immunol* 1984, 57: 51-56
- 32 Kaibara N, Hotokebuchi T, Takagishi K, Katsuki I, Mornaga M, Arita C, Jinguishi S. Pathogenetic difference between collagen arthritis and adjuvant arthritis. *J Exp Med* 1984, 159: 1388-96
- 33 Yocum DE, Allen JB, Wahl SM, Calandra GB, Wilder RL. Inhibition by cyclosporin A of streptococcal cell wall-induced arthritis and hepatic granulomas in rats. *Arthritis Rheum* 1986, 29: 262-73
- 34 Altman PL, Katz DD, eds. Inbred and genetically defined strains of laboratory animals. Bethesda: Federation of American Societies for Experimental Biology, 1979: 324
- 35 Larsson P, Holmdahl R, Dencker L, Klareskog L. *In vivo* treatment with W3/13 (anti-pan T) but not with OX8 (anti-suppressor, cytotoxic T) monoclonal antibodies impedes the development of adjuvant arthritis in rats. *Immunology* 1985, 56: 383-91
- 36 Billingham MEJ, Hicks C, Carney S. Monoclonal antibodies and arthritis. *Agents Actions* 1990, 29: 77-87
- 37 Sedgwick JD. Long-term depletion of CD8<sup>+</sup> T cells *in vivo* in the rat: no observed role for CD8<sup>+</sup> (cytotoxic/suppressor) cells in the immunoregulation of experimental allergic encephalomyelitis. *Eur J Immunol* 1988, 18: 495-502
- 38 Srinam S, Carroll L. *In vivo* depletion of Lyt-2 cells fails to alter acute and relapsing EAE. *J Neuroimmunol* 1988, 17: 147-57
- 39 van den Broek MF, de Heer E, van Bruggen MCJ, de Roo G, Kleiverda K, Eulderink F, van den Berg WB. Immunomodulation of streptococcal cell wall-induced arthritis: Identification of inflammatory cells and regulatory T cell subsets by mercuric chloride and *in vivo* CD8 depletion. *Eur J Immunol* 1992, 22: 3091-5
- 40 Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. *J Immunol* 1986, 136: 2348-57
- 41 Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. *Ann Rev Immunol* 1989, 7: 145-73

## CHAPTER 6

Susceptibility to adjuvant arthritis: relative importance of adrenal activity and bacterial flora

*Clin. Exp. Immunol.* **97**: 33-38, 1994.



## Susceptibility to adjuvant arthritis: relative importance of adrenal activity and bacterial flora

A G M VAN DE LANGERIJT, P L E M VAN LEENT, A R M M HERMUS\*, C G J SWEEPT, A R COOLS† & W B VAN DEN BERG *Departments of Rheumatology \*Endocrinology †Experimental and Chemical Endocrinology and ‡Psychoneuropharmacology University Hospital Nijmegen Nijmegen The Netherlands*

(Accepted for publication 23 March 1994)

### SUMMARY

Previous studies on the regulation of bacterial-induced arthritis in rats have focused on endocrine aspects as well as differences in T cell immunity against bacterial epitopes. We analysed the role of both adrenal activity and bacterial flora in determining susceptibility to bacterial-induced arthritis. Outbred Wistar rats show a low incidence of adjuvant arthritis. Moderate sensitivity to adjuvant arthritis was found in a selected stress-resistant line of the Wistar rat, whereas no arthritis was found in a stress-susceptible Wistar line. Plasma corticosterone responses after IL-1 $\alpha$  exposure were however, identical in these two lines, excluding a direct correlation between susceptibility and corticosterone levels. In line with previous findings in germ-free (GF) F344 rats, GF Wistars also appeared highly susceptible to arthritis. We further analysed the corticosterone responses in GF and conventional (CV) rats. Administration of IL-1 $\alpha$  induced identical corticosterone responses in both CV and GF F344 rats. In addition, plasma corticosterone levels were measured around the time of onset of arthritis. Whereas no rise was seen in the arthritis-resistant CV rats, a significant increase was observed from day 14 in GF rats, at the moment of onset of arthritis. Although this corticosterone response was insufficient to prevent arthritis, it may have ameliorated disease expression in the GF F344 rats. Our data indicate that the bacterial flora, and therefore T cell tolerance, is of prime importance in determining susceptibility, whereas the activity of the hypothalamus-pituitary-adrenal (HPA) axis may modulate disease severity.

**Keywords:** adjuvant arthritis, susceptibility, corticosterone, bacterial flora

### INTRODUCTION

Chronic erosive polyarthritis like adjuvant arthritis (AA) [1] and streptococcal cell wall (SCW)-induced arthritis [2], can be induced in susceptible rat strains. Several investigators have examined mechanisms which determine the susceptibility for this type of joint inflammation. It was found that susceptibility is strain dependent and appears to be controlled by an autosomal dominant gene locus linked to the MHC [3,4].

Not only genetic factors but also factors like the bacterial flora seem to regulate susceptibility to AA. For example, Lewis rats are highly susceptible, while the histocompatible F344 rat is resistant and the germ-free (GF) F344 rat is again susceptible [5,6]. We showed that the ability to generate tolerance determines susceptibility since only the susceptible Lewis rats were able to mount a specific T cell response against the injected bacteria [6,7]. Furthermore, Wilder and co-workers showed that the Lewis strain has a deficient response of hypothalamic

corticotropin releasing hormone (CRH) to various stressful inflammatory stimuli, while the F344 strain responded in a more robust manner [8]. As a result, the Lewis strain showed a deficient response of plasma corticosterone to these stimuli [9] and it was postulated that this diminished response of the hypothalamus-pituitary-adrenal (HPA) axis plays a role in determining the susceptibility in the Lewis and F344 strains.

In contrast to the Lewis strain, F344 rats display aggressive and stressful behaviour. Recently two pharmacogenetically selected Wistar lines have been described which seem to differ in their neurochemical and neurobiological organization behaviour: the apomorphine susceptible (APO-SUS) and apomorphine unsusceptible (APO-UNSUS) lines [10]. The APO-UNSUS rats exhibit a decreased general locomotor activity and are less reactive to stressful stimuli than the APO-SUS animals [10,11]. Of interest, the APO-UNSUS rat showed enhanced susceptibility to experimental autoimmune encephalomyelitis (EAE) [11].

To examine the relative importance of the neuroendocrine and immune system, we compared the susceptibility to AA in the outbred conventional (CV) and GF Wistar rats, as well as in

Correspondence: Dr A G M van de Langerijt, Department of Rheumatology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands.

the APO-SUS and APO-UNSUS lines. Moreover, we determined plasma levels of corticosterone after IL-1 $\alpha$  injection or during arthritis in the selected Wistar lines and in CV and GF F344 rats.

## MATERIALS AND METHODS

### Animals

Pharmacogenetically selected F14 offspring female Wistar rats (APO-SUS and APO-UNSUS) were obtained from the Department of Psychoneuropharmacology. Selection was made on their gnawing response to the dopamine receptor agonist apomorphine as described by Cools *et al* [10]. Rats with gnawing responses < 10/45 min were designated as apomorphine unsusceptible (APO-UNSUS), and rats with gnawing responses > 500/45 min were called apomorphine susceptible (APO-SUS). Retention of genetic selection was tested in rats of the first litter of each generation. At the age of 60 days these rats were injected with apomorphine and tested as described earlier [10]. APO-UNSUS rats with the lowest scores and APO-SUS rats with the highest scores were selected and used for subsequent development of the next generation. Rats of the second and third litter of each generation were used for experiments. Female CV outbred Wistar rats were obtained from Harlan CPB (Zeist, The Netherlands) and female CV inbred F344 rats from the Zentral Institut für Versuchstierzucht (Hannover, Germany). Female Lewis rats were bred in our own facilities and were originally obtained from the Zentral Institut für Versuchstierzucht.

Female GF F344 rats were originally obtained from Jackson Laboratories (Bar Harbor, ME), and female GF Wistar rats from the Zentral Institut für Versuchstierzucht and both were bred in our own facilities (Central Animal Laboratory) in overpressure isolators. The isolators and faeces were screened once every 2 weeks for bacterial contamination.

The rats weighed between 140 and 180 g at the beginning of each experiment and were housed in rooms illuminated from 6:00 a.m. to 6:00 p.m. Standard food and tap water were given *ad libitum*.

### Induction of adjuvant arthritis

Arthritis was induced by an intradermal injection at the base of the tail with 100  $\mu$ l of 10 mg/ml *Mycobacterium tuberculosis* (H37RA, Difco Labs, Detroit, MI) suspended in Freund's incomplete adjuvant (FIA, Difco). Arthritis was scored by measuring hind paw thickness with an industrial micrometer. In addition, in some experiments we performed a visual scoring on both hind and fore feet on the basis of 0 = no signs of redness or swelling, 1 = mild swelling and redness, 2 = severe swelling and redness.

### In vivo cannulation experiments

In order to determine plasma corticosterone levels in response to administration of IL-1 $\alpha$  or during AA, blood was collected from freely moving rats by means of a chronic cannula. Cannulation of the rats was performed according to the technique described by Steffens [12] with some minor modifications as described by Sweep *et al* [13]. After cannulation, the animals were housed individually and handled daily by the experimenter to diminish stress caused by the experimental procedures.

Animals were allowed to recover from the operation for at least 6 days. At the start of the experiment, a polyethylene cannula was attached to the stainless steel tube on the skull of the head. Two hours later time course experiments were started ( $t = 0$  min) by injection of 1  $\mu$ g of IL-1 $\alpha$  intravenously. Recombinant human IL-1 $\alpha$  was a generous gift from Dr P. T. Lomedico (Roche Research Centre, Nutley, NJ). Control rats received saline alone. At every time point 300  $\mu$ l blood were collected for corticosterone measurements, and subsequently 300  $\mu$ l of saline were returned to the animal. Regarding the time course experiments in AA, blood withdrawal always started around 11:00 a.m., to exclude differences in corticosterone levels due to the circadian rhythm.

### In vitro corticosterone measurements

Blood samples were collected in dry lithium-heparin tubes and centrifuged at 1500 g for 10 min at 4 C. Plasma was separated and stored at -20 C until assayed.

Corticosterone measurements were performed as described by Sweep *et al* [13]. Briefly, plasma corticosterone was extracted with 7.5 ml of dichloromethane (Baker, Deventer, The Netherlands). The water phase was discarded and the dichloromethane phase was evaporated. The residue was dissolved in 2 ml 0.2% ethylene glycol water (EGW), and the concentration of corticosterone in the eluate was measured by a radioimmunoassay using an antiserum raised in sheep against a B-21-hemisuccinate bovine serum albumin (BSA) conjugate.

The sensitivity of the assay was 25–45 fmol/tube. The intra- and interassay coefficients of variation were 5% and 8%, respectively.

### Statistical analysis

In the arthritis susceptibility experiments, the hind paw thickness between the different groups was compared by the Wilcoxon rank sum test. The  $\chi^2$  test with Yates' correction was used to analyse the results of the visual scoring.

All corticosterone data are presented as the mean  $\pm$  s.d. of five to eight animals. Comparisons between the corticosterone levels in the arthritis experiments were made by the ANOVA test with repeated measurements. Only when the ANOVA revealed a significant difference between both groups were values at specific time points further evaluated by Student's *t*-test for unpaired observations.

## RESULTS

### Susceptibility of the different Wistar rat lines for AA

AA was induced in the APO-SUS and APO-UNSUS Wistar rat lines, and the incidence and severity of AA was compared with observations in CV and GF Wistar rats. All APO-SUS rats were resistant, while 10 out of 16 APO-UNSUS rats appeared to be susceptible for AA ( $P = 0.0001$ ,  $\chi^2$  test) (Table 1). When we measured the paw thickness, only a moderate increase was noted in the APO-UNSUS rats, with a late onset (Fig. 1).

The susceptibility of the CV Wistar rats, compared with the APO-SUS and APO-UNSUS rats, appeared to be intermediate (3 out of 14). On the other hand, almost all the GF Wistar rats were susceptible for AA, and developed a severe and chronic joint inflammation (Fig. 1, \* $P = 0.0001$  versus CV Wistar rats, Wilcoxon rank sum test).

**Table 1.** Clinical expression of adjuvant arthritis (AA) in the different Wistar rats after the induction of AA

	0	1	2
APO-SUS	16	-	-
APO-UNSUS	6	6	4
CV Wistar	11	3	-
GF Wistar	1	4	6

The severity of arthritis was scored visually on a scale of 0-2; 0 = no redness or swelling; 1 = mild swelling and redness; 2 = severe swelling and redness. The data shown are the number of animals belonging to each group, 20 days after induction of arthritis. The susceptibility to AA between apomorphine susceptible (APO-SUS) and apomorphine unsusceptible (APO-UNSUS) was significantly different ( $P = 0.0001$ ,  $\chi^2$  test).


*Corticosterone levels after IL-1 $\alpha$  injection in APO-SUS and APO-UNSUS rat lines*

We analysed the effect of IL-1 $\alpha$  injection on plasma corticosterone levels in both APO-SUS and APO-UNSUS rats. This proinflammatory cytokine is able to stimulate the HPA axis, resulting in an increased plasma concentration of the anti-inflammatory steroid hormone corticosterone.


Intravenous (i.v.) injection of 1  $\mu$ g IL-1 $\alpha$  in cannulated APO-SUS and APO-UNSUS rats resulted in an increase of plasma corticosterone levels at 30 min (Fig. 2). No significant differences could be detected between corticosterone levels in the APO-SUS and APO-UNSUS rats. Corticosterone levels in control animals, injected with saline alone, remained low throughout the entire experiment.

*Corticosterone levels after AA induction in Wistar rat lines*

We examined corticosterone levels after the induction of AA in cannulated APO-SUS and APO-UNSUS rats. As shown in



**Fig. 1.** Susceptibility of the same Wistar rats as shown in Table 1, but now scored by measuring the hind paw thickness with an industrial micrometer. Values represent the mean  $\pm$  s.d. of 11-16 rats per group. The germfree (GF) Wistar rats ( $\square$ ) were significantly more susceptible than the conventional (CV) Wistar rats ( $\circ$ ). \*  $P = 0.0001$ , Wilcoxon rank sum test.  $\bullet$ , Apomorphine susceptible (APO-SUS);  $\blacksquare$ , apomorphine unsusceptible (APO-UNSUS).



**Fig. 2.** Plasma corticosterone levels in apomorphine susceptible (APO-SUS) ( $\bullet$ ) and apomorphine unsusceptible (APO-UNSUS) ( $\blacksquare$ ) rats after i.v. injection of 1  $\mu$ g of recombinant human IL-1 $\alpha$  (closed symbols) at  $t = 0$  min. Each time point represents the mean  $\pm$  s.d. of eight animals. The control groups received saline alone (open symbols).


**Fig. 3.** no significant differences could be detected in plasma corticosterone between these two different rat lines (ANOVA, days 15, 18, 21).

*Susceptibility to AA in Lewis, CV F344 and GF F344 rats*

It is known from previous studies that GF F344 rats are highly susceptible, whereas CV F344 are resistant to bacterial arthritis. We analysed the corticosterone response in these rats, both after IL-1 exposure and after induction of AA. Figure 4 shows the difference in AA susceptibility between the CV and GF F344 rats in this set of experiments. For comparison, data from Lewis rats are also given.

*Corticosterone levels after IL-1 $\alpha$  injection in F344 rats*

The corticosterone response after i.v. injection of IL-1 $\alpha$  was similar in CV and GF F344 rats (Fig. 5). Of interest, the peak levels were twice as high in F344 rats as in Wistar rats (Fig. 2). The control animals, injected with saline alone, showed no increase in plasma corticosterone.



**Fig. 3.** Plasma corticosterone levels in apomorphine susceptible (APO-SUS) ( $\bullet$ ) and apomorphine unsusceptible (APO-UNSUS) ( $\blacksquare$ ) rats after induction of adjuvant arthritis (AA) at day 0. Blood samples were collected at 11:00 a.m. Values represent the mean  $\pm$  s.d. of five animals per group. ANOVA (days 15, 18, 21) revealed no significant difference between both groups.




Fig. 4. Different susceptibility of Lewis ( $\circ$ ), conventional (CV) F344 ( $\blacksquare$ ) and germ-free (GF) F344 ( $\bullet$ ) rats to the induction of adjuvant arthritis (AA). The arthritis was scored by measuring the hind paw thickness with an industrial micrometer. The values represent the mean  $\pm$  s.d. of four animals per group

#### Corticosterone levels after induction of AA in F344 rats

Finally, we analysed the course of corticosterone responses after immunization and during the onset of AA in F344 rats. Figure 6 shows that plasma corticosterone levels remained low in the resistant CV F344 rats during the whole period of observation. Compared with the CV F344, a significant increase (ANOVA  $P < 0.01$ , days 14, 18, 21) in corticosterone levels was observed during the onset of AA in the GF F344 rats (day 18, \*  $P < 0.05$ , Student's  $t$ -test).

## DISCUSSION

There is now increasing evidence that not only the genetic background, but also the bacterial flora and neuroendocrine system determine the overall immune response of an individual. In this study we analysed the relative importance of the activity of the HPA axis and the bacterial flora in determining susceptibility to AA.

The observation that the stress-susceptible APO-SUS Wistar rats were significantly less susceptible to AA than the




Fig. 5. Plasma corticosterone levels in conventional (CV) ( $\blacksquare$ ) and germ-free (GF) F344 ( $\bullet$ ) rats after the injection of  $1 \mu\text{g}$  IL- $1\alpha$  intravenously at  $t = 0$  min (closed symbols). Values represent the mean  $\pm$  s.d. of six to eight animals per group. The control groups received saline alone (open symbols).




Fig. 6. Plasma corticosterone levels in conventional (CV) ( $\blacksquare$ ) and germ-free (GF) F344 ( $\bullet$ ) rats after the induction of adjuvant arthritis (AA). Blood samples were collected at 11:00 a.m. Values represent the mean  $\pm$  s.d. of six animals per group. ANOVA revealed a statistically significant difference for both groups (days 14, 18, 21), day 18 \*  $P < 0.05$ , Student's  $t$ -test.

stress-resistant APO-UNSUS rats is in agreement with recent findings in the EAE model [11], although the differences appeared to be more pronounced in the latter model. These findings suggest that different types of behavioural and neuroendocrinological responses to stress are correlated to different susceptibility to AA. Although we may not conclude that there is a causal relationship between stress and susceptibility to AA, several other data do indicate that stress can affect susceptibility. For instance, it has been observed that susceptibility to EAE can be partially suppressed by environmental stress [14]. Similarly, we observed that stress, induced by daily injection of a vehicle substance, may result in almost complete prevention of murine type II collagen arthritis ([15], manuscript in preparation). In addition, studies in patients with rheumatoid arthritis (RA) also demonstrated immunosuppressive effects of stress [16,17]. In contrast, other investigators emphasize that stress may selectively affect the T suppressor cell system in RA patients [18].

Interestingly, very recent differences were observed in T cell responsiveness between APO-SUS and APO-UNSUS rats (A. Kavelaars *et al.*, manuscript in preparation). It appeared that lymphocytes from APO-SUS rats had an increased mitogen reactivity and a higher number of natural killer (NK) and T suppressor/cytotoxic cells than lymphocytes from APO-UNSUS rats.

The fact that CV outbred Wistar rats show intermediate susceptibility [19], compared with the APO-SUS and APO-UNSUS rats, fits in with the fact that the APO-SUS and APO-UNSUS rats represent extremes in an unselected population of rats [10]. Furthermore, the observation that the GF Wistar rats were highly susceptible suggests that the bacterial flora seem to be extremely important in determining susceptibility to AA. This is in line with several previous studies, in which it was demonstrated that GF F344 rats were susceptible to bacterial-induced arthritis [5,6] and that conventionalization of these GF rats could dramatically moderate disease severity [6,20].

Analysis of corticosterone levels in response to administration of IL- $1\alpha$  showed that the genetic background can determine the activity of the HPA axis, since we observed a twice as high corticosterone response in the F344 rats compared with

the Wistar rats Interestingly all the time course experiments with IL 1 $\alpha$  showed identical total corticosterone levels between the Wistar rat lines and between the CV and GF F-344 strains This suggests that the activity of the HPA axis does not determine the susceptibility to AA in these different rats These data support our previous findings [21] but are in contrast with the findings in the susceptible CV Lewis rats [8-9] in which a clear defect of the HPA axis was observed Furthermore a recent study showed that RA patients may also have an abnormal HPA axis response to stress [22] On the other hand we can not totally exclude that differences in plasma steroid hormone levels may still determine susceptibility since we did not discriminate between free corticosterone and carrier bound corticosterone Regarding this Rots *et al* [23] also observed no differences in total corticosterone levels when the same Wistar rat lines were exposed to a novel environment as stress stimulus However when they compared free corticosterone as well as adrenocorticotrophic hormone levels they were then able to show a small increase in the HPA axis activity of the APO SUS rats

Analysis of the corticosterone levels after AA induction showed no significant differences between the APO SUS and APO UNSUS rats over a broad time span This finding parallels the only minor differences in arthritis severity between these two rat lines In the GF F-344 rats however we were able to detect a significant increase in corticosterone levels after the onset of arthritis This increase may be due to the stress of the disease itself The latter phenomenon has also been observed during the onset of the clinical signs of FAE in the Lewis rat [24-25] On the other hand a recent report in AA shows increased levels of plasma corticosterone already at day 7 after immunization in Sprague Dawley rats [26] At that time point there were still no clinical signs of arthritis The difference might be explained by the fact that the HPA axis responsiveness during chronic stress is strain dependent

Finally no increase in corticosterone levels was observed in the resistant CV F344 rats which suggests that resistance of the F344 strain can not be explained by an increased HPA axis activity This indicates that the arthritogenic responses are probably controlled at another level A likely candidate is T cell tolerance especially in the light of our previous findings in which we were able to detect a correlation between T cell responses and susceptibility [6-7] On the other hand we can not exclude that the adrenal response in the CV F344 rats may only increase just after immunization (between days 0 and 7) and in this way directs the immune response to either suppression or reactivity However this is not very likely since an adrenalectomy study in the EAE model showed that corticosterone only had an important regulatory role just before the clinical onset of EAE in the susceptible Lewis strain [24] as well as in the resistant PVG strain [27]

In conclusion our data indicate that differences in behavioural and neuroendocrinological responses to stressors are correlated to differences in susceptibility to bacterial arthritis However the bacterial flora seem far more important in regulating susceptibility Furthermore the corticosterone data suggest that the HPA axis activity correlates with disease severity instead of being a mechanism to prevent disease Analysis of free corticosterone levels in the different susceptible rats and lymphocyte proliferation assays is now in progress These experiments will provide further insight into the relative

importance of steroid hormone levels and T cell tolerance in susceptibility to bacterially induced arthritis

#### ACKNOWLEDGMENTS

We would like to thank Dr M van der Meer for his assistance in performing these studies Mrs C Blom Jongencien Mrs W van de Velde van Leeuwen and Mr D Lozekoot are acknowledged for their analytical support Mr G Grutters from the Central Animal Laboratory is acknowledged for his excellent biotechnical assistance This study was supported by a research grant from Het Nationaal Reuma fonds of The Netherlands

#### REFERENCES

- 1 Pearson CM Development of arthritis peri-arthritis and periostitis in rats given adjuvants Proc Soc Exp Biol Med 1956 91 95-101
- 2 Cromartie WJ Craddock JG Schwib JH Andrie SK Yang C Arthritis in rats after systemic injection of streptococcal cells or cell walls J Exp Med 1977 146 1585-602
- 3 Battisto JR Smith RN Beckman K Sternlicht M Willes WL Susceptibility to adjuvant arthritis in DA and F344 rats a dominant trait controlled by an autosomal gene locus linked to the major histocompatibility complex Arthritis Rheum 1982 25 1194-1200
- 4 Wilder RL Calandra GB Garvin AJ Wright KD Hinsen CT Strain and sex variation in the susceptibility to streptococcal cell wall induced polyarthritis in the rat Arthritis Rheum 1982 25 1064-72
- 5 Kohashi O Kuwata J Umehara K Umehara F Takahashi T Ozawa A Susceptibility to adjuvant induced arthritis among germ free specific pathogen free and conventional rats Infect Immun 1979 26 791-4
- 6 van den Broek MF van Bruggen MCJ Knoopman JP Hazenberg MP van den Berg WB Gut flora induces and maintains resistance against streptococcal cell wall induced arthritis in F-344 rats Clin Exp Immunol 1992 88 313-7
- 7 van den Broek MF van Bruggen MCJ van de Putte IBA van den Berg WB T cell responses to streptococcal antigens in rats relation to susceptibility to streptococcal cell wall induced arthritis Cell Immunol 1988 116 216-29
- 8 Sternberg EM Young WS III Bernardini R Calogero A Chrousos GP Gold PW Wilder RL A central nervous system defect in biosynthesis of corticotropin releasing hormone is associated with susceptibility to streptococcal cell wall arthritis in Lewis rats Proc Natl Acad Sci USA 1989 86 4771-5
- 9 Sternberg EM Hill JM Chrousos GP Kamilaris I Listwak SJ Gold PW Wilder RL Inflammatory mediator induced hypothalamic pituitary adrenal axis activation is defective in streptococcal cell wall arthritis susceptible Lewis rats Proc Natl Acad Sci USA 1989 86 7174-8
- 10 Cools AR Brachten R Heeren D Willkens A Ellenbroek B Search after neurobiological profile of individual specific features of Wistar rats Brain Res Bull 1990 24 49-69
- 11 Cools AR Rots NY Ellenbroek B de Kloet FR Bimodal shape of individual variation in behaviour of Wistar rats The overall outcome of a fundamentally different make up and reactivity of the brain the endocrinological and the immunological system Neuropsychobiol 1993 28 100-5
- 12 Steffens AB A method for frequent sampling of blood and continuous infusion of fluids in the rat without disturbing the animal Physiol Behav 1969 4 833-6
- 13 Sweep CGJ van der Meer MJM Hermus ARMM *et al* Chronic stimulation of the pituitary adrenal axis in rats by interleukin 1 $\beta$  infusion in vivo and in vitro studies Endocrinology 1992 130 1151-64
- 14 Levine S Strubel R Wenk EJ Harman PJ Suppression of experi



- mental allergic encephalomyelitis by stress Proc Soc Exp Biol Med 1962 **109** 294-8
- 15 Joosten LAB Helsen MMA van den Berg WB Accelerated onset of collagen induced arthritis by remote inflammation Clin Exp Immunol in press
  - 16 McFarlane AC Brooks PM Psychoimmunology and rheumatoid arthritis: concepts and methodologies Int J Psychiatry Med 1990 **20** 307-22
  - 17 Harrington L Affleck G Urrows S Tennen H Higgins P Zautra A Hoffman S Temporal covariation of soluble interleukin 2 receptor levels, daily stress, and disease activity in rheumatoid arthritis Arthritis Rheum 1993 **36** 199-203
  - 18 O'Leary A Stress, emotion, and human immune function Psychol Bull 1990 **108** 363-82
  - 19 Awouters F Lenaerts PMH Niemegeers CJG Increased incidence of adjuvant arthritis in wistar rats Arzneimittel Forsch (Drug Res) 1976 **26** 40-3
  - 20 Kohashi O Kohashi Y Takahashi T Ozawa A Shigematsu N Suppressiv effect of *Escherichia coli* on adjuvant induced arthritis in germfree rats Arthritis Rheum 1986 **29** 547-53
  - 21 van de Langerijt AGM van Lent PLEM Hermus ARMM van de Putte LBA van den Berg WB Regulation of resistance against adjuvant arthritis in the Fisher rat Clin Exp Immunol 1993 **94** 150-5
  - 22 Chikanza IC Petrou P Kingsley G Chrousos G Panayi GS Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis Arthritis Rheum 1992 **35** 1281-8
  - 23 Rots NY Cools AR de Jong J De Kloet ER Characterization of the pituitary-adrenal response in rats selected for differential responsiveness of the nigrostriatal dopaminergic system Submitted for publication
  - 24 MacPhee IAM Antoni FA Mason DW Spontaneous recovery of rats from experimental allergic encephalomyelitis is dependent on regulation of the immune system by endogenous adrenal corticosteroids J Exp Med 1989 **169** 431-45
  - 25 Levine S Sowinski R Steinetz B Effects of experimental allergic encephalomyelitis on thymus and adrenal: Relation to remission and relapse Proc Soc Exp Biol Med 1980 **165** 218-24
  - 26 Sarlis NJ Chowdrey HS Stephanou A Lightman SL Chronic activation of the hypothalamo-pituitary-adrenal axis and loss of circadian rhythm during adjuvant induced arthritis in the rat Endocrinology 1992 **130** 1775-9
  - 27 Mason DW MacPhee I Antoni F The role of the neuroendocrine system in determining genetic susceptibility to experimental allergic encephalomyelitis in the rat Immunology 1990 **70** 1-5

# CHAPTER 7

Role of  $\beta 2$  integrins in the recruitment of phagocytic cells in joint inflammation in the rat

*Clin. Immunol. Immunopathol. in press.*



## Role of $\beta 2$ Integrins in the Recruitment of Phagocytic Cells in Joint Inflammation in the Rat

A G M VAN DE LANGERIJT, I HUITINGA,\* L A B JOOSTEN, C D DIJKSTRA,\* P L E M VAN LENT, AND  
W B VAN DEN BERG

Department of Rheumatology, University Hospital Nijmegen, P O Box 9101, 6500 HB Nijmegen, and \*Department of Cell Biology, Medical Faculty, Vrije Universiteit, van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands

Adhesion molecules of the  $\beta 2$  family of integrins play an important role in adhesion and migration of leukocytes to inflammatory sites. Several *in vivo* studies indicate that not only monoclonal antibodies (mAbs) directed against the common  $\beta$  subunit (CD18) but also to the individual  $\alpha$  subunits (CD11a, CD11b) can effectively inhibit different types of inflammation. In this study we report that in the adjuvant arthritis (AA)  $\alpha$ CD11a,  $\alpha$ CD11b, or even  $\alpha$ CD18 treatment could not prevent disease development. Moreover, we examined the same mAbs in an acute nonspecific inflammation at different sites in the rat. We found that pretreatment with  $\alpha$ CD11a or  $\alpha$ CD11b could significantly block a zymosan peritonitis, but appeared to have no effect on a locally induced joint or dermal inflammation. Interestingly,  $\alpha$ CD18 treatment, which blocks the entire CD11/CD18 complex, was able to inhibit the influx of inflammatory cells in a peritonitis as well as in a joint and dermal inflammation. These data not only indicate that the type of joint inflammation determines which adhesion molecules play a role in transendothelial migration, but also that involvement of the  $\beta 2$  integrins is highly site specific. © 1994 Academic Press Inc

### INTRODUCTION

The process of adhesion and transendothelial migration of leukocytes plays an important role in the onset of inflammatory reactions. Adhesion molecules involved in the attachment to the vascular endothelium comprise the integrins, a group of receptors containing several subfamilies (1). The CD11/CD18 complex belongs to the  $\beta 2$  subfamily of integrins and has three members with distinct  $\alpha$  chains, CD11a, CD11b, and CD11c, and a common noncovalently bound identical  $\beta$  chain, CD18. CD11a/CD18 (LFA-1), CD11b/CD18 (CR3), and CD11c/CD18 (p150,95) are expressed on monocytes and granulocytes, whereas CD11a is also expressed on B and T lymphocytes (1, 2).

At present, monoclonal antibodies (mAbs) are available, which are directed specifically against CD18, CD11a, CD11b, or their ligand, the intercellular adhesion molecule-1 (ICAM-1). This makes it possible to examine the role of the different adhesion molecules in

inflammatory models, like joint inflammation. Lately, several *in vivo* studies have tested the effects of these mAbs in different types of joint inflammation. Pretreatment with anti-CD18 ( $\alpha$ CD18) could inhibit the influx of polymorphonuclear cells (PMN) to an IL-8-induced joint inflammation (3), whereas both  $\alpha$ ICAM-1 as well as  $\alpha$ CD11a are able to suppress a peptidoglycan/muramyl dipeptide-induced arthritis (4). Furthermore, treatment with  $\alpha$ CD18 not only inhibited the initial influx of inflammatory cells in the acute phase, but also resulted in an amelioration of the chronic phase of an antigen-induced arthritis (5).

Finally, it has been shown that adjuvant arthritis (AA) can be suppressed with  $\alpha$ ICAM-1 (6) and collagen-induced arthritis with either  $\alpha$ ICAM-1 or  $\alpha$ CD11 (4). However, in the latter studies treatment was started early and also affected the generation of cell-mediated immunity against the injected antigen. Therefore, it is hard to determine whether these mAbs selectively interfered with the migratory processes of inflammatory cells to the joint. Of interest, the migration of PMNs to the AA joint seems to be mediated through CD11a, whereas T cells appear to use CD11a/CD11b-independent mechanisms (7).

The aim of the present study was twofold. First, we investigated whether different adhesion molecules in the joint may be utilized for leukocyte migration, depending on the type of inflammation. Second, we investigated whether the joint differs from other sites in the body with respect to the type of adhesion molecules used during inflammation. We first analyzed whether the onset of AA can be prevented by blocking the migratory processes with mAbs against CD11a, CD11b, or all the  $\beta 2$  integrins. This chronic joint disease can be induced in Lewis rats by immunization with heat-killed *Mycobacterium tuberculosis* in Freund's incomplete adjuvant (FIA) (8). Moreover, we examined the effects of pretreatment with the same mAbs in an acute, nonspecific inflammation. For this purpose, zymosan was injected in the joint, peritoneum, or derm.

It was found that none of the mAbs prevented the onset of AA. Furthermore, pretreatment with  $\alpha$ CD11a

or  $\alpha$ CD11b only inhibited the migration of phagocytes to an inflamed peritoneum but not toward an inflamed joint or dermal inflammation. In contrast, treatment with  $\alpha$ CD18 was able to block effectively, independent of the site of inflammation.

## MATERIALS AND METHODS

### Animals

Lewis rats were originally obtained from the Zentral Institut für Versuchstierzucht (Hannover, FRG) and were bred in our own facilities. Rats weighed 160–220 g at the start of the experiments and were fed tap water and standard chow *ad libitum*.

### mAb Production and Treatment

Hybridomas secreting  $\alpha$ CD18 (WT-3, mouse IgG1),  $\alpha$ CD11a (WT-1, mouse IgG2a) (9), both a kind gift from Dr M Miyasaka, or  $\alpha$ CD11b (ED7, mouse IgG1) (10) were used to produce ascites fluid in BALB/C *rnur/nur* mice by standard methods. mAbs were purified using protein G-Sepharose CL-4B (Pharmacia LKB, Uppsala, Sweden) and stored at 4°C in saline (4 mg/ml). The control group received BOM22 (mouse IgG1 anti-human CD74), kindly provided by Dr W A Allebes (11). Rats were injected intravenously (i.v.) into the tail vein.

### Induction of AA

To induce AA, female Lewis rats were immunized intradermally at the base of the tail with 100  $\mu$ l of 10 mg/ml *M tuberculosis* (H37RA, Difco Laboratories, Inc., Detroit, MI) suspended in FLA (Difco). The arthritis was scored macroscopically by measuring hind paw thickness with an industrial micrometer. At the end of the experiment ankle joints were removed and the level of inflammation was determined by histology.

### Induction of Sterile Peritonitis

To induce sterile peritonitis, male or female Lewis rats were injected intraperitoneally (i.p.) with 5 mg zymosan (Sigma, St. Louis, MO) dissolved in 2 or 4 ml of saline. After 18 hr rats were sacrificed and the peritoneal cavity was washed once with 40 ml saline. The isolated peritoneal cells were washed and counted in a Coulter counter. Differential leukocyte counts of the peritoneal cells were determined morphologically using Wright Giemsa stained cytospin preparations. At least 200 nucleated cells were counted per preparation.

### Induction of Unilateral Joint Inflammation

A nonspecific unilateral joint inflammation was induced by injecting either 0.2 or 0.6 mg zymosan in 60  $\mu$ l phosphate-buffered saline (PBS) into the right knee joint of female Lewis rats. As a control, 60  $\mu$ l PBS was

injected into the left knee joint of the same animal. After 24 hr animals were sacrificed and the severity of arthritis was determined by histology.

### Induction of Intradermal Inflammation

A unilateral intradermal inflammation was induced by injecting 40  $\mu$ g zymosan in 10  $\mu$ l PBS into the pinna of the right ear in female Lewis rats. As a control, 10  $\mu$ l PBS was injected into the left ear. After 24 hr the increase in ear thickness was determined using an industrial micrometer. The severity of ear swelling was expressed as the ratio of the thickness in the right ear over the left (control) ear. The rats were then sacrificed to determine the level of inflammation by histology.

### Histology

Knee or ankle joints and ears were removed and processed for histology as described (12). Paraffin sections (7  $\mu$ m) were made and stained with hematoxylin and eosin (H&E). Scoring of inflammation was done by two independent observers on coded sections.


### mAb Treatment

In all the zymosan-induced inflammation experiments the animals were pretreated for 1 hr before in-

TABLE 1  
Peritoneal Recruitment Assay

Treatment	n	Total cell number $\times 10^7$ obtained from peritoneum	% Blockade	Identification of peritoneal cells	
				PMN	Mo
<b>Expt 1</b>					
Control IgG	5	5.4 $\pm$ 1.3	—	ND	
$\alpha$ CD18		ND			
$\alpha$ CD11a	5	1.5 $\pm$ 0.6*	72	ND	
$\alpha$ CD11b	5	1.8 $\pm$ 0.8*	63	ND	
<b>Expt 2</b>					
Control IgG	10	10.2 $\pm$ 2.7		63 $\pm$ 3	37 $\pm$ 3
$\alpha$ CD18	10	1.6 $\pm$ 1.3*	82	66 $\pm$ 4	34 $\pm$ 4
$\alpha$ CD11a	10	6.6 $\pm$ 2.2**	35	63 $\pm$ 3	37 $\pm$ 3
$\alpha$ CD11b	10	6.0 $\pm$ 2.5**	41	69 $\pm$ 4	31 $\pm$ 4
<b>Expt 3</b>					
Control IgG	6	14.3 $\pm$ 2.2		ND	
$\alpha$ CD18	6	1.7 $\pm$ 0.3*	88	ND	
$\alpha$ CD11a	6	8.2 $\pm$ 1.3**	43	ND	
$\alpha$ CD11b	6	9.1 $\pm$ 3.3**	36	ND	

*Note.* Effect of mAb pretreatment on leukocyte migration to the peritoneum of female (Experiment 1) and male (Experiment 2) Lewis rats 18 hr after 5 mg zymosan in 2 ml saline. In Experiment 3 the peritonitis was induced in male Lewis rats with 5 mg zymosan in 4 ml of saline. Blockade of the migration compared to the control is significant. \* $P < 0.001$  and \*\* $P < 0.02$  (Wilcoxon rank sum test). In Experiment 2 differential leukocyte counts were performed morphologically using Wright Giemsa stained slide preparations. The ratio of polymorphonuclear (PMN) cells and mononuclear (Mo) cells was determined by counting at least 200 nucleated cells. ND, not done. Presented are the mean values  $\pm$  SD ( $n$  = number of animals per group). The majority of cells in the peritoneum are PMNs.



**FIG 1** Effect of intravenous injections of 4 mg of αCD18, αCD11a, αCD11b and IgG1 control on the development of AA. Treatment was performed every other day starting at Day 7 after immunization. The arthritis score is expressed as the sum of both hind paws. Each group consisted of six animals per group.

duction of the inflammation. Furthermore, all mAbs were injected into the tail vein at a dose of 2 mg, dissolved in 1 ml saline.

Regarding the AA model, each animal was injected iv with 4 mg of each mAb (in 1 ml saline) every other day, starting at Day 7 after induction of the disease.

**FACS Analysis**

In AA the treatment protocol was verified at Day 19 by collecting heparin blood of each animal for FACS analysis. This FACS analysis was carried out using standard procedures. Briefly, 100 μl heparin blood of each animal was incubated for 30 min at 4°C with either the control mAb or with the mAb used for *in vivo* treatment. The samples were then washed in PBS-1% BSA and 0.1% sodium azide, and labeled at 4°C with FITC-conjugated F(ab')<sub>2</sub> fragments of rabbit anti-mouse IgG (Dakopatts, Denmark). After 30 min the erythrocytes were lysed and the cells were washed with

PBS-1% BSA and 0.1% sodium azide. Finally 5000 cells from each sample were analyzed in a Coulter Epics flow cytometer.

In addition, serum of each animal was collected and analyzed for the presence of free mAbs. Therefore, cytopins of naive peritoneal cells were incubated for 1 hr with sera from the AA rats, which were injected with αCD18, αCD11a, αCD11b, or the control IgG1. These murine IgGs were then detected with rabbit anti-mouse IgG peroxidase (Dakopatts, Denmark).

**RESULTS**

*Effect of mAbs in Zymosan-Induced Peritonitis*

We first determined the inhibitory effects of a single treatment with 2 mg of either mAb in an acute peritonitis. Blocking of either CD11a or CD11b appeared to be equally effective in inhibiting the influx of inflammatory cells (Table 1). In a relatively mild peritonitis, inhibition with both mAbs was even more prominent (Table 1, Experiment 1). Furthermore, pretreatment with the αCD18 mAb, which blocks the common β chain of the entire β2 integrin subfamily, almost completely blocked the influx of inflammatory cells into the peritoneum.

Differential leukocyte counts showed that two-thirds of the infiltrating cells were PMN cells and one-third were mononuclear (Mo) cells. No differences were observed in the PMN/Mo ratio between the different groups (Experiment 2).

Since we observed that these mAbs were effective in an acute peritonitis, similar dosages were used for modulation of joint inflammation.

*Effect of mAbs on Development of AA*

In AA 2 mg of either mAb was injected every other day, starting 7 days after induction of disease (6 days before the first macroscopic signs). Since no effect was

**TABLE 2**  
FACS Analysis on Circulating Phagocytes from Animals Treated with Different Anti-β2 Integrins during AA

Origin cells	Incubated with mAb	Mean fluorescent intensity and % blockade		
		PMNs	Lymphocytes	Mononuclear cells
Control IgG group	Control IgG	13 ± 1	8 ± 1	9 ± 1
	αCD18	214 ± 16	28 ± 3	540 ± 63
	αCD11a	170 ± 11	37 ± 3	529 ± 51
	αCD11b	124 ± 7	11 ± 1	235 ± 25
	αCD18	181 ± 13 (93%)	17 ± 2 (81%)	564 ± 79 (95%)
αCD18 group	Control IgG	194 ± 20	21 ± 3	596 ± 54
	αCD18	104 ± 23 (81%)	15 ± 2 (100%)	488 ± 71 (95%)
αCD11a group	Control IgG	128 ± 28	15 ± 3	512 ± 61
	αCD11a	169 ± 14 (97%)	11 ± 2 (92%)	184 ± 13 (97%)
αCD11b group	Control IgG	174 ± 15	12 ± 1	190 ± 21
	αCD11b			

*Note:* Circulating blood cells from the different groups of animals were incubated with either the control isotype or the mAb used for *in vivo* treatment and the mean fluorescent intensity was determined on a FACS. Each value represents the mean ± SD of six animals.




FIG. 2. Histology of rat knee joints 24 hr after 200  $\mu$ g zymosan ia previously injected with either (a) aCD18 or (b) IgG1 control. Control joint was injected ia with PBS (c). Staining: hematoxylin & eosin. Original magnification:  $\times 23$ . F, femur; P, patella.

observed with this protocol (data not shown), not even in the αCD18-treated animals, it was decided to increase the mAb dose to 4 mg. However, even treatment with the high dose of either mAb did not suppress paw swelling in comparison with the control IgG1 (Fig. 1). Moreover, histological analysis of the joints revealed no effect at all on the number of infiltrating cells, not even in the αCD18-treated animals (data not shown).

At the end of the experiment, 2 days after the last mAb injection, a FACS analysis was performed on the circulating leukocytes. This was done in order to determine whether sufficient concentrations of either mAb had been administered. This analysis showed that the binding of IgG to the various β2 integrins on the circulating phagocytes was still high and could hardly be increased by *ex vivo* incubation with the same mAbs (Table 2). Furthermore, Table 2 shows a high fluorescence intensity on PMNs and Mo cells, while incubation with αCD11a and αCD18 only showed a low fluorescence intensity on T cells. In addition, a two-fold increase was found in the number of circulating phagocytes in the αCD18-treated animals, a phenomenon which was also observed in CD18-deficient patients (13).

Finally, immunocytochemistry showed that free mAbs were still present in sera of the different groups of animals, since peritoneal cells obtained from untreated rats, incubated with these sera, became positive for the various anti-β2 integrins (data not shown). Altogether these data indicate adequate mAb titers in the treated animals.

*Effect of mAbs on Locally Induced Zymosan Inflammation*

Given the different effects of the anti-β2 integrin mAbs in a peritonitis, as compared with AA, it became of interest to investigate the role of the β2 integrins in inflammations at different sites, elicited with the same stimulus. Zymosan was therefore injected in either the joint or derm after the animals were pretreated with αCD11a, αCD11b, or αCD18. Since 2 mg of either mAb was sufficient to inhibit the influx of phagocytes to the peritoneum, the same dose was used in the joint and derm.

In a zymosan-induced joint inflammation, a dose-dependent increase of infiltrating cells in the control mAb-treated animals was observed and consisted predominantly of PMNs (Fig. 2B). As seen in Table 3, αCD18 pretreatment blocked the influx of inflammatory cells in both the 0.2- and 0.6-mg zymosan-induced inflammation. In contrast, with the peritonitis experiments, both αCD11a and αCD11b groups showed no decrease in the number of infiltrating cells. Remarkably, αCD11b pretreatment even caused a minor, but not significant, increase in the level of inflammation at the highest dose.

Injection of 40 μg of zymosan in the derm of the ear induced an inflammation which almost exclusively attracted PMNs (Fig. 3B). Both αCD18 and αCD11a were able to reduce ear swelling, although αCD11a was less prominent (Table 4). αCD11b appeared to have no effect on the swelling (compared to the control mAb). Histological analysis of the H&E-stained sections showed that αCD18 pretreatment almost completely blocked the influx of PMNs. In contrast, treatment with αCD11a alone tended to decrease the number of infiltrating cells, but this was variable and did not reach significance. αCD11b pretreatment exhibited no effect at the histological level.

DISCUSSION

Adhesion of inflammatory cells such as lymphocytes, granulocytes, and monocytes to the vascular endothelium is essential for transendothelial migration toward an inflamed site. Several studies have already showed that *in vivo* phagocyte migration to the joint can be partially or completely blocked using specific mAbs raised against the β2 integrins or their ligand ICAM-1 (3-5).

Our peritonitis data are in agreement with earlier findings on anti-β2 integrin treatment of an inflamed peritoneum in mice (14, 15). A single study in the rat (10) showed a similar trend, although the net suppression of cell influx was less impressive. In contrast, a recent report (16) observed a CD11/CD18-independent phase (24 hr) in a rabbit peritonitis model. However, this study used different stimuli (peptone or *Escherichia coli*) to induce the peritonitis, suggesting that the regulation of migration might be stimulus dependent. In addition, our data clearly indicate that these mAbs are effective for investigating the *in vivo* role of the β2 integrins in joint inflammation.

TABLE 3  
Histology Scores of Unilateral Zymosan Inflammation 24 hr after Intraarticular Injection

Treatment	Zymosan dose (mg)	Inflammation	% Blockade
Expt 1			
Control IgG	0.2	1.8 ± 0.3	
αCD18	0.2	0.7 ± 0.3*	60
αCD11a	0.2	1.6 ± 0.7	9
αCD11b	0.2	1.9 ± 0.5	-7
Expt 2			
Control IgG	0.6	2.4 ± 0.3	
αCD18	0.6	1.3 ± 0.4*	47
αCD11a	0.6	2.4 ± 0.4	0
αCD11b	0.6	2.8 ± 0.2	-16

Note: Histological scores 24 hr after zymosan intraarticular. Level of inflammation was scored on coded, hematoxylin and eosin stained slides: 0, no inflammation; 3, large mass of inflammation. \*P < 0.01 (Wilcoxon rank sum test). Values represent the mean ± SD of six animals per group.






FIG. 3. Histology of rat ears 24 hr after 40  $\mu$ g zymosan intradermally, previously injected with either (A)  $\alpha$ CD18 or (B) control isotype. Control ear was injected with PBS (C). Staining: hematoxylin & eosin. Original magnification:  $\times 90$ .

**TABLE 4**  
**R/L Ratios of Ear Thickness and Histology Scores 24 hr after Intradermal Zymosan Injection**

Treatment	Swelling		Histological scores	
	R/L ratio	% Inhibition	Inflammation	% Blockade
Control IgG	1.83 ± 0.12		2.3 ± 0.7	
αCD18	1.45 ± 0.08*	46	0.3 ± 0.2*	89
αCD11a	1.66 ± 0.08**	20	1.8 ± 0.7	22
αCD11b	1.76 ± 0.03	8	2.1 ± 0.3	8

*Note:* Effect of MAb pretreatment on ear thickness and leukocyte migration 24 hr after inducing an intradermal inflammation. The severity of ear swelling is expressed as the ratio of the thickness in the right over that of the left ear \*P < 0.01 and \*\*P < 0.05 (Wilcoxon rank sum test). Level of inflammation was scored on coded hematoxylin and eosin stained slides: 0 = no inflammation, 3 = large mass of inflammation. Values represent the mean ± SD of six animals per group.

Earlier studies demonstrated that the β2 integrins play a role in Ag presentation (17) and cell-cell interactions between antigen-presenting cells and T cells (4, 6). To exclude this type of interference on generation of immunity in our adjuvant arthritis studies, we decided to start treatment with either mAb 7 days after induction of AA, at that time point AA can already be transferred with lymphocytes (18). Our protocol did not prevent AA, suggesting that the dominant migration of cells to arthritic joints is at least in part mediated via CD11a/CD11b-independent mechanisms. This is in agreement with recent studies showing that a major portion of the PMNs and T cells use CD11a/CD11b-independent mechanisms during AA, αCD11a partially inhibited only the influx of PMNs (7), while αVLA-4 (α4β1) was able to selectively inhibit the influx of T cells (19). Furthermore, αICAM-1 treatment appeared to have at best minimal effects on the onset of AA in an adoptive transfer experiment (6).

In contrast, studies in other models, e.g., insulin-dependent diabetes mellitus (20) and experimental autoimmune uveitis in mice (21) or autoimmune glomerulonephritis in rats (22), showed suppression of disease development with early anti-β2 treatment. However, since late treatment showed no effects, interference with cell-cell interaction and the generation of autoreactive T lymphocytes may very well have accounted for these protective effects. Interestingly, late treatment (Day 7) with αCD11b in rat EAE inhibited disease development (10). However, histological analysis showed no reduction in the number of infiltrating macrophages, suggesting that this treatment protocol may have influenced other phagocyte functions rather than migration. Recent reports that αICAM-1 mAbs had no effect on EAE (23, 24) support the latter.

Our FACS analysis data show that the expression of the CD11a and of course CD11b molecules was very low on circulating lymphocytes. This suggests that the influx of T cells, which play such an important role in AA (18), is not suppressed and that the T cell-mediated

regulation of phagocyte influx uses different integrins as compared with nonimmune inflammation. Integrins like VLA-4 are expressed at higher levels on lymphocytes (25) and therefore may form a more promising target in inhibiting T cell-driven arthritis. Interestingly, several *in vitro* studies show a prominent role for VLA-4 in the lymphocyte-rheumatoid synovium interactions (26-28).

Our results with αCD18 treatment in nonimmune inflammation are in agreement with earlier reports on αCD18 mAbs in the joint (3, 5) and other acute inflammatory models (29-35). Regarding the selective blocking of either CD11a or CD11b, variable results have been reported. Slight inhibitory effects were found with αCD11a in the joint (4, 7) and derm (36). Recently, Mulligan *et al.* (37) reported that a PMN-dependent inflammation could be effectively blocked with αCD11a, whereas an inflammation in which macrophages were the main effector cells appeared to be more CD11b dependent. In our zymosan-induced joint and dermal inflammation, PMNs were the main infiltrating cells, yet we did not observe significant suppression with αCD11a. Pretreatment with αCD11b had no effect in a dermal inflammation and even slightly enhanced a joint inflammation. Interestingly, this latter effect has also been reported in a dermal inflammation model (36). In that study it was suggested that blocking of CD11b may prime or activate phagocytes for a more efficient response to C5a.

In conclusion, the relative contribution of the various adhesion molecules seems site and stimulus specific, a phenomenon which has also been observed *in vitro* (38). Our data suggest that inhibition of one β2 integrin in the joint and derm is insufficient and might even facilitate the usage of other β2 integrins. In the peritoneum, influx requires the combined expression of CD11a and CD11b since blocking one or the other is already sufficient to diminish the influx of PMNs and macrophages. Whether these differences reflect low expression of adhesion molecules on peritoneal endothelium per se or local release of different cytokine balances remains to be investigated. Future studies with mAbs directed against other integrins (VLA-4, CD11c) or combinations of these mAbs should help unravel the applicability to block particular joint inflammations.

**ACKNOWLEDGMENTS**

We are grateful to Dr. M. Miyasaka, Department of Immunology, The Tokyo Metropolitan Institute of Medical Science, Tokyo, for the WT-1 and WT 3 hybridomas and Dr. W. Allebes (University Transfusion Service Nijmegen) for providing BOM22. In addition, we thank Gerry Grutters and Jan van Wezel (Central Animal Laboratory) for technical assistance and animal care. This study was supported by a research grant from the Dutch League against Rheumatism.

**REFERENCES**

1. Springer, T. A. Adhesion receptors of the immune system. *Nature* 346, 425-434, 1990.

- 2 Arnaout, M A, Structure and function of the leukocyte adhesion molecules CD11/CD18 *Blood* 75, 1037-1050, 1990
- 3 Forrest, M J, Eiermann, G J, Meurer, R, Walakovits, L A, and MacIntyre, D E, The role of CD18 in IL-8 induced dermal and synovial inflammation *Br J Pharmacol* 106, 287-294, 1992
- 4 Kakimoto, K, Nakamura, T, Ishii, K, Takashi, T, Igou, H, Yagita, H, Okumura, K, and Onoue K, The effect of anti-adhesion molecule antibody on the development of collagen-induced arthritis *Cell Immunol* 142, 326-337, 1992
- 5 Jasin, H E, Lightfoot, E, Davis, L S, Rothlein, R, Faanes, R B, and Lipsky, P E, Amelioration of antigen-induced arthritis in rabbits treated with monoclonal antibodies to leukocyte adhesion molecules *Arthritis Rheum* 35, 541-549, 1992
- 6 Igo, Y, Takashi, T, Tamatani, T, Miyasaka, M, Higashida, T, Yagita, H, Okumura, K, and Tsukada, W, ICAM-1-dependent pathway is critically involved in the pathogenesis of adjuvant arthritis in rats *J Immunol* 147, 4167-4171, 1991
- 7 Issekutz, A C, and Issekutz, T B, A major portion of polymorphonuclear leukocyte and T lymphocyte migration to arthritic joints in the rat is via LFA-1/MAC-1-independent mechanisms *Clin Immunol Immunopathol* 67, 257-263, 1993
- 8 Pearson, C M, Development of arthritis, peri-arthritis and periositis in rats given adjuvants *Proc Soc Exp Biol Med* 91, 95-101, 1956
- 9 Tamatani, T, Kotani, M, and Miyasaka, M, Characterization of the rat leukocyte integrin CD11/CD18, by the use of LFA-1 subunit-specific monoclonal antibodies *Eur J Immunol* 21, 627-633, 1991
- 10 Huitinga, I, Damoiseaux, J G M C, Dopp, E A, and Dijkstra, C D, Treatment with anti-CR3 antibodies ED7 and ED8 suppresses experimental allergic encephalomyelitis in lewis rat *Eur J Immunol* 23, 709-715, 1993
- 11 Allebes, W A, Knops, R, Bontrop, R E, Otting, N, Raemakers, J, Haanen, C, and Capel, P J A, Phenotypic and functional changes of tumor cells from patients treated with monoclonal anti-idiotypic antibodies *Scand J Immunol* 32, 441-449, 1990
- 12 Van den Berg, W B, Van Beusekom, H J, Van de Putte, L B A, Zwarts, W A, and Van der Sluis, M, Antigen handling in antigen induced arthritis in mice. An autoradiographic and immunofluorescence study using whole knee joint sections *Am J Pathol* 108, 9-16, 1982
- 13 Anderson, D C, Schmalsteig, F C, Finegold, M J, Hughes, B J, Rothlein, R, Miller, L J, Kohl, S, Tosi, M F, Jacobs, R L, Waldrop, T C, Goldman, A S, Shearer, W T, and Springer, T A, The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency Their quantitative definition and relation to leukocyte dysfunction and clinical features *J Infect Dis* 152, 668-689, 1985
- 14 Rosen, H, and Gordon, S, Monoclonal antibody to the murine type 3 complement receptor inhibits adhesion of myelomonocytic cells in vitro and inflammatory cell recruitment in vivo *J Exp Med* 166, 1685-1702, 1987
- 15 Jutila, M A, Rott, L, Berg, E L, and Butcher, E C, Function and regulation of the neutrophil MEL-14 antigen in vivo Comparison with LFA-1 and MAC-1 *J Immunol* 143, 3318-3324, 1989
- 16 Winn, R K, and Harlan, J M, CD18-independent neutrophil and mononuclear leukocyte emigration into the peritoneum of rabbits *J Clin Invest* 92, 1168-1173, 1993
- 17 Schlesinger, L S, Bellinger-Kawahara, C G, Payne, N R, and Horwitz, M A, Phagocytosis of *Mycobacterium tuberculosis* is mediated by human monocyte complement receptors and complement component C3 *J Immunol* 144, 2771-2780, 1990
- 18 Taurog, J D, Sandberg, G P, and Mahowald, M L, The cellular basis of adjuvant arthritis I Enhancement of cell-mediated passive transfer by concanavalin A and by immunosuppressive treatment of the recipient *Cell Immunol* 75, 271-282, 1983
- 19 Issekutz, T B, and Issekutz, A C, T lymphocyte migration to arthritic joints and dermal inflammation in the rat Differing migration patterns and the involvement of VLA-4 *Clin Immunol Immunopathol* 61, 436-447, 1991
- 20 Hutchings, P, Rosen, H, O'Reilly, L, Simpson, E, Gordon, S, and Cooke, A, Transfer of diabetes in mice prevented by blockade of adhesion-promoting receptor on macrophages *Nature* 348, 639-642, 1990
- 21 Whitcup, S M, DeBarge, L R, Caspi, R R, Harning, R, Nussenblatt, R B, and Chan, C, Monoclonal antibodies against ICAM-1 (CD54) and LFA 1 (CD11a/CD18) inhibit experimental autoimmune uveitis *Clin Immunol Immunopathol* 67, 143-150, 1993
- 22 Nishikawa, K, Guo, Y, Miyasaka, M, Tamatani, T, Collins, A B, Sy, M, McCluskey, R T, and Andres, G, Antibodies to intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 prevent crescent formation in rat autoimmune glomerulonephritis *J Exp Med* 177, 667-677, 1993
- 23 Willenborg, D O, Simmons, R D, Tamatani, T, and Miyasaka, M, ICAM-1-dependent pathway is not critically involved in the inflammatory process of autoimmune encephalomyelitis or in cytokine-induced inflammation of the central nervous system *J Neuroimmunol* 45, 147-154, 1993
- 24 Cannella, B, Cross, A H, and Raine, C S, Anti-adhesion molecule therapy in experimental autoimmune encephalomyelitis *J Neuroimmunol* 46, 43-56, 1993
- 25 Issekutz, T B, Wykretowicz, A, Effect of a new monoclonal antibody, TA-2, that inhibits lymphocyte adherence to cytokine stimulated endothelium in the rat *J Immunol* 147, 109-116, 1991
- 26 Van Dinther-Janssen, A C, Horst, E, Koopman, G, Newmann, W, Scheper, R J, Meijer, C J L M, and Pals, S T, The VLA-4/VCAM-1 pathway is involved in lymphocyte adhesion to endothelium in rheumatoid synovium *J Immunol* 147, 4207-4210, 1991
- 27 Morales-Ducret, J, Wayner, E, Elices, M J, Alvaro-Gracia, J M, Zvaifler, N J, and Firestein, G S, Alpha4/b1 integrin (VLA-4) ligands in arthritis *J Immunol* 149, 1424-1431, 1992
- 28 Fischer, C, Thele, H G, and Hamann, A, Lymphocyte-endothelial interactions in inflamed synovia Involvement of several adhesion molecules and integrin epitopes *Scand J Immunol* 38, 158-166, 1993
- 29 Nourshargh, S, Rampart, M, Hellewell, P G, Jose, P J, Harlan, J M, Edwards, A J, and Williams, T J, Accumulation of <sup>111</sup>In-neutrophils in rabbit skin in allergic and non-allergic inflammatory reactions in vivo *J Immunol* 142, 3193-3198, 1989
- 30 Tuomanen, E I, Saukkonen, K, Sande, S, Cioffe, C, and Wright, S D, Reduction of inflammation, tissue damage and mortality in bacterial meningitis in rabbits treated with monoclonal antibodies against adhesion-promoting receptors of leukocytes *J Exp Med* 170, 959-968, 1989
- 31 Arfors, K E, Lundberg, C, Lindbom, L, Lundberg, K, Beatty, P G, and Harlan, J M, A monoclonal antibody to the membrane glycoprotein complex CD18 inhibits polymorphonuclear leukocyte accumulation and plasma leakage in vivo *Blood* 69, 338-340, 1987
- 32 Price, T H, Beatty, P G, and Corpuz, S R, In vivo inhibition of neutrophil function in the rabbit using monoclonal antibody to CD18 *J Immunol* 139, 4174-4177, 1987
- 33 Lundberg, C, and Wright, S D, Relation of the CD11/CD18

- family of leukocyte antigens to the transient neutropenia caused by chemoattractants *Blood* 76, 1240-1245, 1990
- 34 Till, G O , Lee, S, Mulligan, M S , Reimer Wolter, J , Wayne Smith, C , Ward, P A , and Marak, G E , Adhesion molecules in experimental phacoanaphylactic endophthalmitis *Invest Ophthalmol Vis Sci* 33, 3417-3423, 1992
- 35 Mulligan, M S , Johnson, K J , Todd, R F , III, Issekutz, T B , Miyasaka, M , Tamatani, T , Wayne Smith, C , Anderson, D C , and Ward, P A , Requirements for leukocyte adhesion molecules in nephrotoxic nephritis *J Clin Invest* 91, 577-587, 1993
- 36 Issekutz, A C , and Issekutz, T B , The contribution of LFA-1 (CD11a/CD18) and MAC-1 (CD11b/CD18) to the in vivo migration of polymorphonuclear leucocytes to inflammatory reactions in the rat *Immunology* 76, 655-661, 1992
- 37 Mulligan, M S , Wilson, G P , Todd, R F , Wayne Smith, C , Anderson, D C , Varani, J , Issekutz, T B , Miyasaka, M , Tamatani, T , Rusche, J R , Vaporçyan, A A , and Ward, P A , Role of β1, β2 integrins and ICAM-1 in lung injury after deposition of IgG and IgA immune complexes *J Immunol* 150, 2407-2417, 1993
- 38 Arnaout, M A , Lanier, L L , and Faller, D V , Relative contribution of the leukocyte molecules Mo1, LFA 1 and p150.95 (LeuM5) in adhesion of granulocytes and monocytes to vascular endothelium is tissue- and stimulus-specific *J Cell Physiol* 137, 305-309, 1988

Received March 2, 1994, accepted May 10, 1994



# CHAPTER 8

## SUMMARY/SAMENVATTING



## SUMMARY AND CONCLUDING REMARKS

Rheumatoid arthritis (RA) is a chronic and erosive joint inflammation of an unknown etiology. To facilitate research on this autoimmune disease, several animal models are available, which contribute to the elucidation of the pathogenesis of this joint inflammation. Two well studied bacterial arthritis models are the adjuvant arthritis (AA) and the streptococcal cell wall-induced arthritis (SCW-induced arthritis). For AA and SCW-induced arthritis both polymorph and mononuclear cells as well as T cells are essential for the development and maintenance of disease. However, the exact pathogenesis of these bacterial-induced arthritis models is still unknown. On the one side one can think of a specific T cell reaction against bacterial fragments, which are present in the joint, while on the other hand crossreactivity between bacterial epitopes and cartilage may play a role in disease development. Apart from the genetic background and the immune system some studies also suggest that the neuroendocrine system may be crucial in regulating the susceptibility to bacterial-induced arthritis. Furthermore, there is increasing evidence that both the neuroendocrine and immune system are able to communicate through overlapping regulatory mediators.

In this thesis we have studied the regulatory aspects of the immune and neuroendocrine system in bacterial arthritis models. First of all we were interested in whether crossreactivity had any *in vivo* relevance in the pathogenesis of these bacterial arthritis models. In addition, we wanted to gain more insight in the mechanisms which are important in regulating the susceptibility in different rat strains and lines. Finally, we investigated several ways to modulate arthritis with selective blocking or elimination of the inflammatory cells.

In the first study we confirm earlier findings, that T cells are important in these bacterial-induced arthritis models. Treatment with anti-CD4 in a prophylactic protocol resulted in virtual absence of SCW-induced arthritis, while on an established disease only a minimal suppression was observed. Furthermore, we found that treatment with anti-CD4 plus SCW induces a long-term resistance to both SCW-induced arthritis and AA. This indicates that induction of T cell tolerance can be a powerful mechanism to maintain prolonged resistance against this type of arthritis (Chapter 2) Recently, clinical trials have been started with chimeric monoclonal anti-CD4 antibodies. These studies show that treatment with these antibodies were able to decrease the number of circulating T cells, while no significant adverse effects like e.g. infectious complications were observed. Regarding the efficacy of this treatment the data are not unequivocal, but do indicate that the type of antibody, the dosage and treatment regimen are crucial factors in determining the clinical outcome.

In SCW-induced arthritis and AA the exact pathogenesis is still unknown. Several *in vitro* studies suggest that cross-reactivity between bacterial epitopes and cartilage may be involved in disease development. However, *in vivo* indications for this hypothesis are limited. So far, only immuno-modulatory effects of cartilage proteoglycan (PG) fractions have been described. Therefore, we studied the relevance of the *in vitro* cross-reactive responses against cartilage PG. First, we examined Safranin-O stained ankle sections, and found only minimal PG depletion in both AA and SCW-induced arthritis. These histological observations do not fully support the hypothesis that arthritis may be initiated by released PG's and structural mimicry between bacterial epitopes and cartilage. Interestingly, T lymphocytes of these arthritic rats were able to respond to the PG



fractions in vitro. In addition, we performed experiments in Lewis rats immunized with SCW in Freund's incomplete adjuvant (FIA) to generate T cell immunity, without spontaneous arthritis. In these rats however, we were not able to elicit a joint inflammation by an intraarticular injection of papain. Such an injection resulted in the release of large amounts of potential cross-reactive cartilage epitopes. These data again indicate that cross-reactivity may not play a key role in the initiation of bacterial arthritis. However, whether cross-reactivity becomes important at later stages in the disease remains to be investigated (Chapter 3).

In addition, we investigated whether lymphocytes of arthritic donor rats are able to specifically migrate to the synovium and subsequently initiate arthritis. Therefore, we performed adoptive transfer experiments with fluorescent T cells obtained from rats with AA, and determined the distribution of these transferred cells in various types of tissue (Chapter 4). If cross-reactivity between bacterial epitopes and cartilage may be involved in the initiation of bacterial-induced arthritis, then one would expect that these bacterial-specific T cells would migrate to the synovium, proliferate in response to cartilage proteoglycans, and initiate arthritis. Interestingly however, we were not able to detect any labelled cells in the joint, suggesting that the cellular infiltrate at the lesion site is mainly host derived. To support these findings further, we performed adoptive transfer experiments to nude Lewis rats, which are reported to lack almost all mature T lymphocytes. These recipients only developed a mild and non-progressive arthritis, which supports the conclusion that a host-derived T-cell population is essential for the development of arthritis by adoptive transfer. Furthermore, these data further indicate that cross-reactivity is not a likely mechanism for the initiation of bacterial arthritis.

Besides the pathogenesis of bacterial-induced arthritis, it was still not completely understood why the Lewis strain is susceptible and the histocompatible F344 (Fisher) resistant. In this respect, we have earlier described that the F344 strain shows T cell unresponsiveness to SCW and explained the underlying mechanism as immunological tolerance. On the other hand, the susceptibility of the Lewis strain was explained by others as a defect in the hypothalamic-pituitary-adrenal (HPA) axis, leading to an impaired corticosterone responsiveness. We further examined the potential mechanisms which may explain the resistance of F344 rat. It was found that the F344 strain can become susceptible for AA, using a more powerful adjuvant. This indicates that the F344 rat does not lack T effector cells and that neither clonal deletion nor clonal anergy can explain its resistance. Next it was tested, whether the HPA activity was the responsible mechanism for suppression. However, we found identical levels of corticosterone after IL-1 $\alpha$  injection in both the resistant F344 and susceptible GF F344. This suggests that corticosterone is not the most important mechanism to suppress disease development in these animals. Finally, we investigated whether active suppression may be responsible for regulating the resistance. This was performed by pretreating the animals with the immunomodulatory drugs cyclophosphamide and cyclosporin A. Our treatment protocol did not make the F344 rat susceptible, indicating that active suppression does not play a role in the induction phase of arthritis. Probably the F344 rat needs to upregulate suppression/tolerance upon bacterial challenge (Chapter 5).

In chapter 6 we further investigated the importance of both the neuroendocrine (HPA axis) and immune system in determining the susceptibility. We observed that the stress-susceptible Wistar rat line (APO-SUS) was completely resistant for AA, while the stress-resistant Wistar rat line (APO-UNSUS) appeared to be moderately susceptible. This indicates that different types of behavioural and neuroendocrinological responses to stress

are correlated to different susceptibility to AA. Furthermore, the germ-free (GF) Wistars were highly susceptible to AA, indicating that the bacterial flora is of prime importance to prevent arthritis. Next it was examined, whether the observed difference in susceptibility was determined by the HPA-axis activity. Therefore, corticosterone levels were analysed in response to IL-1 $\alpha$  in APO-SUS and APO-UNSUS Wistar lines and in GF and conventional (CV) rat strains. The data show that the HPA axis activity did not determine the susceptibility to AA. In addition, we measured plasma corticosterone levels around the onset of AA in both GF and CV F344 rats. Whereas no rise was seen in the arthritis-resistant CV rats, a significant increase was observed in the arthritis susceptible GF rats. This suggests that the HPA axis activity is a determinant in modulation of disease activity, rather than being a mechanism to prevent disease.

Finally, in chapter 7 we examined the role of the  $\beta$ 2 integrins in the recruitment of phagocytic cells in joint inflammation. These adhesion molecules appear to be involved in the adhesion and transendothelial migration of phagocytes to the inflammatory site. The  $\beta$ 2 subfamily of integrins comprises 3 members of adhesion molecules: CD11a/CD18, CD11b/CD18 and CD11c/CD18, which are expressed on monocytes and granulocytes. In addition, CD11a/CD18 is also expressed on B and T lymphocytes, although at a low level. We found that selective blocking of the phagocytic cell influx with antibodies directed against the  $\beta$ 2 subfamily was not effective in suppressing AA. Moreover, we examined the same antibodies in an acute non T cell mediated inflammation at different sites in the rat. For this purpose zymosan was injected in either the joint, peritoneum or derm. We observed that pretreatment with  $\alpha$ CD11a or  $\alpha$ CD11b could only inhibit the influx of phagocytes to an inflamed peritoneum, but not towards an inflamed joint or dermal inflammation. In contrast, treatment with  $\alpha$ CD18 was able to block effectively, independent of the site of inflammation. These data indicate that the relative contribution of the individual  $\beta$ 2 integrins seems site and stimulus specific. Interestingly, a recent report showed prevention of the onset of AA with a single injection of antibodies directed against VLA-4 ( $\beta$ 1 integrin). This suggests, that therapy aimed at other adhesion molecules like VLA-4, may give promising results in discrete blocking of the leukocyte influx in particular joint inflammations.

In conclusion, T cells play a pivotal role in the bacterial-induced arthritis models discussed above and T cell tolerance generated and maintained by the bacterial flora is an important mechanism to regulate the susceptibility. However, whether in vivo crossreactivity plays a role in the pathogenesis of these models remains to be further investigated.

Finally, an always returning question is of course the relevance of these bacterial-induced arthritis models. In the last few years several studies have investigated the effects of antibodies directed against the cytokines interleukin-1 (IL-1) and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) in various arthritis models. For instance, we found that treatment with anti-IL-1 in an established collagen induced arthritis resulted in an amelioration of both inflammation and cartilage destruction, while less effect was observed in the anti-TNF treated animals. On the other hand, when we examined the effects of the same antibodies in an unilateral arthritis, induced by bacterial fragments, we observed exactly the opposite effect. This time anti-TNF treatment was able to significantly suppress the level of inflammation, while anti-IL-1 appeared to have a minor effect. In addition to this, studies have been initiated to examine the effects of anti-TNF treatment in rheumatoid arthritis and the first data show significant clinical and laboratory improvements. The findings

indicate that TNF is not only an important regulator in an unilateral arthritis model induced by bacterial fragments, but also in RA. This suggests some similarity in the pathogenesis. Therefore, it not only remains relevant to perform research in various arthritis models, but also points towards a role of bacteria in the pathogenesis of rheumatoid arthritis.

## SAMENVATTING

Reumatoïde arthritis (RA) is een chronische vorm van gewrichtsontsteking die bij ongeveer 2% van de volwassen bevolking voorkomt. Het is een systemische ziekte, wat inhoudt dat naast de gewrichten ook andere weefsels zoals bijv. bloedvaten, hart en longen aangedaan kunnen zijn. Tot nu toe is de oorzaak van RA onbekend, maar er zijn aanwijzingen, dat bacteriën een rol spelen bij de inductie van arthritis. Zo is er een relatie gevonden tussen bacteriële infecties en arthritis. Bekende humane voorbeelden hiervan zijn de reactieve arthritis en de verhoogde associatie van arthritis met de ziekte van Crohn en jejunum bypass operaties. Daarnaast is het ook mogelijk om in ratten arthritis op te wekken d.m.v. bacteriën. De twee bekendste voorbeelden hiervan zijn adjuvant arthritis, wat geïnduceerd kan worden door het subcutaan inspuiten van kleine hoeveelheden *Mycobacterium in olie*, en het streptococce celwanden-geïnduceerde arthritis model, waarbij grote hoeveelheden celwand-fragmenten van *Streptococcus Pyogenes* intraperitoneaal worden ingespoten. Met behulp van deze experimentele diermodellen kan men inzicht verkrijgen in de ontstaanswijze van chronische gewrichtsontstekingen en nieuwe therapieën uittesten.

Zowel bij adjuvant arthritis als bij streptococce celwanden-geïnduceerde arthritis zijn mononucleaire fagocyten (monocyten en macrofagen) en T cellen van essentieel belang. Mogelijke mechanismen die deze chronische arthritis modellen kunnen verklaren berusten enerzijds op een specifieke T cel reactie tegen bacterieel materiaal, wat zich in de gewrichten bevindt, anderzijds op inductie van kruisreactiviteit tegen proteoglycanen van het gewrichtskraakbeen. Immers, bacteriën en proteoglycanen vertonen structureel enige overeenkomsten.

Betreffende de gevoeligheid voor deze vorm van arthritis, is niet alleen de genetische achtergrond bepalend, maar schijnt er ook een regulerende rol weggelegd te zijn voor de bacteriële flora. Zo is de Lewis rat gevoelig, de vrijwel genetisch identieke Fisher ongevoelig en de kiemvrije Fisher weer wel gevoelig voor bacteriële arthritis. Daarnaast suggereren een aantal andere studies, dat ook het neuroendocriene systeem een regulerende rol heeft in de gevoeligheid. Daarbij moet men niet uit het oog verliezen, dat het neuroendocriene en het immuun systeem goed met elkaar kunnen communiceren door middel van overlappende regulatoire mediators.

In de eerste studie (hoofdstuk 2) bewijzen we de cruciale rol van T cellen in streptococce arthritis. Eliminatie van de T cellen m.b.v. antilichamen gericht tegen de CD4 moleculen ten tijde van arthritis inductie, resulteerde in een langdurige resistentie. Zelfs als in een later stadium deze T cellen weer op een normaal niveau waren gekomen, bleken deze proefdieren nog steeds resistent tegen de inductie van bacteriële arthritis.

Vervolgens probeerden we meer inzicht te verkrijgen in het ontstaan van deze vorm van gewrichtsontsteking. Een mogelijke hypothese is kruisreactiviteit tussen bacteriële epitopen en kraakbeen. Zo zijn er een aantal in vitro studies, die dit soort kruisreagerende T cel responsen aantonen. Echter, in vivo bevindingen, die de relevantie van kruisreactiviteit onderbouwen zijn zeer beperkt en deze hypothese is nader getoetst. Zo konden wij in hoofdstuk 3 inderdaad in vitro kruisreacties van T cellen aantonen, maar bij analyse van de ontstoken gewrichten bleek het kraakbeen slechts minimaal beschadigd te zijn. Deze bevindingen duiden erop dat kruisreactiviteit waarschijnlijk minder belangrijk is in het ontstaan van bacteriële arthritis. Deze conclusie werd vervolgens indirect onderbouwd door de proeven, waarbij de ziekte passief werd overgebracht d.m.v.

T cellen (hoofdstuk 4). Immers, wanneer wij arthritogene T cellen merken met een fluorescerend label en inspuiten in gezonde ontvanger dieren, konden wij geen accumulatie van deze fluorescerende T cellen in de gewrichten aantonen. Dit zou je niet verwachten, wanneer kruisreactiviteit een rol speelt bij arthritis inductie. Tevens suggereert het, dat de ontstekingscellen (T cellen) in het gewricht voornamelijk afkomstig zijn van de ontvanger zelf. Deze conclusie wordt gesteund door proeven, waarbij de ziekte passief werd overgebracht naar naakte ontvanger dieren. Deze ratten missen functionele T cellen in hun immuun systeem en bleken slechts matig gevoelig te zijn voor deze vorm van arthritis inductie. Alhoewel de combinatie van deze bevindingen het belang van kruisreactiviteit in dit model in twijfel trekt, kunnen we niet uitsluiten dat kruisreactiviteit een rol gaat spelen in latere stadia van ontsteking.

Los van het feit, dat het mechanisme leidend tot gewrichtsontsteking in adjuvant arthritis nog onbekend is, is het ook nog steeds niet duidelijk, waarom de Lewis rat gevoelig is voor bacteriële arthritis, de genetisch identieke Fisher rat ongevoelig en de kiemvrije Fisher rat weer wel gevoelig. Om hier meer duidelijkheid in te krijgen, werden in hoofdstuk 5 een aantal potentiële mechanismen onderzocht, die de ongevoeligheid van de Fisher rat zouden kunnen verklaren. Zo vonden we in deze studie, dat de Fisher ratten geen T effector cellen missen, want ze konden wel een arthritis krijgen, wanneer we een krachtiger adjuvant gebruikten. Vervolgens toonden we aan, dat na injectie van het ontstekingsbevorderend eiwit interleukine-1 (IL-1) er geen verschil was in de endogene productie van corticosteron in de ongevoelige Fisher en de gevoelige kiemvrije Fisher. Deze bevindingen suggereren, dat niet alleen een hoge activiteit van de hypothalamus-hypofyse-bijnier (HHB) as (het neuroendocrien systeem) verantwoordelijk kan zijn voor de ongevoeligheid van de Fisher rat. Tenslotte vonden we, dat de F344 rat ongevoelig bleef voor arthritis na voorbehandeling met immunosuppressieve middelen, wat erop duidt dat actieve suppressie geen rol speelt in de inductie fase van de arthritis. Een voorlopige conclusie is, dat de Fisher rat zijn suppressie/tolerantie mechanisme pas activeert bij hernieuwd contact met bacteriën.

In hoofdstuk 6 onderzochten we niet alleen het belang van de bacteriële flora, maar ook of een verschillend type gedrag op stressvolle omstandigheden de gevoeligheid voor bacteriële arthritis kan bepalen. Zo vonden we, dat de stress-gevoelige Wistar rattelijn (APO-SUS) totaal ongevoelig was voor adjuvant arthritis, terwijl de stress-ongevoelige Wistar rattelijn (APO-UNSUS) matig gevoelig bleek te zijn. Dit betekent, dat verschillend gedrag en neuroendocrinologische responsen op stress correleren met een verschillende gevoeligheid voor arthritis. Daarnaast vonden we in deze studie, dat de kiemvrije Wistar ratten zeer gevoelig bleken te zijn voor arthritis. Deze bevindingen duiden erop, dat de bacteriële flora uitermate belangrijk is voor het voorkómen van arthritis. Tenslotte bestudeerden we, of deze verschillen in gevoeligheid verklaard konden worden door een verschil in de activiteit van de HHB-as. Echter de resultaten laten zien dat de activiteit van de HHB-as meer een regulerende rol vervuld in de ernst van de ontsteking, dan een mechanisme is om de arthritis te voorkomen.

Uiteindelijk onderzochten in hoofdstuk 7 de rol van de  $\beta 2$  integrinen in het rekruteren van ontstekingscellen tijdens arthritis. Immers, wanneer ontstekingscellen naar een ontstekingsgebied migreren, maken deze cellen gebruik van adhesiemolekulen om via de bloedvaatwand de bloedbaan te kunnen verlaten. De  $\beta 2$  subfamilie van integrinen bestaat uit 3 verschillende type adhesie moleculen: CD11a/CD18, CD11b/CD18 en CD11c/CD18, welke zich bevinden op zowel monocyten als macrofagen. Bovendien bevindt CD11a/CD18 zich ook nog op B en T cellen, alhoewel op een laag niveau. Deze

studie laat zien, dat het blokkeren van de influx van fagocyten m.b.v. antilichamen gericht tegen de  $\beta 2$  subfamilie ( $\alpha$ CD11a,  $\alpha$ CD11b en  $\alpha$ CD18) geen effect had op het onderdrukken van adjuvant arthritis. Daarnaast onderzochten we ook de effecten van dezelfde antilichamen in een acute niet T cel gemedieerde ontsteking op verschillende plaatsen in de rat. Deze experimenten laten zien, dat voorbehandeling met  $\alpha$ CD11a of  $\alpha$ CD11b alleen de influx van fagocyten naar een ontstoken buikholte konden blokkeren, terwijl we geen effect zagen in een ontstoken gewricht of huidontsteking. Daarentegen, bleek  $\alpha$ CD18 voorbehandeling zeer effectief te zijn, onafhankelijk van de plaats van de ontsteking. Dit suggereert, dat de relatieve bijdrage van de individuele  $\beta 2$  integrinen plaats en stimulus afhankelijk is.

Concluderend, T cellen spelen een onmisbare rol in bacterieel geïnduceerde arthritis modellen. Daarnaast is T cel tolerantie, opgebouwd en onderhouden door de bacteriële flora, een uitermate belangrijk mechanisme om de gevoeligheid voor arthritis te bepalen en schijnt neuroendocriene regulatie minder essentieel. Tenslotte, lijkt het onwaarschijnlijk, dat kruisreactiviteit met kraakbeen een belangrijke rol speelt bij het ontstaan van bacteriële arthritis.



## DANKWOORD

De totstandkoming van dit proefschrift werd mede mogelijk door de steun van vele anderen. Alhoewel ik me realiseer, dat je gemakkelijk iemand vergeet, wil ik toch bij deze een poging wagen om al diegene te bedanken, die op enigerlei wijze een bijdrage hebben geleverd aan dit proefschrift.

Op de eerste plaats natuurlijk mijn promotor Prof.dr. W.B. van den Berg. Beste Wim, bedankt voor het vertrouwen en de vrijheid die ik heb gekregen tijdens het uitvoeren van mijn promotie-onderzoek. Ik heb een hoop geleerd, vooral als ik door de bomen het bos niet meer zag. Met jouw overzicht bleef de rode draad in mijn onderzoek behouden, wat vaak niet gemakkelijk was in zo'n gecompliceerde ziekte als arthritis.

Mijn co-promotor Peter van Lent en collega Leo Joosten wil ik bedanken voor het feit, dat ze gedurende het onderzoek mijn grote steun en toeverlaat waren. Jullie interesse in mijn werk is een grote stimulans geweest en de open discussies over de wetenschap waren leerzaam. Beste Leo, ik zal je grappen missen.

Verder wil ik Erica en Michel bedanken voor hun analytische ondersteuning en Monique, Elly en Liduine voor het verwerken van de histologie. Ook alle andere collega's: Marike, Gerjo, Harrie, Pernelle, Fons, Peter, Marianne, Onno, Astrid, Sandra en in het bijzonder mijn kamergenoten Henk en Joyce wil ik bedanken voor de goede werksfeer.

Mijn dank gaat ook uit naar alle medewerkers van het Centraal Dierenlaboratorium voor zowel de verzorging van de proefdieren als het uitvoeren van de experimenten. Tevens wil ik ook de mensen van verscheidene andere onderzoeksgroepen bedanken voor de prettige samenwerking in de afgelopen jaren.

Ook het genootschap van de bourgondeliërs en oud-huisgenoten wil ik bedanken voor de nodige ontspanning onder het genot van een biertje.

Mijn ouders wil ik niet alleen bedanken voor het feit dat ze me de gelegenheid hebben gegeven om te kunnen studeren, maar ook voor de morele steun gedurende de gehele periode.

Lieve Daniëlle, jij was echt onmisbaar in elk opzicht. Een dubbel-promotie is toch wel heel bijzonder!





## CURRICULUM VITAE

De schrijver van dit proefschrift werd geboren op 7 augustus 1961 te Oisterwijk. In 1981 behaalde hij het diploma Gymnasium  $\beta$  aan het Stedelijk Gymnasium te 's-Hertogenbosch. In dat zelfde jaar werd een begin gemaakt met de studie biologie aan de Rijks Universiteit Utrecht. In januari 1985 behaalde hij zijn kandidaatsexamen Biologie. Daarna volgde een bijvak Moleculaire Genetica aan de Rijks Universiteit Utrecht (Prof.dr. van Arkel), een hoofdvak Medische Microbiologie op de afdeling Immunology and Medical Microbiology (Prof. W.W. Hauswirth) aan de University of Florida, in Gainesville, USA en een hoofdvak Veterinaire Immunologie op de afdeling Pathologie van het Rijksinstituut voor Volksgezondheid en Milieuhygiene (Dr. H. van Loveren). Het doctoraal examen B5\* (Medische Biologie) werd behaald in november 1987. In 1988 werd een postdoctoraal onderzoek uitgevoerd bij de vakgroep Immunology and Medical Microbiology aan de University of Florida op uitnodiging van Prof. Hauswirth. Van februari 1989 tot mei 1994 was hij werkzaam als onderzoeker op het laboratorium reumatische ziekten van het Academisch Ziekenhuis St. Radboud te Nijmegen. Vanaf mei 1994 is hij werkzaam op de medische afdeling van de firma Roussel als clinical research associate.



## STELLINGEN

behorende bij het proefschrift  
"Regulation of bacterial induced arthritis".

1. T-cel tolerantie, opgebouwd en onderhouden door de bacteriële flora, is een uitermate belangrijk mechanisme om de gevoeligheid voor arthritis te bepalen.  
*Dit proefschrift*
2. Bij het ontstaan van bacteriële arthritis lijkt het onwaarschijnlijk dat kruisreactiviteit met kraakbeen een belangrijke rol speelt.  
*Dit proefschrift*
3. Bij de keuze van radionucliden voor radioimmunotherapie zal de veiligheid van het betrokken medisch personeel een steeds belangrijkere rol gaan spelen.  
*Martijn Gerretsen, Proefschrift 1993, Vrije Universiteit Amsterdam*
4. Lever macrofagen kunnen prolifereren.  
*Rein Hoedemakers, Proefschrift 1993, Universiteit Groningen*
5. Het feit dat de SCW-arthritis gebruik maakt van dode bacteriën is een prettige bijkomstigheid, nu blijkt dat *Streptococcus pyogenes* ook vleesetende capaciteiten blijkt te bezitten.
6. De anti-rookcampagnes houden te weinig rekening met het feit, dat nicotine ook heilzame effecten kan uitoefenen, zoals het vertragen of voorkómen van ziekten als Parkinson en Alzheimer.
7. Het is de vraag wie het meeste voordeel heeft van een promotie-onderzoek: de promotor of de promovendus.
8. Het gebruik van afkortingen binnen de farmaceutische industrie neemt zulke vormen aan, dat deze wellicht binnenkort in boekvorm kunnen worden uitgegeven.
9. Het is goed dat Nederland niet Italië is, anders zou Joop van den Ende nu premier zijn.
10. Het werken met naakte ratten is een schamele troost voor kalende wetenschappers.





ISBN 90 9007603 4